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ABSTRACT
 The goal of the works presented in this volume is to develop a magnetic 
resonance imaging (MRI) probe for non-invasive detection of extracellular matrix 
(ECM) underlying fenestrated endothelia. The ECM is the scaffold that supports 
tissue structure in all organs. In fenestrated structures the such as the kidney 
glomerulus and the hepatic sinusoid the ECM serves a unique role in blood 
filtration and is directly exposed to blood plasma. An assessment of the ECM in 
fenestrated organs such as the kidney and liver reports on the organ’s ability to 
filter blood - a process critical to maintaining homeostasis. Unfortunately, clinical 
assessment of the ECM in most organs requires biopsy, which is focal and 
invasive. 
 This work will focus on visualizing the ECM underlying fenestrated 
endothelia with natural nanoparticles and MRI. The superparamagnetic ferritin 
protein has been proposed as a useful naturally-derived, MRI-detectable 
nanoparticle due to its biocompatibility, ease of functionalization, and modifiable 
metallic core. We will show that cationized ferritin (CF) specifically binds to the 
anionic proteoglycans of the ECM underlying fenestrated endothelia and that its 
accumulation is MRI-detectable. We will then demonstrate the use of CF and 
MRI in identifying and measuring all glomeruli in the kidney. We will also explore 
the toxicity of intravenously injected CF and consider other avenues for its 
application, including detection of microstructural changes in the liver due to 
chronic liver disease. This work will show that CF is useful in detected 
fenestrated microstructures in small animals and humans alike, indicating that CF 
may find broad application in detecting and monitoring disease in both preclinical 
and clinical settings.
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CHAPTER 1
INTRODUCTION
 The goal of the works presented in this dissertation is to develop a cationic, 
MRI-detectable probe for non-invasive detection of kidney glomeruli and the 
perisinusoidal space of the liver. Targeted MRI contrast agents have been 
developed to detect molecules and cells throughout the body (Cormode, Jarzyna, 
Mulder, & Fayad, 2010; Geninatti Crich et al., 2005; S. Zhang, Merritt, Woessner, 
Lenkinski, & Sherry, 2003). Superparamagnetic iron oxide nanoparticles (SPIOs) 
of approximately 10-50 nm are one such type of contrast agent that create a 
detectable change in the MRI signal. Ferritin, a 13 nm protein-based SPIO, has 
been proposed as a useful natural nanoparticle contrast agent due to its uniform 
size, biocompatibility, and ease of functionalization (Bennett, Shapiro, Sotak, & 
Koretsky, 2008; Bulte et al., 1995; Uchida et al., 2008). Because the ferritin 
nanoparticle has a superparamagnetic iron oxide core, its accumulation creates a 
darkening in the MR image that can be detected using T2*-weighted MRI.
 We will describe the development and application of this extracellular 
matrix-specific, cationized ferritin probe in three parts: First, in chapters 2-4 we 
will discuss the use of CF in detecting, identify, and measuring kidney glomeruli; 
second, in chapter 5 we will explore the toxicity of intravenously injected CF and 
other avenues for its application; and finally, in chapter 6, we will show that CF 
may be used to detect microstructural changes to the liver in chronic liver 
disease. In this chapter we will provide the necessary background for the studies 
presented in Chapters 2-6.
MAGNETIC RESONANCE IMAGING
 Magnetic resonance imaging (MRI) is a vital tool in clinical diagnostics and 
preclinical research. MRI has found wide application in clinical and preclinical 
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settings due to its versatility in inducing image contrast from tissue and its ability 
to produce very high resolution images. MRI is derived from the older chemical 
characterizing tool called nuclear magnetic resonance (NMR) which, as the name 
suggests, relies on atomic nuclei to precess at a resonant frequency when 
exposed to a magnetic field. It is the manipulation of these precessing nuclei with 
an assortment of circuitry that yields a spatially encoded signal that can be used 
to create an MRI image. NMR and MRI are separated only by MRI’s use of 
magnetic gradients to spatially encode nuclei to produce an image.
 Magnetism, relaxation, and NMR/MRI. The foundation of NMR and MRI is 
not in macroscopic magnetism, but instead lies in the intrinsic spin and magnetic 
moment of fundamental particles. The physical basis of magnetic resonance may 
be described in either a classical or quantum framework. The background 
presented here will be in the classical framework with a few necessary quantum 
principles. Furthermore, this work will focus exclusively on acquisition of MRI 
signal from the hydrogen protons (though we will also discuss the effects of 
electron magnetism on hydrogen protons). The hydrogen nucleus is constructed 
from a single proton and has a spin I = 1/2. We will hereby simply refer to 
hydrogen nuclei as ‘protons’.
 Magnetism stems from three different sources. The first source is the 
circulation of electrons about a nucleus. Elementary classical physics informs us 
that a loop of electric current induces a magnetic field. The orbit of electrons 
about a nucleus is a parallel situation in which orbiting electrons are a circulating 
current that induce a small magnetic field. The second and third sources of 
magnetism come from protons and electrons. Protons and electrons each have a 
magnetic moment, µ, that is linearly proportional to the spin angular momentum, 
S, offset only by a particle’s gyromagnetic ratio, ɣ. The spin angular momentum 
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of protons and electrons, and therefore their magnetic moments, are intrinsic 
properties of the particle - they simply exist. Indeed, the spin and the magnetic 
moment of a particle are so strongly linked that they always point either parallel 
or anti-parallel to one another. The net moment is the sum of the spin moments 
and the orbital moment, where the nuclear contribution is orders of magnitude 
lower than the electronic contribution. In the classical model of NMR/MRI it turns 
out that, when placed into a magnetic field, the spin-axis of a proton or electron 
will precess about the field with a constant angle between the spin-axis and the 
applied magnetic field vector, B0, and at a constant frequency called the “Larmor” 
frequency, defined by ω0=-ɣB0. While the remainder of this section will focus on 
the proton (it is, in fact, the hydrogen protons of water molecules that ultimately 
yield the bulk of the signal in the type of MRI discussed in this work), it is of 
special importance to note that the magnetism of an unpaired electron is orders 
of magnitude stronger than that of a proton. In most materials all of the electrons 
are paired (according to the Pauli Principle) and their magnetism cancelled, 
though there exist elements such as the lanthanides which have many unpaired 
electrons in their outer orbital. These elements are strongly paramagnetic and 
find heavy use as MRI contrast agents - a topic that we will return to soon.
 Of course a sample will never contain only a single proton. Let us instead 
consider a sample of water. Our sample now contains many moles of hydrogen 
protons with an isotropic distribution of nuclear magnetic moments. Immediately 
upon application of an external magnetic field, B0, there exists no net 
magnetization in our water sample but as time goes on a bulk sample 
magnetization grows in the direction of B0 due to the alignment of a very small 
number of nuclear magnetic moments with the external field. This effect stems 
from the thermodynamic nature of our system which dictates that the protons in 
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our system slightly favor a low energy parallel orientation of their nuclear 
magnetic moments with B0 over a high energy anti-parallel orientation. The 
growth of sample magnetization in the direction of B0 is referred to as the 
‘longitudinal relaxation’ and results a macroscopic magnetism in the sample that 
points parallel to B0 at thermodynamic equilibrium. Longitudinal relaxation is 
modeled by the equation Mz(t) = M0(1-e-t/T1), where Mz is the longitudinal 
magnetization of the sample, t is the amount of time after the application of a field 
(or, in future discussion, the amount of time after an RF pulse), and T1 is the fitted 
time constant for the regrowth of longitudinal magnetization. It should be noted 
that, though the bulk sample magnetization along B0 is stable, any given spin in 
the system is free to point in any direction. The presence of B0 merely makes it 
slightly more probable that a nuclear moment will orient itself along B0 (or, in the 
quantum framework, the presence of B0 merely makes it slightly more probable 
that a spin will occupy the parallel versus anti-parallel spin state).
 Detecting a net magnetism that is pointing in the direction of an external 
magnetic field is difficult because the number of nuclear magnetic moments that 
align with field is very small (approximately 1 in 1-10 million) and they do not 
precess in a coherent manner. NMR/MRI overcomes this by creating a coherent 
alignment of spins in the plane transverse to B0. It turns out that the polarization 
of spins along the direction of B0 may be rotated into the transverse plane using 
radio frequency (RF) coils mounted orthogonally to B0 that are tuned to the 
Larmor frequency. These coils are used to ‘tilt’ the sample magnetization away 
from B0, which effectively sums all of the longitudinally aligned nuclear magnetic 
moments into a single coherent sample magnetization in the transverse plane. 
When the RF pulse is shut off, the spins resume their precession around B0, 
except now all of the spins precess about B0 in phase with one another yielding a 
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net magnetization in the transverse plane called ‘transverse magnetization’. The 
transverse magnetization precesses about B0 at the Larmor frequency because it 
is simply a coherent ensemble of spins with their moments aligned in the 
transverse plane. The transverse magnetization is detectable because the spins 
rotate in a coherent (summed) manner, at a well defined frequency. Faraday’s 
law and Maxwell’s equations inform us that this rotating net magnetization may 
be used to induce an oscillating current in an orthogonally mounted receive coil. 
 Transverse magnetization also relaxes, this time modeled as an 
exponential decay. Coherent spins ultimately become incoherent due to the fact 
that each spin in the system samples a unique set of microenvironments and 
local magnetic fields. The different magnetic environments that each spin 
experiences cause the Larmor frequency of each proton to fluctuate with time 
and ultimately yields a ‘dephasing’ of all spins in the transverse plane. This 
dephasing in the transverse plane is called ‘transverse relaxation’. In its most 
simple form, transverse relaxation can be modeled by the equation M⊥(t) = M0 e-t/
T2*, where M⊥ is the transverse magnetization of the sample, t is the amount of 
time after the RF pulse, and T2* is the fitted time constant describing the decay of 
transverse magnetization. The rate at which the transverse magnetization decays 
is strongly affected by the protons’ environment and this model can be expanded 
to a multi-exponential in more complex systems to account for multiple source of 
transverse relaxation. In fact, T2* can further be dissected by defining it as 
T2*=T2’+T2, where T2’ is the time constant fitted to reversible transverse relaxation 
caused by static field inhomogeneities and T2 is the time constant fitted to 
irreversible transverse relaxation that is intrinsic to the system. In tissue, T2 can 
be a strong indicator of disease so it is important to be able to isolate T2. This 
may be accomplished by applying a second RF pulse that flips the transverse 
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magnetization 180° to reverse the static dephasing. This causes a regrowth of 
transverse magnetization that results in a ‘echo’ at the time point where static 
dephasing has been completely reversed.
 MRI. So far we have described the classical physical foundation of NMR - a 
system that represent all protons in the sample equally, regardless of their spatial 
location. The distinction between NMR and MRI lies in MRI’s use of 
electromagnetic gradients to spatially encode protons to produce an image. The 
application of electromagnetic gradients in the system described above produces 
a spatially varying Larmor frequency, defined by ω(x)=-ɣB(x), where x is the 
spatial location along the field gradient. Therefore, electromagnetic gradients 
may control the Larmor frequencies of protons as a function of their spatial 
location in the sample. The periodicity of spin precession in a magnetic field and 
the ability to manipulate the Larmor frequencies of protons as a function of their 
spatial location with gradients provides the opportunity spatially encode protons 
in a sample. The data collected are in the spatial frequency domain and can be 
reconstructed into an image via a Fourier transform. Multiple gradient coils can 
be applied dynamically to manipulate the magnetic field in three dimensions, 
allowing for imaging of all three spatial dimensions at a one time.
 The gradient echo pulse sequence and MRI contrast. The gradient echo  
(GRE) is the MRI pulse sequence that is used in all of the work presented in this 
volume. Briefly, a one dimensional GRE would include an initial RF pulse that 
creates a coherent bulk magnetization in the transverse plane followed by an 
application of a negative magnetic gradient, causing a spatially-dependent 
dephasing effect across the sample. A positive gradient is then applied for twice 
the duration of the negative gradient. Data collection begins at the onset of the 
positive gradient and is centered around the ‘echo time’ (TE) - the time at which 
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the dephasing caused by the negative gradient is cancelled by the rephasing 
from the positive gradient. This experiment may be generalized to two and three 
dimensions. The experiment is repeated to apply different gradient combinations 
such that all of 2D or 3D k-space (the spatial frequency domain in which MRI 
data is collected) may be filled. The time duration at which the experiment is 
repeated is defined by the ‘repetition time’ (TR). Both TE and TR are user defined 
parameters of the experiment and can be adjusted to manipulate image contrast 
between tissue types.
 The three main mechanisms for MRI contrast when using a GRE pulse 
sequence are longitudinal relaxation (T1), transverse relaxation (T2*), and spin 
density (⍴). Each of these mechanisms has an effect on the the MRI signal and 
the way in which the MRI signal is acquired can drastically change the 
proportions by which each mechanism imparts contrast on the image. Typically, 
the user defined TE will modulate the T2*-weighting of an image and the TR will 
modulate the T1-weighting. A longer TE will increase the T2*-weighting while a 
shorter TR will increase the T1-weighting. One would want to minimize both T2*-
weighting (very short TE) and T1-weighting (very long TR) to obtain an image 
primary defined by spin density.
 While this description of MRI is a hugely simplified version of a very 
complex phenomenon, it lays a sufficient foundation to discuss MRI contrast 
agents - the focus of this work.
MRI CONTRAST AGENTS
 Paramagnetism and superparamagnetism. 
 Most MRI contrast agents rely on the effects that the electron magnetism of 
a metal-based agent has on hydrogen protons of the surrounding water. The 
magnetization of the agents used in this work is of either paramagnetic or 
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superparamagnetic form and depends on the strength of the applied magnetic 
field B0 according to the equation M = X B0, where M is the magnetism of the 
nanoparticle, X is the magnetic susceptibility constant for the magnetic material 
of the particle, and B0 is the applied magnetic field. A material is paramagnetic or 
superparamagnetic if the measured susceptibility of a material is greater than 
zero. Typically a superparamagnetic material has a susceptibility much greater 
than zero and its magnetization will saturate and therefore fall out of the linear M 
= X B0 regime at the B0 magnetic field strengths employed in MRI. A material that 
has only paired electrons and a susceptibility of less than zero is called 
diamagnetic, though diamagnetism will be neglected for the remainder of the 
conversation about contrast agents.
 Paramagnetism is usually associated with single metal atoms with unpaired 
electrons such as gadolinium and manganese. Unpaired electrons have a large 
permanent magnetic moment (orders of magnitude greater than a proton’s 
magnetic moment) and are what define an atom as paramagnetic. The magnetic 
moments of the unpaired electrons in paramagnets are free to rotate and tend to 
distribute themselves isotropically at thermal equilibrium in the absence of an 
external magnetic field. Once a magnetic field is ‘turned on’, the electron 
magnetic moment will couple with the external field. This interaction between the 
paramagnet and the applied field is similar to the interaction between a proton 
and a magnetic field. The electronic magnetic moment of a paramagnet is so 
strong that, when in a solution of water, it can exchange energy with the 
surrounding hydrogen protons. This dipolar interaction can shorten the 
longitudinal relaxation time of the hydrogen protons and ultimately yield a 
brightening of MRI signal in T1-weighted MRI.
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 Now consider a material in which bound atoms in a crystal work together to 
form domains; each domain with its own large magnetic moment. A large material 
(greater than 30 nm in diameter) can have many such domains that, when 
magnetized, can couple to one another and perpetuate a large magnetic field in 
the absence of an external field. This is called a ferromagnet (an example of a 
ferromagnet would be a refrigerator magnet). Now imagine a ferromagnet that 
has been cut up until it contains only a single magnetic domain with only a single 
large magnetic moment. Such particles with a single magnetic domain are called 
‘superparamagnets’. In the absence of an external magnetic field, the magnetic 
moments of these superparamagnets will oscillate along the principle axis of the 
crystal thereby appear to have zero magnetization. However, once exposed to a 
magnetic field these superparamagnetic particles will couple so strongly with the 
applied field that its magnetization will saturate (reach its highest possible 
magnetization, regardless of the field it is in) and produce a strong magnetic field 
that reaches far beyond the physical boundaries of the particle. The strong 
magnetic field of a superparamagnet coupled with an external field causes 
dephasing of nearby coherent protons and a shortened transverse relaxation 
time, ultimately yielding a darkening of MRI signal in T2-weighted MRI.
 Nanoparticles as MRI contrast agents. Paramagnetic gadolinium 
chelates are by far the most common MRI contrast agents in use in the clinic, 
though they have a very low relaxivity (the measurement of an agents ‘strength’). 
Alternatively, nanoparticles may be synthesized with paramagnetic or 
superparamagnetic cores for use as highly detectable contrast agents that 
shorten longitudinal relaxation or transverse relaxation, respectively. Typically 
these synthetic nanoparticles are coated with a saccharide such as dextran to 
protect the body from the toxic metal core of the particle and can be as small as 
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a few nanometers in diameter. The strength of a nanoparticle contrast agent is 
reported in terms of relaxivity (r1 for agents that shorten longitudinal relaxation or 
r2 for agents that shorten transverse relaxation), and indicates the agent’s ability 
to brighten (an r1 agent) or darken (an r2 agent) the MR image. The relaxivity of a 
nanoparticle is strongly linked to its size, aggregation state, saturation 
magnetization, and the composition of its metal core (Bennett, Shapiro, Sotak, & 
Koretsky, 2008; Yablonskiy & Haacke, 1994). 
 Ferritin. Natural macromolecules have been employed as biocompatible 
nanoparticle contrast agents that carry paramagnetic or superparamagnetic 
payloads. The ferritin protein is one such natural nanoparticle that comes pre-
packaged with a superparamagnetic iron oxide core. Ferritin is an endogenous 
24-mer protein of approximately 475 kDa that is used by the body to store iron in 
a non-toxic state. The iron is stored in the hollow center of the spherical protein 
shell, which is about 1 nm thick, until it is required for hemoglobin or other iron-
rich cellular components. At 12 nm in diameter, the superparamagnetic ferritin 
protein serves as an excellent naturally derived, biocompatible magnetic 
nanoparticle for T2*-weighted MRI.
 Apoferritin, the empty (iron-free) version of ferritin, provides even greater 
versatility. Without the iron oxide core in place, the apoferritin protein is free to be 
modified in a number of useful ways. The apoferritin protein shell may be loaded 
with large amounts of iron, rendering a naturally derived nanoparticle called 
‘magnetoferritin’, which has a r2 relaxivity of approximately 100 times that of 
native ferritin (Bulte et al., 1995; Clavijo Jordan, Caplan, & Bennett, 2010). More 
recently we have modified this synthesis process with a tungsten dopant. The 
exchange coupling within the crystal is prevented by strategically doping the iron 
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oxide core of apoferritin with tungsten ions, resulting in a large paramagnetic 
nanoparticle with a very high r1 and low r2.
 The surface of the ferritin protein is also readily modified. Aime, et al. have 
shown that the surface of the ferritin protein may be targeted to tumor blood 
vessels by incubating the protein in streptavidin and biotinylated C3d peptides - 
peptides that are specific to receptors expressed by vascular cells (Geninatti 
Crich et al., 2007). The remainder of this work though will focus on the use of 
cationized ferritin (CF) as a targeted molecular imaging agent. CF has long been 
used as an electron dense probe in transmission electron microscopy to label 
charged surfaces in tissue sections (Brody, Vaccaro, Hill, & Rounds, 1984; 
Danon, Goldstein, Marikovsky, & Skutelsky, 1972; Schmidley & Wissig, 1986; 
Voelz, Kondziella, Berens Von Rautenfeld, Brinker, & Lüdemann, 2007) and in 
previous work we have shown the iron oxide core of CF to be MRI-detectable 
using T2*-weighted MRI (Beeman, Georges, & Bennett, 2012;  Beeman et al., 
2011; Bennett, Shapiro, Sotak, & Koretsky, 200811; Bennett, Zhou, Sumner, 
Dodd, Bouraoud, et al., 2008). The work presented in this document will focus on 
the use of CF as a charge-specific MRI contrast agent to detect anionic 
extracellular matrix underlying fenestrated endothelium. 
THE KIDNEY GLOMERULUS
 The human kidney has ~200,000 - 2,000,000 nephrons responsible for 
removing waste from the body and maintaining proper blood ion, glucose, and 
pH levels. Each nephron is composed of a single glomerulus and tubule. The 
glomerulus plays a critical role in renal blood filtration, serving to retain vital 
macromolecules and cells in the blood stream while allowing smaller plasma 
components to flow into the nephron tubules for resorption or expulsion in the 
form of urine. 
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 Measuring glomeruli. A low count of kidney glomeruli (Nglom) may 
suggest a number of renal and systemic diseases including diabetes, obesity, 
and hypertension (Bertram, Soosaipillai, Ricardo, & Ryan, 1992; Brenner, Garcia, 
& Anderson, 1988; Hoy et al., 2008). Furthermore, changes in Nglom and 
glomerular volume (Vglom) have been linked to ~90% of all chronic renal 
diseases (Puelles et al., 2012). A recent study performed by the National Kidney 
Foundation revealed that ~88% of chronic kidney disease (CKD) cases go 
undiagnosed in patients with Type 2 diabetes - a patient population already 
known to be at risk for CKD. Furthermore, current techniques to measure renal 
function are known to report normal measurements when the kidney has actually 
lost much of its filtration capacity, rendering them insufficient to detect renal 
disease early on (Cullen-McEwen, 2003). The number of patients requiring 
dialysis and kidney transplant could be substantially reduced by improving the 
screening of CKD in the offices of primary care physicians and developing robust 
diagnostic tools to detect the early indicators of CKD. 
 Current techniques that estimate glomerular number and size have 
provided substantial insight into renal physiology and its roll in health and 
disease (Beeman et al., 2011; Brenner, Troy, Daugharty, Deen, & Robertson, 
1972; Cullen-McEwen, 2003; Menini et al., 2004; Puelles et al., 2012) but are 
destructive and fail at characterizing individual glomeruli. At this point, 
measurements of Nglom and Vglom are not clinically available; histological 
techniques to measure Nglom and Vglom require resection and destruction of the 
kidney and only yield extrapolated estimates of Nglom and Vglom from small 
sample populations(Bertram et al., 1992). A non-invasive technique to measure 
the number and size of every glomerulus would prove invaluable to preclinical 
and clinical assessment of renal disease. 
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 A potential strategy to non-invasively measure Nglom and Vglom is to 
develop a MRI contrast agent that specifically targets the glomerular basement 
membrane (GBM). We have previously demonstrated that intravenously injected 
CF can be used to detect individual glomeruli with MRI (Beeman et al., 2011; 
Bennett, Zhou, Sumner, Dodd, Bouraoud, et al., 2008). This technique is based 
on selective electrostatic binding of CF to the anionic proteoglycans of the GBM, 
the accumulation of which renders each perfused glomerulus visible with MRI. 
Based on this, we can locate and count each perfused glomerulus in the kidney 
and measure its volume. Furthermore, the three dimensional nature of MRI will 
allow us to study glomerular populations defined by their size and location in the 
kidney - providing a unique insight into intra-renal distributions of glomeruli.
 Clearance of CF from the nephron. An understanding of the mechanism 
of CF clearance from the GBM is of vital importance to this project. The 
traditional model for macromolecular filtration in the glomerulus involves a 
capillary wall that is composed of three layers collectively referred to as the 
filtration barrier. The glomerular capillary wall has a hydrostatic pressure gradient 
across it that drives plasma filtration across the capillary wall and into the 
proximal tubule of the nephron. The first layer of the glomerular capillary wall is a 
fenestrated endothelial layer with 70 - 100 nm fenestrae that allow the passage 
of plasma and macromolecules across the filtration barrier but restricts cells to 
the capillary space. This endothelial layer can also phagocytize macromolecules 
that enter into the second layer - the glomerular basement membrane (GBM). 
The anionic GBM is thought to be the main player in plasma filtration, filtering 
particles by both size and charge. Finally, there exists an epithelial layer 
consisting of cells called podocytes that are thought to serve as a size-selective 
filter. Furthermore, there exist mesangial cells inside the glomerular capillary 
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lumen that work to clear accumulated macromolecules that have been filtered by 
the GBM. It is very likely that the bulk of intravenously delivered CF that has 
accumulated in the GBM is cleared via phagocytosis by the intra-glomerular 
mesangial cells and the endothelium. Nevertheless, a small amount of protein 
can escape the glomerular filtration barrier and enter into the proximal tubule. 
The vast majority of the protein that enters into the proximal tubule of a healthy 
glomerulus will bind to the epithelial glycocalyx and be absorbed by the proximal 
tubule. This process of reabsorption of protein in the proximal tubule is saturable, 
therefore an unhealthy nephron in which large amounts of protein enter the 
proximal tubule will ultimately allow the protein to pass through the entire 
nephron and be excreted in the urine. This is quite damaging to the nephron.
DETECTING MICROSTRUCTURAL CHANGES TO THE HEPATIC SINUSOID
 The liver is a multifaceted organ, serving to synthesize and store proteins, 
produce bile, and filter blood, among a variety of other functions. Chronic liver 
disease affects a huge number of americans per year and accounts for ~30,000 
deaths per year in the United States alone (National Center for Health Statistics, 
2011). There is a strong likelihood of chronic liver disease progressing to 
cirrhosis in the event that it goes untreated. In the case of cirrhosis, a number of 
serious complications arise, including hepatic encephalopathy, renal failure, and 
hepatocellular carcinoma. Excessive deposition of extracellular matrix (ECM) and 
a loss of endothelial fenestrations (Farrell, Teoh, & Mccuskey, 2008; Friedman, 
2000; Iredale, 2007; Lough, Rosenthall, Arzoumanian, & Goresky, 1987; 
Martinez-Hernandez & Amenta, 1995) are characteristic of advanced chronic 
liver disease and lead to a reduction in plasma access to the liver parenchyma. 
This ultimately yields reduced hepatic function (Friedman, 2000; Iredale, 2007). 
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A non-invasive method for detecting such microstructural changes would prove 
vital in clinical and preclinical diagnostics.
 Chapter 6 of this work will demonstrate a new molecular MRI technique to 
detect microstructural changes to the perisinusoidal space of the liver caused by 
the chronic liver disease non-alcoholic steatohepatitis (NASH). The perisinusoidal 
space is the site of exchange between the blood plasma and the hepatocytes 
and is situated between the hepatocytes and a fenestrated layer of endothelia. 
These fenestrated endothelia serve as a size-selective sieve, allowing plasma 
molecules to enter into the perisinusoidal space to interact with the hepatocytes 
while retaining blood cells in the capillary space (Wisse, 1970). Situated inside of 
the perisinusoidal space is a layer of ECM that regulates cell migration, 
proliferation, differentiation and gene expression (Bedossa & Paradis, 2003; 
Friedman, 2000; Iredale, 2007). The advancement of NASH causes thickening of  
the ECM and a loss of endothelial fenestrations (Farrell et al., 2008; Friedman, 
2000; Iredale, 2007; Lough et al., 1987; Martinez-Hernandez & Amenta, 1995) 
which in turn reduces plasma access to the perisinusoidal space and 
hepatocytes. This is detrimental to hepatic function (Friedman, 2000; Iredale, 
2007).
 NASH is differentiated from the more benign fatty liver disease using 
tissue biopsy. Liver fibrosis can be diffuse and a loss of endothelial fenestrations 
is difficult to detect with using an electron microscope, therefore liver biopsy can 
be subject to sampling errors (Bedossa, Dargère, & Paradis, 2003; Siddique, El-
Naga, Madda, Memon, & Hasan, 2003). Clever imaging techniques such as 
ultrasound elastography and magnetic resonance elastography have been 
developed to diagnose liver fibrosis via detection of viscoelastic changes caused 
by the stiffening of the tissue due to fibrosis (Sandrin et al., 2003; Yeh et al., 
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2002). Despite these excellent new, non-invasive tools that detect gross 
anatomical changes, there remains a strong need to detect changes to 
microstructure that follow the development of chronic liver disease. 
 In Chapter 6 we will investigate the use of CF to detect reduced 
macromolecular access to the perisinusoidal space in a rat model of NASH. We 
will show that intravenously injected CF binds transiently to the perisinusoidal 
ECM in healthy rats, allowing visualization of the perisinusoidal space with MRI. 
Furthermore, we will show that CF accumulation is reduced in animals with 
NASH, suggesting that access of CF to the perisinusoidal space is blocked by 
excess uncharged ECM and abutted endothelia. The reduced accumulation of 
CF is detectable using MRI. Reduced CF accumulation may be an early imaging 
biomarker for changes in macromolecular access to the hepatic parenchyma due 
to structural changes to the endothelium and perisinusoidal ECM.
THE CHAPTERS TO COME
 The following chapters are presented unchanged from their forms 
required for publication.
 Chapter 2 will present the first study to measure glomerular number and 
size with MRI. This will be presented verbatim from our 2011 publication in the 
American Journal of Physiology - Renal Physiology (Beeman et al., 2011). The 
goal of this work was to nondestructively and comprehensively measure Nglom 
and Vglom ex vivo in rat kidneys with MRI. In this study we exploit the negatively 
charged glomerular basement membrane as a target for intravenously delivered 
CF. We will discuss the labeling of the glomerulus with CF and how each 
glomerulus may be identified using T2*-weighted MRI. We will also present a 
method for counting and measuring the size of each labeled glomerulus from the 
MRI volumes.
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 Chapter 3 discusses the extension of the research presented in Chapter 2 
to human transplant kidneys. This work is prepared for publication in the Journal 
of the American Society of Nephrology. The goal of this work is to measure the 
number and size of all glomeruli in human kidneys. In this study fresh human 
transplant kidneys were acquired though a donation network (The International 
Institute for the Advancement of Medicine) within 24 hrs of patient death and 
perfused with CF via the renal artery. In this chapter we will discuss how CF and 
MRI may be used to detect, count, and measure glomeruli in human transplant 
kidneys. This work is intended as a proof of concept that human glomeruli may 
indeed be identified with CF and MRI.
 The work presented in Chapter 4 will discuss the development of a new 
cationized MRI probe for improved detection of kidney glomeruli in vivo. Normal 
CF (like that used in the studies of chapters 2 and 3) is superparamagnetic, 
which creates a dark contrast that is hard to detect above the background of 
blood in vivo. This study sets out to develop a ferritin based paramagnetic probe 
that may be cationized and injected to detect glomeruli in vivo. The goal of this 
work is to render glomeruli as bright spots when labeled with the probe and 
imaged with T1-weighted MRI.
 Chapter 5 will be presented as it appears in our 2012 article published in 
Magnetic Resonance in Medicine (Beeman et al., 2012). The goal of this work 
was to establish the toxicity and biodistribution of intravenously delivered CF. The 
three chapters preceding this one make strong assertions about the prospects of 
using cationized ferritin-based agents for detection of kidney glomeruli both ex 
vivo and in vivo. With the ultimate goal of these chapters being translation of this 
technology to the clinic for assessment of renal health, it is vital to establish an 
understanding of how intravenous CF affects the body. The work presented in 
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this chapter is an investigation of the nephro-, hepato-, and immunotoxicity of 
intravenous CF as well as its clearance rate. We also study a number of organs 
for CF-labeling using MRI and immunofluorescence microscopy.
 Chapter 6 presents a CF-based MRI technique to detect changes in 
plasma access to the perisinusoidal space of the liver in chronic liver diseases 
such as non-alcoholic steatohepatitis (NASH). This work is in review with the 
journal Magnetic Resonance in Medicine. The perisinusoidal space of the liver is 
the site of exchange between the blood plasma and the hepatic parenchyma. 
Chronic liver disease causes excessive deposition of extracellular matrix and 
loss of endothelial fenestrations in the hepatic sinusoid, thereby reducing blood 
access to the perisinusoidal space. In this work we will discuss the application of 
CF as a probe to detect microstructural changes to the hepatic sinusoid in the 
chronic liver disease non-alcoholic steatohepatitis.
 Finally, Chapter 7 will summarize the work presented in this volume and 
discuss the future direction of this work.
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CHAPTER 2
MEASURING GLOMERULAR NUMBER AND SIZE IN PERFUSED KIDNEYS 
USING MRI
INTRODUCTION
 Changes in the number and size of glomeruli have been linked to a number 
of renal and systemic diseases (Brenner et al., 1988; Hoy et al., 2008). However, 
current techniques for counting and measuring glomeruli, such as acid 
maceration (Bonvalet, Champion, Wanstok, & Berjal, 1972) and the disector/
fractionator stereology technique (Bertram et al., 1992), require the destruction of 
the entire kidney. Furthermore, conventional histological techniques extrapolate 
the total number and size of glomeruli from a selected number of histological 
sections or isolated glomeruli. Current techniques are thus estimates rather than 
direct measurements, and do not allow for localization of identified functioning 
glomeruli to specific parts of the kidney. A method for directly and non-
destructively measuring number and size of all glomeruli in the kidney would 
serve as a useful tool in animal studies and potentially in the clinic. 
 Recently we demonstrated that intravenous injections of the iron binding 
protein ferritin, functionalized with cationic amine groups (Danon et al., 1972), 
can be used to detect individual glomeruli both in vivo and ex vivo with  magnetic 
resonance imaging (MRI) (Bennett, Zhou, Sumner, Dodd, Bouraoud, et al., 
2008). This method is based on the electrostatic binding of cationic ferritin (CF) to 
the anionic macromolecules of the glomerular basement membrane (GBM) and 
subsequent perturbation of the magnetic field around the labeled GBM by the 
ferritin, resulting in a decrease in the MRI signal at the location of the glomerulus. 
Here we develop and validate the technique of systemic injection of CF to count 
individual glomeruli and measure individual glomerular size with 3D MRI.  We 
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demonstrate that glomerular counts obtained from 3D MRI volumes are 
consistent with counts obtained with established histological methods, with the 
advantage of retaining the intact kidney.
METHODS
 In vitro preparation and imaging. Cationic ferritin (CF) was synthesized 
by conjugating horse spleen ferritin (Sigma Aldrich, St Louis, MO) to N,N-
Dimethyl-1,3-propanediamine (DMPA) using 1-Ethyl-3(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC), according to Danon et al. (Danon et al., 
1972). Male Sprague-Dawley rats weighing between 215 g and 245 g were given 
3 intravenous bolus doses (11mg/ml in phosphate buffered saline at pH 7.2) of 
5.75 mg/100 g of CF (n=6) or native ferritin (NF) (n=6) with 1.5 hours between 
injections. Kidney were perfused and fixed via transcardial perfusion of PBS 
followed by 10% neutral buffered formalin, then resected and stored in 
glutaraldehyde. All experiments involving animals were carried out according to a 
protocol approved by the Arizona State University Institutional Animal Care and 
Use Committee.  The perfused left kidneys were imaged in glutaraldehyde on a 
Varian 19T 89 mm bore NMR (Varian, Inc. Palo Alto, CA), equipped with a DOTY 
3-axis imaging probe and a gradient with a maximum strength of 300 G/cm 
(DOTY Scientific, Inc. Columbia, SC).  Scans were acquired with a 3D gradient 
echo (GRE) sequence with TE/TR = 7/40 ms and a resolution of 62x62x78 µm. 
Total scan time was 6 hours per kidney. 
 Post-processing. Labeled glomeruli in the 3D MRI dataset were counted 
using custom software written in Matlab (The Mathworks, Inc.). A bicubic 
interpolation method was used to resize the 3D MRI datasets and change the 
spatial resolution to 31x31x62 µm. Spatial signal magnitude gradients were then 
calculated to extract any dramatic spatial changes in signal magnitude 
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throughout the volume. Voxels exceeding a signal magnitude difference of 0.11, 
on a signal magnitude scale of 0 to 1, defined regions to be included in following 
operations. Regional minima were located in these areas using an upper signal 
magnitude threshold of 0.4, based on a signal magnitude scale of 0 to 1. Regions 
considered to be glomeruli were then defined based on morphological 
thresholds, assuming that a glomerulus is approximately spherical. A watershed 
transform was computed on these regions to distinguish individual glomeruli 
where signal overlap of multiple glomeruli might occur (Bernardis & Yu, 2010; 
Meyer, 1994; Roerdink & Meijster, 2000).
 MRI-based apparent glomerular volume measurements were made based 
on the number of voxels per glomerulus isolated by the counting algorithm 
multiplied by the post-interpolation voxel dimensions (31x31x62 µm). A superior 
threshold of 64 voxels per glomerulus (38x10-4 mm3 or a glomerular diameter of 
194 µm) was set to eliminate possible ‘false’ glomeruli. Glomeruli containing less 
than 64 voxels were included in the results. We have defined glomerular volumes 
measured using the MRI-based technique as “apparent glomerular volume” 
because the relationship between amount of CF accumulated in the GBM and 
the volume of susceptibility is yet unresolved in this system.
 Histology. We performed two techniques to validate the MRI-based 
measurements of glomeruli: 1) acid maceration and counting and 2) stereology. 
Acid maceration was based on techniques established in the literature (Bonvalet 
et al., 1972). Briefly, kidneys were cut into 1 mm3 pieces immediately after 
resection and incubated in 5 ml of 6 N HCl for 1.5 hours. Incubated tissue was 
crushed and strained until homogenous. The solution was then brought up to 30 
ml with deionized water. Glomeruli in solution were counted in a counting 
chamber (1 mm2 scored 35 mm culture dish, Nunclon delta). The total number of 
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nephrons for each kidney was calculated based on the average number of 
glomeruli per area. 
 Stereology was performed on two kidneys. Serial sections of the left 
(imaged) kidneys were sampled and individual glomeruli across serial sections 
were compared and measured using the physical disector/fractionator method as 
previously described (Bertram et al., 1992).
 Statistics. All statistical analyses comparing the MRI and acid maceration 
or stereological measurements from each respective animal were run as paired 
two-tailed Student’s t-tests to test the null hypothesis that the mean difference 
between pairs is zero at the significance level α = 0.05 (The Mathworks, Inc. 
Natick, MA).
RESULTS
 Excised, perfused kidneys were imaged after systemic CF or NF injections. 
T2*-weighted 3D gradient echo MR images of the kidneys showed dark MRI 
signal at the location of glomeruli after CF injections, but not after NF injections. 
The specific binding of CF, but not NF, was previously confirmed with 
immunofluorescence and electron microscopy (Bennett, Zhou, Sumner, Dodd, 
Bouraoud, et al., 2008). 
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Figure 2.1. Whole-kidney identification of individual glomeruli. A representative 
axial kidney image from a 3D MRI dataset from a CF-injected animal is shown 
(A). The data were analyzed with a 3D counting algorithm to identify glomeruli. 
Regions defined as glomeruli by the computational 3D counting algorithm were 
assigned an arbitrary color exclusively for visualization purposes (B).
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 Figure 2.1 shows the results of an automated 3D segmentation algorithm 
to identify individual glomeruli. In the figure, identified glomeruli are arbitrarily 
colored in axial slices of the 3D images of perfused, excised kidneys of CF-
injected rats (Fig. 2.1B). Counting of CF-labeled glomeruli from 3D MRI datasets 
yielded 33,786±3,753 glomeruli (n=5). One kidney was removed from group 
analyses as an outlier due to erratic stereological and imaging measurements 
(Table 2.1).  The same counting algorithm yielded 1,916±806 nephrons from 3D 
MRI datasets of kidneys from NF-injected rats (n=6). Acid maceration counting of 
contralateral kidneys from CF-injected rats yielded 30,585±2,053 glomeruli (n=6). 
The disector/fractionator stereology yielded counts of 35,421 and 34,504 
glomeruli, compared to MRI-based counts in the same kidneys of 32,789 and 
35,203 glomeruli, respectively. Paired two-tailed Student’s t-tests to test the null 
hypothesis that the mean difference between pairs is zero showed that there 
were no significant differences between glomerular counts from the MRI-based 
method and from the acid maceration or stereological methods (at the 
significance level α = 0.05).  Counting results of all CF-injected rats are reported 
in Table 2.1. False positives counted in the control kidneys indicate a counting 
error of approximately 2,000 extra glomeruli per kidney, or ~5.5% error. 
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Table 2.1
The number of labeled glomeruli and apparent glomerular volumes (Vglom) 
measured with the MRI-based technique, compared to the values obtained with 
acid maceration and stereology.
 
   Stereology MRI MRI
MRI Maceration Stereology Vglom Av IVglom IVglom SD
# # # mm3 x 10-4 mm3 x 10-4 mm3 x 10-4
Rat A 32,789 27,504 34,504 5.01 5.2 4.87
Rat B 35,203 31,190 35,421 4.98 4.58 4.3
Rat C 31,772 31,075 - - 4.07 3.4
Rat D 39,482 33,321 - - 5.7 4.92
Rat E 29,682 31,478 - - 4.89 4.33
Mean 33,786 30,914 34,963 4.99 4.89 4.36
SD 3,753 2,112 648 0.02 0.62 0.61
Outlier 37,625 28,944 24,156 8.37 9 7.28
Table 2.1. Measurements of intra-renal standard deviation in apparent glomerular 
volumes are unique to the MRI-based glomerular counting technique. One kidney 
was removed from group analyses (labeled ‘outlier’) due to erratic stereological 
and imaging measurements. Vglom, mean glomerular volume; Av IVglom, the 
average apparent glomerular volume of all individual glomeruli in a kidney; IVglom 
SD, the standard deviation of apparent glomerular volumes of all glomeruli in a 
kidney; SD, standard deviation. 
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 Individual apparent glomerular volumes were calculated based on the 
number of voxels per individual glomerulus and the voxel dimensions. Apparent 
volume measurements of labeled glomeruli using the MRI-based technique 
yielded 4.89x10-4 mm3 (n=5), compared to stereological volume measurements 
of 4.99x10-4 mm3 (n=2). Using the MRI-based technique, we were also able to 
calculate the intra-renal standard deviation of apparent glomerular volumes.  This 
measurement is not obtained by stereology because the average glomerular 
volume measured using stereology is based on the extrapolated total volume of 
glomeruli divided by the extrapolated total number of glomeruli per kidney.  
Glomerular volumes are reported in Table 2.1 and volume distributions are 
shown as a histogram in Figure 2.2.
DISCUSSION
 In this work we have developed a nondestructive method for measuring 
nephron number based on the accumulation of CF in the GBM. There were 
insignificant systematic differences between MRI-based measurements and 
measurements obtained with acid maceration and stereology. MRI-based counts 
yielded slightly more glomeruli than acid maceration and slightly fewer than 
stereology.  Over counting is due to the identification of non-glomerular regions 
that are of similar signal magnitude and shape of glomeruli.  This error is 
observed in the measurement of ~2,000 glomeruli per kidney in unlabeled 
kidneys.
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Figure 2.2. Histogram of apparent glomerular volumes in the kidneys of 5 rats 
from 3D MRI data. Apparent glomerular volumes were measured from 3D 
magnetic resonance images based on the number of image voxels in a 3D 
cluster considered glomerular, multiplied by the imaging voxel dimensions. 
Average measured apparent glomerular volume was 4.89x10-4 mm3 ± 0.617x104. 
Error bars show mean ± SD between 5 rats.
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 We note that both of the established techniques for counting glomeruli, 
and thereby nephrons, are based on extrapolations of a limited number of counts 
to the entire kidney, while the MRI-based technique counts all glomeruli in the 
entire kidney. The MRI-based technique is advantageous for measuring 
glomerular volume because the volume of each labeled glomerulus in the entire 
kidney is measured and recorded. The intra-renal distribution of apparent 
glomerular volumes is a potentially new parameter for investigation.   
 While our average apparent glomerular volume measurements compare 
well to the volumes measured using stereology, care should be taken when 
interpreting glomerular volumes measured using MRI and superparamagnetic 
agents such as CF, as the volume of magnetic susceptibility may be dependent 
upon the amount and the manner in which the agent accumulates in the GBM. 
Thus, we have defined the MRI-based glomerular volume measurements as 
“apparent glomerular volume” to address the uncertainty of the origin of this 
measurement. The strong correlation between MRI-based measurements of 
apparent glomerular volume and those from stereology suggests that the fringe 
field of the accumulated CF does not extend beyond the glomerulus. It is likely 
that larger superparamagnetic particles of higher relaxivity would not be suitable 
for such measurements due to a larger fringe field.  
The magnetic field strength of the MRI scanner should also be taken into 
consideration when making these measurements.  While we have seen adequate 
labeling of glomeruli with a 5.75 mg/100g dose of CF at 7T (data not shown), it 
should be noted that the effects of CF accumulation on signal decrease with field 
strength.  This means that greater doses of CF or particles of higher relaxivity 
may be required for visualization of glomeruli at fields less than 7T. Magnets of 
lower field strength may achieve the same spatial resolution, though this may 
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require improved RF probes built specifically for kidney imaging. Conversely, 
magnets of higher field strength have their own unique challenges, including B1 
inhomogeneities and substantial RF deposition into tissue. While unnecessary in 
the present study due to the small size of the kidneys imaged, corrections to the 
B1 field and RF coils may be required to image larger kidneys at high fields.
 One potential complication of MRI-based counting is the possibility that CF 
labels only functioning glomeruli, or that labeling of glomeruli may be affected by 
disease. Indeed, our recent work demonstrated that CF labeling of the GBM is 
affected by early- and late-stage puromycin-induced glomerulosclerosis (Bennett, 
Zhou, Sumner, Dodd, Bouraoud, et al., 2008).  These effects may be focal or 
global, depending on the nature of the disease. Care must be taken to establish 
the effectiveness of MRI-based counts in any animal disease model. In addition, 
while MRI is faster and less labor intensive than stereological techniques, it 
requires both clean anatomical perfusion to avoid MRI artifacts from blood in the 
excised kidney as well as significant expertise in scanner operation. There is 
room for significant improvements in MRI acquisition strategies to reduce 
sensitivity to artifacts and shorten scan times via improvements in pulse 
sequence and acquisition design. 
While this work has focused on labeling and measuring glomeruli ex vivo, 
this is a first step in establishing whole-kidney nephron measurements in vivo.  
We have shown in previous work (Bennett, Zhou, Sumner, Dodd, Bouraoud, et 
al., 2008) that labeled glomeruli may be detected in vivo using the same labeling 
and MRI techniques. Future work will be focused on establishing the optimum 
dose of CF required to detect individual glomeruli in vivo, and overcoming partial 
volume effects due to decreased resolution to achieve reasonable in vivo scan 
times. Furthermore, thorough in vivo toxicity screens of CF will be required if this 
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technique is to be used as an in vivo tool for assessment of renal health. Initial 
toxicology suggests that intravenously delivered CF is not acutely toxic, though 
these studies are ongoing. Nonetheless, in vivo measurements of nephron 
number and single glomerular function could be important for longitudinal studies 
of focal and segmental renal diseases and to monitor the progress of therapy.
 Conclusions. We conclude that the MRI-based technique is capable of 
measuring the number and apparent size of individual glomeruli in 3D and yields 
comparable results to established methods. This result, along with previous in 
vivo detection of glomeruli with MRI, suggests the possibility of measuring 
glomeruli in living animals and in the clinic. To the best of our knowledge, this is 
the first report of a technique to nondestructively measure every glomerulus in 
the whole kidney. 
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CHAPTER 3
DETECTING, COUNTING, AND MEASURING THE SIZE OF GLOMERULI IN 
HUMAN TRANSPLANT KIDNEYS - A PROOF OF CONCEPT
INTRODUCTION
 The goal of this work is to count the number (Nglom) and measure the 
volume (Vglom) of every glomerulus in human kidneys with magnetic resonance 
imaging (MRI). Changes in the number and size of glomeruli have been linked to 
~ 90% of all chronic renal diseases as well as systemic diseases including 
diabetes and hypertension (Brenner et al., 1988; Puelles et al., 2012). 
Unfortunately, current histological methods to assess Nglom and Vglom require 
resection and destruction of the entire kidney and merely extrapolate 
measurements from small sample populations (Bertram et al., 1992). These 
techniques are neither clinically viable due to their destructive nature nor 
comprehensive in their assessment of Nglom and Vglom in preclinical research. 
A method to assess Nglom and Vglom in humans that is 1) non-invasive and 2) 
comprehensive (measures every glomerulus) would prove invaluable to clinicians 
and preclinical scientists alike.
 Recently it has been shown that Nglom and Vglom may be measured ex 
vivo by simply injecting the extracellular matrix (ECM) specific cationic ferritin 
(CF) probe and imaging with MRI (Beeman et al., 2011; Bennett, Zhou, Sumner, 
Dodd, Bouraoud, et al., 2008; Heilmann et al., 2012). This method shows 
promise for application in humans as it does not require destruction of the kidney 
and identifies and measures every CF-labeled glomerulus in the kidney. CF is the 
cationized version of the iron-binding ferritin protein which, due to its endogenous 
origins, exhibits minimal toxic effects at MRI-detectable doses (Beeman et al., 
2012). These previous studies have exploited the anionic proteoglycans of the 
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glomerular basement membrane (GBM) to bind CF. The superparamagnetic iron 
oxide core of the protein to induce local proton de-phasing (MRI-signal 
darkening) in regions where CF has accumulated. Since CF specifically 
accumulates in the GBM, all perfused glomeruli in the kidney are rendered MRI-
visible after intravenous injection of CF. Here we propose to adapt this same 
technique to count every glomerulus in human transplant kidneys.
 This work is presented as a proof of concept that human glomeruli may 
be targeted by a molecular imaging probe and subsequently detected with 3D 
MRI. Furthermore, we will show that, once glomeruli have been imaged, a 
number of glomerulus-specific measurements may be made including glomerular 
number and size.
METHODS
 Sample preparation. Cationized ferritin (CF) was synthesized according 
to Danon, et al. (Danon et al., 1972). Four human kidneys were acquired though 
a donation network (The International Institute for the Advancement of Medicine). 
Kidneys were received in University of Wisconsin preservation solution within 24 
hours of donor death. Kidneys were viable organs throughout the procedure, up 
until formalin fixation. The renal artery of three of the kidneys (one from a male, 
two from females) was catheterized and the kidney was perfused with phosphate 
buffered saline (PBS), then a 44 mg of CF in PBS, then PBS, then formalin. The 
fourth kidney was prepared in the same way but remained naive to CF (control). 
~ 1 mm3 tissue biopsies were taken from the renal cortex from each kidney and 
prepared for immunofluorescence microscopy (detailed below). All kidneys were 
stored in 10% neutral buffered formalin.
 MRI. Prior to imaging, kidneys were removed from formalin storage and 
washed three times in 500 ml PBS. The kidneys were then imaged using a 
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Bruker 7T/35 MRI scanner and a 72-mm quadrature transmit/receive radio 
frequency coil (Bruker, Billerica, MA). A T2*-weighted (TE/TR = 20/39 ms) three-
dimensional gradient echo fast low angle shot (FLASH) sequence was used to 
image the entire kidney. MRI volumes were acquired with a 117x117x117 µm 
resolution (field of view = 6x6x10.5 cm, matrix size = 512x512x896, 5 averages, 
total scan time = 10 hr 39 min).
 Immunofluorescence. ~ 1 mm3 tissue biopsies were taken during 
sample preparation (described above). The biopsies were placed in 10% neutral 
buffered formalin for four hours. Then washed in PBS overnight. Samples were 
then cryoprotected in sucrose, rapidly frozen, and sectioned at 35 µm. Sections 
were washed in PBS, permeablized, incubated in rabbit anti-horse spleen ferritin, 
an Alexa594 goat anti-rabbit secondary antibody and 4’,6-diamidino-2-
phenylindole (Invitrogen), and imaged on a Zeiss 710 laser scanning confocal 
microscope.
 Image processing. Nglom and Vglom were measured from the MRI 
volumes using custom software written in MATLAB (The Mathworks, Natick, MA). 
Briefly, we derived the Hessian matrix for each voxel in the volume. This matrix 
describes the ‘curvature’ of each voxel based on its magnitude value relative to 
its neighbors’. This algorithm robustly detects the centroid voxels of glomeruli 
(assumed to be the darkest voxel of a single glomerulus) and their surrounding 
‘glomerular’ voxels . Voxels that constitute a glomerulus are the clustered using a 
gaussian mixture model. Minimum and maximum size thresholds were then 
placed at 1 voxel and 16 voxels, respectively, as it was assumed that human 
glomeruli would be no less than 1.60x106 µm3 and no more than 25.6x106 µm3.
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RESULTS
 CF-labeled, fixed human kidneys were imaged on a 7T MRI scanner. MRI 
imaging of the human kidneys perfused with CF revealed punctate spots of 
signal darkening (Fig. 3.1 A and C). Each dark spot represents a single 
glomerulus and is caused by the accumulation of the superparamagnetic CF in 
the glomerular basement membrane. The control kidney showed no such spots 
(Fig. 3.1 B). The specific binding of CF to the glomerulus was confirmed with 
immunofluorescence microscopy (Fig. 3.1 D and E). 
 Our algorithm was able to identify labeled glomeruli in the MRI volumes of 
CF-inoculated kidneys (Fig. 3.1D). In this figure, glomeruli identified by the 
algorithm are assigned an arbitrary color for the purpose of distinguishing 
neighboring glomeruli from one another.  The total number of regions defined as 
glomeruli by the algorithm was then tallied to yield total glomerular number 
(Nglom). This yielded a count of 772,922 glomeruli for the kidney from the male, 
and 328,181 and 702,506 for the two kidneys from the females. These numbers 
are consistent with those reported in the literature (Nyengaard & Bendtsen, 
1992).
 FInally, the apparent volume of each glomerulus may be measured based 
on the number of voxels composing each region defined as a glomerulus 
multiplied by the voxel dimensions. Using this method, we report glomerular 
volumes of 8.0x106 ± 4.28x106 µm3 for the kidney from the male, and 6.9x106 ± 
3.9x106 µm3 and 6.8x106 ± 2.9x106 µm3 for the two kidneys from the females. 
These volumes are consistent with those reported in the literature (Nyengaard & 
Bendtsen, 1992).
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Figure 3.1. MRI of a CF-labeled human kidney reveals punctate dark spots 
throughout the organ. Each spot represents a single glomerulus (A and C). A 
control kidney showed no such spots (B). Immunofluorescence confirmed the 
accumulation of CF (red) in glomeruli of CF inoculated kidneys (D). Naive control 
glomeruli remained clear of CF-related immunofluorescence (E). Each 
glomerulus may be identified and counted in the entire kidney (F).
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Figure 3.2. Histogram of apparent glomerular volume distribution of a CF-
inoculated kidney from a human male. Since the MRI-based method for counting 
glomeruli measures every labeled glomerulus in the kidney, this new method 
presents a unique opportunity to assess the distribution of glomeruli defined by 
their size. The average ± the standard deviation of glomerular sizes measured in 
this kidney was 8.0x106 ± 4.28x106 µm3.
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DISCUSSION
 In this work we set out to show that human glomeruli may be labeled with 
the MRI-visible, naturally derived cationized ferritin (CF) probe and subsequently 
visualized, counted and their sizes measured using MRI. Immunofluorescence 
confirmed that CF binds specifically to the glomerulus and T2*-weighted MRI 
confirmed that the labeled glomeruli are MRI-detectable. Once imaged with MRI, 
we were then able to identify, count, and measure the size of every glomerulus in 
these fresh human transplant kidneys. This MRI-based technique for measuring 
Nglom and Vglom in human kidneys also allows for assessment of the intra-renal 
glomerular volume distribution - a parameter exclusive to this technique that will 
allow glomerular populations defined by size to be correlated with renal and 
systemic diseases. As an example, a histogram of the intra-renal glomerular 
volume distribution in the kidney from the male donor is presented in figure 3.2.
 In our previous works that first established this MRI-based technique we 
used the disector/fractionator method for validation (Beeman et al., 2011). We 
have elected to forgo this process in the current work because 1) the above 
mentioned work has already validated the technique in rodents and 2) our 
method is the only method to date that allows for identification of every 
glomerulus in the kidney. It is this second point that raises this potentially 
controversial question: Have prior histological techniques, which extrapolate 
Nglom and Vglom for only 30 - 40 sampled glomeruli, really yielded accurate 
results in human kidneys? Though the chances are slim, there exists a real 
possibility that these histological methods are inaccurate. We assert here that the 
MRI-based technique is the only way to identify, count, and measure every 
glomerulus in the kidney and should therefore not be bound by the assumptions 
made in prior histological techniques that merely extrapolate these 
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measurements. This work presents the unique opportunity to retrospectively 
assess the accuracy of the previous histological techniques for measuring Nglom 
and Vglom.
 Conclusions. These results, along with previous in vivo detection of 
glomeruli and counts made in the rat, suggest the possibility of counting 
glomeruli in the clinic.
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CHAPTER 4
A HIGH T1-RELAXIVITY NANOPARTICLE FOR IN VIVO MRI-DETECTION OF 
GLOMERULI
INTRODUCTION
 The goal of this work is to develop a non-invasive, MRI-based method for 
detecting kidney glomeruli in vivo. A single human kidney has between 200,000 
and 2,000,000 nephrons which are responsible for maintaining homeostasis by 
balancing blood ion and glucose concentrations and blood pH levels. Each 
nephron begins with a single glomerulus that serves as a filter to retain blood 
cells and vital macromolecules in the blood stream while allowing smaller plasma 
constituents to pass from the capillary space into the nephron tubule. In the 
tubule small plasma molecules and water are either reabsorbed into the blood 
stream or expelled in the form of urine. 
 Diabetes, obesity, and hypertension are strongly linked to a low number of 
glomeruli (Nglom) (Brenner et al., 1988) and the volume of glomeruli (Vglom) has 
been linked to ~ 90% of chronic kidney diseases (CKD) (Puelles et al., 2012). 
Furthermore, recent evidence suggests that ~ 88% of of patients with Type 2 
diabetes (a patient population known to be at risk for CKD) also have a case of 
undiagnosed CKD . The insensitivity of current techniques to the early loss of 
healthy glomerular filtration surface area is a contributing factor to the poor rate 
of CKD diagnosis (Cullen-McEwen, 2003). It is likely that the number of patients 
requiring dialysis or kidney transplant could be greatly reduced if there existed a 
more robust method for detecting the early stages of CKD. There are already 
excellent histological techniques for measuring Nglom and Vglom but these 
techniques require resection and destruction of the entire organ (Bertram et al., 
1992) - a procedure that is not clinically applicable. 
39
 Previous works have shown that Nglom and Vglom may measured ex 
vivo using intravenous injection of the MRI-visible cationized ferritin (CF) 
nanoparticle and magnetic resonance imaging (MRI) (Beeman et al., 2011; 
Bennett, Zhou, Sumner, Dodd, Bouraoud, et al., 2008; Heilmann et al., 2012). 
When injected intravenously in vivo, CF will bind specifically to the anionic 
proteoglycans of the glomerular basement membrane (GBM). Each perfused 
glomerulus is rendered visible with T2*-weighted MRI when CF-inoculated 
kidneys are imaged ex vivo. CF-labeled glomeruli may then be identified and 
their number and size measured from the MRI volumes using custom image 
processing software. This new technique is the first to measure all glomeruli in a 
kidney and has opened the door to the in vitro study of glomerular populations 
defined by their size and location in the kidney.
 The ability to detect glomeruli in vivo would certainly serve a strong 
clinical purpose. CF has been shown to be non-toxic at MRI detectable doses 
(Beeman et al., 2012) and previous work has shown in vivo detection of glomeruli 
with CF and MRI to be possible, though quite difficult (Bennett, Zhou, Sumner, 
Dodd, Bouraoud, et al., 2008). It is difficult because the iron core of CF yields 
signal darkening when it accumulates in the glomerulus. When imaged in vivo, 
the contrast agent must compete against the blood background which also 
causes signal darkening. A paramagnetic agent that yields a bright signal but 
otherwise behaves in the same manner as CF when injected would certainly 
make in vivo imaging of the kidney glomerulus a simpler task and would 
potentially lower the required dose of contrast agent to detect glomeruli.
 The ferritin protein is quite versatile when applied as a MRI contrast 
agent. It has been shown that apoferritin, the empty version of ferritin, may be 
loaded with iron in vitro to create a T2 MRI contrast agent that is 100-times more 
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detectable than native ferritin (Bulte et al., 1994; Clavijo Jordan et al., 2010). 
More recent we have developed a high relaxivity, paramagnetic T1 MRI contrast 
agent inside of the ferritin protein shell, thereby allowing for brightened signal 
when imaged with T1-weighted MRI. This is accomplished by doping the iron core 
of the ferritin protein with tungsten. This tungsten-iron loaded (WFe) ferritin 
nanoparticle is detectable with T1-weighted MRI at concentrations as low as 25 
nM. The goal of this work is to detect kidney glomeruli in vivo by cationizing WFe 
ferritin, injecting the cationized WFe ferritin (hereby referred to as paramagnetic 
cationized ferritin, or paraCF), and imaging the kidneys with T1-weighted MRI.
METHODS
 Loading the apoferritin core. 48mM FeCl2 was added at a rate of 
12.5µl/min to a 2µM solution of apoferritin in an oxygen free environment using a 
syringe pump for a total of 140 minutes. 50 minutes into FeCl2 pumping, 48mM 
Na2WO6 was added at a rate of 12.5µl/min using a syringe pump for a total of 40 
minutes. A total of 1.75ml of FeCl2 and 500µl of Na2WO6 was added to the 
protein solution. 200µl of 300mM sodium citrate was then added to the solution to 
chelate any remaining metal ions. The solution was the sonicated and 
centrifuged for 10 minutes at 957·g then dialyzed overnight against 3L of de-
ionized water. Once dialyzed, the protein solution was filtered using 0.8µm and 
0.2µm surfactant free cellulose acetate syringe filters to rid the solution of coarse 
non-specific metal oxides. A total tungsten and iron-loaded (WFe) ferritin protein 
concentration was obtained with a Coomassie Plus Bradford Assay Kit and 
inductively coupled plasma – optical emission spectroscopy (ICP-OES) was used 
to measure metal concentrations.
 Cationization of WFe ferritin. WFe ferritin was cationized by coating its 
surface with amine groups via a carbodiimide conjugation of N,N-Dimethyl-1,3-
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propanediamine (DMPA) to the carboxyl groups of the ferritin surface using 1-
Ethyl-3(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC). This process 
has been detailed by Danon, et al. (Danon et al., 1972) and in our previous works 
(Beeman et al., 2011; 2012). The resulting cationized WFe ferritin will hereby be 
referred to as paraCF. Once the cationization process was complete, the 
resulting paraCF solution was dialyzed against phosphate buffered saline (pH = 
7.2) and concentrated to 11 mg paraCF per ml of PBS.
 Animal preparation and imaging. ParaCF was injected intravenously to 
three male sprague-dawley rats at a dose of 4.4 mg/100 g. Three rats remained 
un-injected as naive controls. Rats were imaged in vivo at 7T with a 2D T1-
weighted gradient echo MRI pulse sequence using a custom built, kidney-specific 
radio frequency coil (TE/TR = 10/54 ms, resolution = 117x117x400 µm), then 
sacrificed and fixed by transcardial perfusion of PBS followed by 10% neutral 
buffered formalin. Right kidneys were be prepared for immunofluorescence 
histology.
 Immunofluorescence. Once resected, right kidneys were bathed in 10% 
neutral buffered formalin for three hours, then washed in PBS overnight. Kidneys 
were then bathed in 15% sucrose, then 30% sucrose until fully infiltrated. Once 
cryoprotected by sucrose, kidneys were embedded in optimal cutting 
temperature (OCT) medium and rapidly frozen to -80 °C. Frozen kidney were 
sectioned at 35 µm on a cryostat (Leica Microsystems CM3050 S, Buffalo Grove, 
IL). Sections were thoroughly washed in PBS, permeablized, blocked in bovine 
serum, and incubated in a rabbit anti-horse ferritin (1:500) primary antibody 
(Invitrogen). Sections were then thoroughly washed and incubated in an 
Alexa594 goat anti-rabbit secondary antibody and 4’,6-diamidino-2-phenylindole 
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(Invitrogen). Sections were mounted and imaged with a Zeiss 710 laser scanning 
confocal microscope.
 Data analysis. Signal changes in the renal cortex due to the 
accumulation of paraCF in glomeruli was quantified by normalizing the mean 
signal magnitude in the renal cortex of paraCF-inoculated and naive rats to the 
mean signal magnitude of the muscle surrounding the rat’s spine. This is an 
effective method for quantifying the effects of CF accumulation as it does not 
accumulate in muscle. Normalized signal magnitude values in paraCF-injected 
rats was compared to that of naive controls using a two-tailed Student’s t-tests (α 
= 0.05) (The Mathworks, Inc. Natick, MA).
RESULTS
 In vivo detection of glomeruli. 1% agarose phantoms were used to 
establish the MRI-detectability of tungsten and iron loaded (WFe) ferritin. WFe 
ferritin was found to be detectable at concentrations as low as 25 nM (Fig. 4.1 a) 
and, when injected into the striatum, was found to be detectable in vivo at a 
concentration of 195 nM (Fig. 4.1 b and c) using a T1-weighted gradient echo 
sequence at 7T. The presence of WFe ferritin reveals itself as bright signal in T1-
weighted MRI and shortens T1 by approximately 22% compared to the 
contralateral control striatum.
 WFe ferritin was then cationized (paraCF) and injected intravenously into 
healthy rats. T1-weighted gradient echo MRI revealed signal enhancement in the 
renal cortex of paraCF-injected animals (Fig. 4.1 d). No such enhancement was 
seen in the renal cortex of naive controls (Fig. 4.1 e). An ~ 50% increase in MRI 
signal magnitude was observed in the renal cortex of paraCF-injected rats 
compared to naive controls (when the signal magnitude of the renal cortex is 
normalized against that of muscle) (Fig. 4.1 f and g).
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Figure 4.1. WFe nanoparticles are detected in vivo with T1-weighted MRI. a) 2D 
Gradient Echo T1-weighted image of a 1% agarose phantom. Increasing 
concentrations of WFe-apoferritin result in increased positive image contrast.  b) 
3D Gradient Echo T1-weighted image of an in vivo inoculation of 8ul of 195nM 
WFe nanoparticles and native ferritin into a rat striatum. c) T1 map color overlay 
showing an average T1 for each ROI at the injection sites. The injection of WFe 
nanoparticles resulted in an average T1 that was 22% shorter than the 
contralateral ROI. d) In vivo intravenous injection of paraCF labeling kidney 
glomeruli, spleen, and liver. e) Control image of a rat in vivo with no injection of 
agent. f) Thresholded image of paraCF labeled and, g) no injection of agent. 
Highlighted in red are pixels with intensities 50% higher than background muscle 
tissue, insets show cortex of paraCF kidney and control kidney. It is clear that the 
kidney is labeled with paraCF showing evident hyperintensities, while control did 
not show significant enhancement over background. 
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Figure 4.2. Confocal microscopy of a paraCF-labeled kidney glomerulus and a 
control glomerulus. ParaCF is labeled with a red fluorophore and cell nuclei are 
labeled with blue DAPI. A ribbon of red fluorescence was observed in the 
glomerulus in sections of paraCF-inoculated kidneys but not naive controls, 
indicating that paraCF is bound to the glomerulus. Scale bar = 20 µm.
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 Immunofluorescence. ParaCF-inoculated and naive control kidneys 
were sectioned and stained with an anti-ferritin antibody, which was then labeled 
with a red fluorophore. When imaged using a confocal microscope, a ribbon of 
red fluorescence was observed in the glomerulus in sections of paraCF-
inoculated kidneys but not naive controls (Fig. 4.2). The ribbon of red observed in 
paraCF-inoculated kidneys is consistent with the distribution of the GBM in the 
glomerulus, indicating that intravenously delivered paraCF specifically targets the 
GBM. It is this accumulation of paraCF in the glomerulus that yields in vivo 
visualization of glomeruli when imaged wit T1-weighted MRI.
DISCUSSION
 In this work we have shown that tungsten-iron loaded (WFe) ferritin, a 
highly detectable T1 nanoparticle, may be cationized to produce a new targeted 
nanoparticle called paraCF (paramagnetic cationized ferritin).  Regular cationized 
ferritin is superparamagnetic and causes spin dephasing at the site of 
accumulation and a dark MRI signal. Unfortunately, this accumulation of CF is 
difficult to visualize in vivo in highly vascularized organs like the kidney because 
of the competing dark blood background. The paramagnetic nature of paraCF, on 
the other hand, causes signal brightening at its binding site. We have shown that 
paraCF can be used to detect glomeruli in vivo using T1-weighted MRI and that 
its bright signal enhancement is easily visualized against the blood background 
of the kidney.
 In vivo visualization of glomeruli with paraCF requires one quarter of the 
dose for detection compared to the studies in which glomeruli were labeled with 
regular CF and imaged in vivo. In fact, the high r1 relaxivity of paraCF may allow 
for the dosage necessary to detect glomeruli in vivo to be reduced as much as 
20-fold compared to regular CF. Though regular CF has already been shown to 
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have minimal effects on renal, hepatic, and immune function at MRI detectable 
doses (Beeman et al., 2012), the ability to reduce the dosage of contrast agent 
will only be beneficial to the translation of cationized ferritin-based agents from ex 
vivo applications to preclinical and clinical diagnostics. 
 The resolution required to image individual glomeruli in humans is 
approximately 117 µm3 (see Chapter 3). This is an unlikely in vivo resolution due 
to the lower signal-to-noise ratio of in vivo MRI. At a more likely resolution, say 1- 
2 mm3, there would be approximately 10 to 20 glomeruli within a single voxel. 
While outside of the scope of this work, T1-weighted MRI may be used to 
dynamically monitor the uptake of paraCF in the glomerulus in vivo. By 
monitoring the rate at which paraCF accumulates in vivo in a single voxel 
containing multiple glomeruli we believe that MRI and paraCF can be used to 
measure either total glomerular filtration surface area or the total glomerular 
filtration rate (GFR) within a single voxel. This hypothesis is discussed further in 
Chapter 7.
 Conclusions. The goal of this work was to develop a glomerulus-specific 
MRI contrast agent that can be easily detected in vivo. Regular cationized ferritin 
has a superparamagnetic core that is difficult to detect above the dark blood 
background in highly vascularized organs. We have shown that the metallic core 
of ferritin may be modified with a tungsten dopant that blocks the exchange 
coupling within the metallic core of the protein. This renders the tungsten-doped 
ferritin highly paramagnetic. We go on to show that the paramagnetic tungsten-
doped ferritin may be cationized to form a new targeted MRI contrast agent 
called paramagnetic cationized ferritin (paraCF). We show that, when 
administered intravenously, paraCF binds to the glomerular basement membrane 
with high specificity and renders glomeruli MRI-visible. This highly detectable, 
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glomerulus-specific paramagnetic nanoparticle may be used to dynamically 
detect glomerular structure and function in vivo on a spatial scale that has 
previously been impossible.
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CHAPTER 5
TOXICITY, BIODISTRIBUTION, AND EX VIVO MRI DETECTION OF 
INTRAVENOUSLY INJECTED CATIONIZED FERRITIN
INTRODUCTION
The extracellular matrix (ECM) plays a vital role in development and 
structural integrity of tissue throughout the body and is crucial for cell signaling, 
proliferation, and apoptosis (Adams & Watt, 1993; Boudreau, Werb, & Bissell, 
1996; Rana, Mischoulon, Xie, Bucher, & Farmer, 1994; Sanes, 1983; 1989; 
Schindler et al., 2006). The ECM is exposed directly to circulation in a number of 
organs, functioning as a filter or as a site for macromolecular diffusion into the 
parenchyma. Sulfated, anionic proteoglycans, which are common molecular 
components of the ECM, associate with structural macromolecules such as 
collagen, forming part of the network that supports cells of varying types. 
Because of the functional nature of the ECM in development and maintenance of 
a healthy system, the ability to monitor the structure and function of the ECM 
may be important for basic noninvasive biological and toxicology studies and 
potentially in the clinic.
Ferritin, a superparamagnetic iron storage protein, is useful as an MRI 
contrast agent because of its small size (13 nm in diameter) and ease of 
functionalization. The payload of the ferritin molecule can be readily modified to 
increase the MRI relaxivity (Bulte et al., 1995; 1994; Clavijo Jordan et al., 2010; 
Meldrum, Heywood, & Mann, 1992). Cationized ferritin (CF), a chemically 
modified version of native ferritin, was originally proposed as an electron-dense 
label for electron microscopy of tissue (Danon et al., 1972) and has been further 
developed as a superparamagnetic contrast agent for imaging of the renal 
glomerular basement membrane (GBM) (Bennett, Zhou, Sumner, Dodd, 
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Bouraoud, et al., 2008) and measurement of whole-kidney nephron endowment 
with MRI (Beeman et al., 2011; Heilmann et al., 2012). CF has an equivalent 
relaxivity to unmodified native ferritin and is advantageous as an MRI contrast 
agent due to its small diameter, ease of functionalization and modification of the 
superparamagnetic core, and detectability using immunohistochemistry (IHC) for 
histological validation of labeling. In the kidney, the use of CF as a contrast agent 
may lead to a better understanding of renal function in the susceptibility to 
cardiovascular and kidney disease (Brenner et al., 1988; Hoy et al., 2008) and 
may yield a unique noninvasive measurement of renal glomerular function. CF 
has been also proposed as a contrast agent to detect the liver hepatic sinusoid in 
vivo (S. Beeman, mandarino, Rakela, & Bennett, 2011b), potentially allowing for 
assessment of liver disease. We have also shown that the distribution of CF is 
altered in a rat model of focal and segmental glomerulosclerosis (Bennett, Zhou, 
Sumner, Dodd, Bouraoud, et al., 2008), as detected with MRI, suggesting the 
possible use of CF as an MRI contrast agent to detect and evaluate early onset 
kidney disease. Cationized nanoparticles such as CF, when detected by MRI, 
may thus play an important future role in understanding the function of ECM in 
normal physiology and in disease.
The goal of this work was to establish the toxicity and biodistribution of 
CF after intravenous injection. Others have studied the biodistribution of 
magnetic nanoparticles and magnetoferritin after intravenous injection (Bulte et 
al., 1995), but cationization leads to distinct patterns of CF uptake related to the 
surface charge. This work is a step toward further in vivo studies of ECM using 
CF and MRI. The ability to detect ECM in vivo would improve monitoring of a 
variety of diseases in which changes to the ECM structure occur, including 
glomerulonephritis in the kidney (Harendza, Schneider, Helmchen, & Stahl, 1999) 
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and possibly fibrosis in the liver (Bedossa & Paradis, 2003). Furthermore, 
electron microscopy studies with CF have been useful to characterize outflow of 
cerebrospinal fluid in the brain ultrastructure (Voelz et al., 2007), and other basic 
biological processes (Brody et al., 1984; Danon et al., 1972; Schmidley & Wissig, 
1986), raising the possibility of detecting similar processes dynamically with MRI.
In this work we report kidney and liver toxicology biomarkers, total 
leukocyte counts, and organ distribution of CF after intravenous injection using 
both ex vivo MRI and immunofluorescence. In addition to confirming the 
previously observed labeling of glomeruli in the kidney, we show that CF is also 
taken up into the hepatocytes, Kupffer’s cells, and endothelial cells of the liver, 
into macrophages in the red pulp of the spleen, and into alveolar endothelial cells 
of the lungs. To establish whether CF is toxic in MRI-detectable doses, we 
performed a blood panel for acute and chronic renal and hepatic toxicity after 
intravenous injection. We show that MRI-detectable doses (5.75 mg/100 g) of 
intravenously injected CF do not appear to have a detrimental effect on renal and 
hepatic function and do not significantly increase blood leukocyte counts. These 
results suggest that CF may be useful as an intravenous MRI contrast agent to 
detect ECM structure throughout the body.
METHODS
Synthesis of cationized ferritin. CF was synthesized according to 
Danon et al. (Danon et al., 1972). Commercial horse spleen ferritin (Sigma-
Aldrich, Saint Louis, MO) was conjugated to N,N-dimethyl-1,3-propanedi- amine 
by adding 1-ethyl-3(3-dimethyl-aminopropyl) carbodiimide hydrochloride. Briefly, 
2 mL of an aqueous solution of 2 M N,N-dimethyl-1,3-propanediamine was 
adjusted to a pH of 6 with appropriate volumes of 2 N and 0.2 N HCl and NaOH. 
We then added 0.5 mL of 55 mg/mL horse spleen ferritin to the solution followed 
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by 200 mg of 1-ethyl-3(3-dimethyl-aminopropyl) carbodiimide hydrochloride. The 
resulting solution was monitored for 2 h to maintain the pH at 6. The solution was 
then sealed and left overnight at room temperature. The solution was then 
dialyzed twice against 3.5 L of phosphate buffered saline (PBS) at 4°C for 12–24 
h for each pass. CF was stored in PBS at 4°C.
Animal preparation and blood collection. Toxicity and ex vivo MRI 
detection of CF. Eighteen male Sprague-Dawley rats were used in the study of 
renal and hepatic toxicity as well as ex vivo MRI detection of CF. All animal 
protocols were approved by the Arizona State University Institutional Animal Care 
and Use Committee and performed in accordance with the NIH guide for the care 
and use of laboratory animals. Nine rats were anesthetized with a 5% isoflurane 
mixture in oxygen and administered 5.75 mg/100 g of CF in PBS via intravenous 
injection, in three doses spaced 1.5 h apart. The remaining nine rats did not 
receive any contrast injection (naive rats). Three injections were used because all 
previous studies with CF for MRI have used multiple injections, and we have not 
yet detected CF by MRI after a single injection. It is possible that concentrated 
CF could be delivered in a single bolus, but we have not evaluated whether 
concentrated doses result in CF aggregation. It is also possible that concentrated 
CF would lead to changes in how it labels the ECM. Another group of nine rats 
received no CF as controls.
Blood was collected from all 18 animals 1.5 h after the third injection, after 
which three animals from each group were sacrificed via transcardial perfusion 
and tissue was prepared for IHC and ex vivo MRI (tissue preparation described 
below). The remaining six animals from each group were used for chronic toxicity 
studies. The time points of the toxicity study were defined as acute (1.5 h after 
the last injection) and chronic (1 week after injections and 2 weeks after 
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injections). At each time point, 0.5 mL of blood was collected from each rat from 
the lateral saphenous vein via puncture with a 23-G needle. Blood was collected 
while animals were awake and manually restrained. Blood samples were 
immediately centrifuged to separate the serum from cells. Serum levels of 
calcium, blood urea nitrogen, creatinine, and albumin (ALB) were measured to 
assess renal function and alanine transaminase, aspartate transaminase, 
alkaline phosphatase, and total bilirubin to assess hepatic function. Analysis was 
performed by Charles River Laboratories (Wilmington, MA) in which biomarkers 
were measured by photometric absorbance using an ACE Alera Clinical 
Chemistry System (Alfa Wassermann, West Caldwell, NJ).
Immune response. A separate group of 12 male Sprague-Dawley rats 
was used to test the immune response of rats inoculated with CF. Eight rats were 
injected with CF as described above and four rats were not given any injection 
(naive). Blood was collected from the CF-injected rats via cardiac puncture 2 h (n 
= 4) and 1 week (n = 4) after injection. Blood was also collected via cardiac 
puncture from the naive rats. Whole blood samples were collected and shipped 
in heparinized Ethylenediaminetetraacedic acid (EDTA) tubes (Charles River). 
Total leukocyte counts were performed by Radil Research Laboratory using a 
Hemavet 950FS automated hematology analyzer.
Biodegradation. Biodegradation of CF in the liver and kidney was 
assessed by injecting four rats as described above and sacrificing via 
transcardial perfusion at 1.5 h, 2, 4, and 7 days after injection. Livers and kidneys 
were prepared for ex vivo MRI. The liver was chosen to assess biodegration of 
CF based on the major role the liver plays in removing ferritin from the circulation 
via receptor mediated and reticuloendothelial system clearance (Bulte et al., 
1995) and our observation that the detection of CF is robust in the liver.
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Imaging. Tissue Preparation. Rats were given intravenous injections of 
CF or no CF as described earlier. Rats designated for IHC and ex vivo MRI were 
sacrificed 1.5 h after the third bolus injection via transcardial perfusion of PBS 
until liver and kidneys were visibly cleared of blood. The PBS was followed by 
perfusion of 10% neutral buffer formalin. Kidneys, livers, spleens, pancreas, and 
lungs were resected. Sections of each organ were placed in solutions of either 
2% glutaraldehyde/0.1 M cacodylate solution for MRI or in 10% neutral buffered 
formalin for 2 h and then PBS for IHC.
Immunohistochemistry. IHC was performed on excised kidneys, livers, 
lungs, spleens, and pancreas to determine the distribution of intravenously 
injected CF in these organs. Tissues fixed for IHC were bathed in 15% sucrose 
for 1 day followed by 30% sucrose for 3 days, and rapidly frozen to -80°C in 
optimal cutting temperature compound. Optimal cutting temperature-embedded 
tissues were sectioned at 35 mm in a cryostat (Leica Microsystems CM3050 S, 
Buffalo Grove, IL). Tissue sections were washed three times in PBS, 
permeabilized with 0.3% Triton X-100 (Sigma-Aldrich), and blocked for 1 h with 
Image-iT FX signal enhancer (Invitrogen, Carlsbad, CA) followed by CAS-block 
(Invitrogen) for 1 h. Sections were then incubated overnight at 4°C in chicken 
antifibronectin (1:200) and rabbit anti-horse ferritin (1:500) primary antibodies 
(Invitrogen). Following primary antibody incubation, sections were washed three 
times with PBS, and incubated for 2 h at room temperature in Alexa488 goat anti-
chicken and Alexa594 goat anti-rabbit secondary antibodies (Invitrogen). 
Sections were then incubated in 4’,6-diamidino-2-phenylindole for 15 min to stain 
cell nuclei and then washed three times in PBS. Sections were mounted on 
slides with Vectashield fluorescent mounting media (VectorLabs, Burlingame, 
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CA). Tissue sections were imaged with a Zeiss 710 laser scanning confocal 
microscope.
Ex vivo MRI-detection of CF. In order to determine whether labeling with 
CF was detectable with MRI, intact kidneys, livers, lungs, spleens, and 
pancreases were imaged ex vivo in PBS in either 20-ml syringes (livers) or 12-ml 
tubes on a Bruker 7T small animal imaging system (Bruker, Billerica, MA) with a 
72-mm rat volume transmit coil and a rat brain surface coil (Bruker).  All tissue 
was imaged using a T2*-weighted 2D gradient echo (FLASH) sequence with a 
30° flip-angle, though each tissue type required a unique echo time/repetition 
time. A TE/TR of 20/28 ms was used for kidneys, 15/23 ms for liver, 20/80 ms for 
lungs, and 3.4/30 ms for spleen. Kidneys were imaged using a field of view of 
1.5x1.5 cm and a matrix size of 200x200 (75x75 µm) and a slice thickness of 500 
µm.  Livers were imaged using a field of view of 2.1x2.1 cm and a matrix size of 
300x300 (70x70 µm) and a slice thickness of 1,000 µm. Lungs, spleens, and 
pancreases were imaged using a field of view of 1.5x1.5 cm and a matrix size of 
200x200 (75x75 µm) and a slice thickness of 1,000 µm.  
Ex vivo MRI to assess biodegradation. Livers and kidneys prepared for 
the biodegration study were imaged in 20-ml syringes using T2*-weighted 2D 
gradient echo (FLASH) sequence with a 30° flip-angle and a TE/TR of 15/23. T2*-
maps of livers were also produced using a multi-gradient echo (MGE) sequence 
and echo times of 4, 11, 18, 25, 32, 39, 46, 53, 60, 67, 74, and 81 ms.
Data analysis. All statistical analyses were run as two sample, two-tailed 
Student’s t-tests in MATLAB (The Mathworks, Natick, MA) to test the null 
hypothesis that the mean difference between groups is zero at the significance 
level α = 0.05. We compared all kidney and liver serum biomarker concentrations 
from CF inoculated animals against those of controls. Furthermore, to quantify 
55
MRI signal differences in organs from CF inoculated and control animals, six 
randomly chosen regions of interest (ROIs) inside of the tissue were normalized 
against six randomly chosen ROIs in the surrounding buffer. We then compared 
the normalized signal values from CF inoculated animals against those of 
controls. T2* values in the biodegradation experiments were calculated in T2*-map 
ROIs.
RESULTS
Toxicity. To determine renal toxicity of intravenously injected CF, serum 
levels of calcium (CAL), blood urea nitrogen (BUN), creatinine (CRE), and 
albumin (ALB) were measured 1.5 hours after injection, 1 week after injection, 
and 2 weeks after injection.  The same measurements at the same time points 
were made in animals not administered CF.  Serum levels of each kidney 
biomarker did not differ significantly from those of control animals at 1.5 hrs, 1 
week, or 2 weeks after injection (α = 0.05), indicating no acute or chronic renal 
toxicity after CF injection.  The data are summarized in box plots in Figure 5.1. 
Central lines represent the median, the box edges represent the 25th and 75th 
percentiles, and caps represent the most extreme points not considered outliers.  
Stars represent these outliers.
To determine hepatic toxicity of intravenously injected CF, serum levels of 
alanine transaminase (ALT), aspartate transaminase (AST), alkaline 
phosphatase (ALK), and total bilirubin (TBIL) were measured 1.5 hours after 
injection, one week after injection, and two weeks after injection.  The same 
measurements at the same time points were made in animals not administered 
CF.  Serum levels of each liver biomarker did not differ significantly from those of 
control animals at 1.5 hrs, 1 week, or 2 weeks after injection (α = 0.05). The data 
are summarized in box plots presented in Figure 5.2.
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Figure 5.1. Blood serum measurements of calcium (A), blood urea nitrogen (B), 
creatinine (C), and albumin (D) in rats after intravenous injection of cationized 
ferritin (CF) or without injection (CTRL). The central line represents the median, 
the box edges represent the 25th and 75th percentiles, and the caps represent 
the most extreme points not considered outliers. Stars represent outliers. Serum 
measurements of all of biomarkers of renal function from CF-injected rats do not 
differ significantly from those from control animals (α = 0.05) at acute (n=9 per 
group) or chronic (n=6 per group) stages after CF administration.
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Figure 5.2. Blood serum measurements of alanine transaminase (A), aspartate 
transaminase (B), alkaline phosphatase (C), and total bilirubin (D) in rats after 
intravenous administration of cationized ferritin (CF) or without injection (CTRL). 
The central line represents the median, the box edges represent the 25th and 
75th percentiles, and the caps represent the most extreme points not considered 
outliers.  Stars represent outliers. Serum measurements of all of biomarkers of 
liver function from CF injected animals do not differ significantly from those from 
control animals not administered protein (α = 0.05), at acute (n = 9 per group) 
and all chronic time points (n = 6 per group) after injection of CF.
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Figure 5.3. Total leukocyte counts. The total leukocyte counts of rats two hours 
( 9.255 ± 1.89 x 10-3 cells/µL) and one week (9.33 ± 1.39 x 10-3 cells/µL) after 
CF-injection did not differ significantly (α = 0.05) from those of the control group 
(11.18 ± 2.06 x 10-3 cells/µL).
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To determine whether there was an immune response to intravenously 
injected CF, we measured total leukocyte counts at two hours and one week after 
injection. Total leukocyte counts were also made in naive rats receiving no CF. 
The total leukocyte counts of rats (Fig. 5.3) two hours ( 9.255 ± 1.89 x 10-3 cells/
µL) and one week (9.33 ± 1.39 x 10-3 cells/µL) after CF-injection did not differ 
significantly (α = 0.05) from those of the naive group (11.18 ± 2.06 x 10-3 cells/
µL).
Biodegradation. Ev vivo T2*-maps of cationized ferritin inoculated livers 
revealed that T2* returns to baseline seven days after injection of CF. T2* in ROIs 
was 18.7 ± 0.45 ms 1.5 hours after injection, 13.9 ± 0.93 ms two days after 
injection, 12.3 ± 1.2 ms four days after injection, and 21.5 ± 0.4 ms seven days 
after injection. For comparison, liver T2* to be 20.9 ± 0.73 ms in naive rats. CF 
accumulation was not detectable in kidneys two days after CF injection.
Tissue distribution studies. We performed both immunofluorescence 
and ex vivo MRI to determine the tissue distribution and detectability of 
intravenously injected CF. 
Immunofluorescence. Confocal imaging of kidneys from animals 
injected with CF suggests distinct localization of CF (red) to the glomerulus (Fig. 
5.4A). Confocal imaging of kidneys from animals not injected with CF reveal 
minimal fluorescence associated with CF (Fig. 5.4E).  This is consistent with 
previous observations that CF binds with high specificity to the GBM (Beeman et 
al., 2011; Bennett, Zhou, Sumner, Dodd, Bouraoud, et al., 2008; Heilmann et al., 
2012).  
Confocal imaging of livers from animals injected with CF showed 
substantial colocalization of CF (red) with fibronectin (green) surrounding the 
hepatic sinusoid, suggesting that CF binds to the extracellular matrix of Disse’s 
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Space.  Furthermore, signal attributed to the presence of CF was observed 
inside of hepatocytes, endothelial cells of the hepatic sinusoid, and Kuppfer’s 
cells, suggesting internalization of CF by these cells (Fig. 5.4B).  Minimal 
fluorescence associated with CF was observed in livers from animals not 
administered CF. (Fig. 5.4F).
Immunofluorescence from CF (red) was observed in the lung, as shown 
in Figure 5.4C. The distribution of fluorescence in these sections suggests that 
CF is bound to the surface of endothelial cells lining the lung capillaries and also 
endocytosed. Some red fluorescence was observed in the lung sections from 
animals not administered CF (Fig. 5.4G). We attributed this to nonspecific binding 
of IHC antibodies inside of alveolar macrophages.
Substantial red fluorescence was observed in spleen sections from 
animals in both the CF-injected and control groups, suggesting nonspecific 
binding of the antibody to cells in the spleen. Nonetheless, there were differences 
in the distribution of immunofluorescent signal between injected animals and 
control animals.  Punctate red signal associated with CF accumulation was 
observed inside of the macrophages at the border of the white and red pulp (Fig. 
5.4D), suggesting that these cells take up CF as blood filters through the red 
pulp.  
While red fluorescence was observed in pancreases prepared for IHC, we 
were unable to discern a difference between the CF-injected and control cohorts.  
No pattern was observed in CF-inoculated sections that would specifically 
suggest accumulation of CF (data not shown).  We attribute the red fluorescence 
observed in both CF-inoculated and control pancreases to non-specific binding of 
the antibodies.
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Figure 5.4. Confocal imaging of perfused, excised kidneys (A and E), livers (B 
and F), lungs (C and G), and spleens (D and H) of rats after intravenous injection 
of cationized ferritin or no injection (control). Confocal imaging of kidneys from 
CF inoculated animals shows localization of red (CF) signal to the glomerulus 
(A). Kidneys from animals not injected with CF show minimal fluorescence on the 
red channel (E). Confocal imaging of livers from animals injected with CF showed 
colocalization of CF with the fibronectin (green) surrounding the hepatic sinusoid 
as well as punctate red signal inside of hepatocytes, endothelial cells, and 
Kuppfer’s cells, suggesting internalization of CF by these cells (B).  Minimal red 
fluorescence was observed in livers from control animals (F). Red fluorescence 
associated with the presence of CF is apparent in the lung sections prepared 
from animals injected with CF on confocal images (C). The distribution of red 
fluorescence in these sections suggests that CF is likely bound to the surface of 
and taken up into the endothelial cells lining the capillaries.  Minimal red 
fluorescence was observed in the lung sections from control animals (G). Spleen 
sections prepared from animals injected with CF show punctate red fluorescence 
associated with CF accumulation (arrows) inside of the macrophages at the 
border of the white and red pulp (D).  Red fluorescence was also observed inside 
of macrophages at the border of white and red pulp in the spleen sections from 
control animals due to non-specific binding of the anti-horse spleen ferritin 
antibody (H). Scale bar = 20 µm.
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MRI. Gradient echo MRI (GRE-MRI) of kidneys excised from rats injected with 
CF revealed distinct spots of hypointensity throughout the cortex of the kidney 
(TE/TR = 20/28 ms), as shown in Figure 5.5A. MRI of kidneys from animals not 
administered CF showed no similar labeling (Fig. 5.5E).  The distribution of 
hypointensity in CF-inoculated kidneys is consistent with the spatial distribution of  
glomeruli throughout the cortex and juxtamedulary regions of the kidney 
observed with immunofluorescence and with MRI results published in previous 
work at 9.4T, 11.7T, and 19T (Beeman et al., 2011; Bennett, Zhou, Sumner, 
Dodd, Bouraoud, et al., 2008; Heilmann et al., 2012). The voxel magnitude in six 
regions of interest (ROIs) in the cortex of the kidney were normalized to six ROIs 
in the buffer surrounding the tissue. The normalized MRI signal magnitudes were 
significantly different (α = 0.05) between groups, with normalized magnitudes in 
CF inoculated and control kidneys of 0.86 ± 0.045 and 0.94 ± 0.02, respectively 
(Fig. 5.6).
GRE-MRI (TE/TR = 15/23 ms) of liver sections from rats administered CF 
showed striations of hypointensity throughout the liver (Fig. 5.5B), consistent with 
the known spatial distribution of the hepatic sinusoid. No similar pattern was 
observed in livers from control animals (Fig. 5.5F).  The normalized MRI signal 
magnitudes were significantly different (α = 0.05) between livers of CF-injected 
and control animals, with normalized magnitudes of 0.78 ± 0.04 and 1.26 ± 0.07, 
respectively (Fig. 5.6).
GRE-MRI (TE/TR = 20/80 ms) of the lungs of rats inoculated with CF 
showed substantial labeling throughout compared to lungs of control animals 
(figure 5.5C and G).  IHC suggests that this labeling is due to the binding of CF to 
endothelial cell surfaces and internalization of CF into endothelial cells. The 
normalized MRI signal magnitudes were significantly different (α = 0.05) between 
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groups, with normalized signal magnitude of CF-inoculated and control lungs of 
0.64 ± 0.07 and 0.93 ± 0.02, respectively (Fig. 5.6).
Spleens from rats injected with CF had substantial labeling by CF in 
inoculated animals, compared to controls. The white pulp appears lighter than 
the surrounding red pulp in GRE-MRI (TE/TR = 3.4/30 ms), as shown in Figure 
5.5D and 4H. IHC indicates that this may be due to the uptake of CF into the 
macrophages at the interface between the red and white pulp of the spleen (Fig. 
5.5D and H). The normalized MRI signal magnitudes were significantly different 
(α = 0.05) in CF-inoculated and control spleen, respectively. The magnitudes 
were 0.43 ± 0.02 and 0.98 ± 0.05, respectively (Fig. 5.6).
No signal magnitude differences were observed between CF inoculated 
and control pancreas using GRE-MRI.
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Figure 5.5. 7T GRE-MRI (TE/TR = 20/28 ms) of kidneys from rats inoculated with 
CF revealed distinct spots of hypointensity throughout the cortex of the kidney 
(A).  The distribution of hypointense spots in kidneys of rats after CF 
administration is consistent with the spatial distribution of glomeruli throughout 
the cortex and juxtamedulary regions of the kidney.  GRE-MRI of kidneys from 
control animals (no ferritin administration) are clear (E).  GRE-MRI (TE/TR = 
15/23 ms) of liver sections from rats administered CF showed striations of 
hypointensity throughout the parenchyma of the liver (B), likely due to the 
localization of CF to the ECM and cells surrounding the hepatic sinusoid.  The 
entire parenchyma of the livers from control animals appear bright and without 
striation (F).  GRE-MRI (TE/TR = 20/80 ms) of lungs from animals inoculated with 
CF show substantial darkening of the tissue (C) while lungs from control animals 
appear bright throughout the entire organ (G).  GRE-MR images (TE/TR = 3.4/30 
ms) of spleens of CF inoculated animals appear very dark (D) compared to 
controls (H).  It appears that MRI-detectable CF accumulation is isolated to the 
red pulp of CF labeled spleens.
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Figure 5.6. Normalized GRE-MRI signal magnitudes in organs of CF-injected rats 
and control rats with no injection. All CF-labeled organs are significantly darker 
than control tissue (α = 0.05).   The error bars represent a single standard 
deviation based on 6 randomly chosen regions of interest inside of the tissue 
divided by 6 randomly chosen regions of interest in the surrounding PBS.
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DISCUSSION
In this work we investigated the tissue distribution and toxicity of 
intravenously injected cationized ferritin. The ferritin nanoparticle is useful as an 
in vivo label of the glomerular basement membrane (Bennett, Zhou, Sumner, 
Dodd, Bouraoud, et al., 2008) and can be used to count and measure glomeruli 
with MRI (Beeman et al., 2011; Heilmann et al., 2012). CF may be useful to study 
ECM structure and function throughout the body with MRI, and the data reported 
here is an important step towards using CF in future in vivo studies. 
Measurements of serum levels of enzymes associated with kidney 
function indicated that intravenous injection of CF at MRI-detectable doses (5.75 
mg/ 100 g) does not significantly affect renal function. Similarly, CF did not 
significantly affect liver function as measured by serum markers. Together, these 
results suggest that CF is not toxic to renal and hepatic function at doses that are 
detectable using MRI. Furthermore, the amount of CF required for in vivo MRI 
detection of the ECM may be decreased by creating cationized magnetoferritin, 
in which apoferritin is filled with as many as ~5,000 iron atoms, as compared to 
~1,000 iron atoms inside of normal ferritin and has an increased particle and 
metal relaxivity (Bulte et al., 1995; 1994; Clavijo Jordan et al., 2010; Meldrum et 
al., 1992).
Confocal imaging suggests that CF specifically labels the glomerular 
basement membrane.  Control kidneys did not show such labeling of the 
glomerulus.  This result is supported by ex vivo MRI, which shows punctuate 
spots of hypointensity throughout the cortex and juxtamedulary regions of the 
kidney that are consistent with the spatial distribution of glomeruli.  All previous 
work in detecting glomeruli with MRI was performed at 9.4T or greater. This is the 
first report of detection of glomeruli at 7T, suggesting that the techniques 
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described in previous studies are robust and practical using typical small animal 
MRI systems. 
It is likely that the binding of CF to the glomerular basement membrane is 
due to an electrostatic interaction between the cationized ferritin and the anionic 
proteoglycans on the glomerular basement membrane. This interaction is 
facilitated by the large pressure gradient across the glomerular capillary wall, 
which shuttles the CF through the endothelial fenestration into direct contact with 
the glomerular basement membrane.  Previous work has also suggested that 
some CF is internalized into podocytes and that some passes completely through 
the glomerular filtration barrier into Bowman’s capsule (Bennett, Zhou, Sumner, 
Dodd, Bouraoud, et al., 2008). There is still a need to characterize how CF 
accumulates dynamically in the kidney and how accumulation reports on renal 
function.
Confocal and MR imaging suggest that most of the CF accumulation in 
the liver occurs in the ECM and cells immediately surrounding the hepatic 
sinusoids.  Just as in the kidney, it is likely that the colocalization of CF with the 
ECM surrounding the hepatic sinusoid is due to an electrostatic interaction 
between CF and the anionic proteoglycans of the ECM.  Furthermore, confocal 
microscopy shows that CF is also taken up into Kupffer’s cells (macrophages 
inside the hepatic sinusoid), endothelial cells surrounding the hepatic sinusoid, 
and hepatocytes.
Colocalization of CF with the endothelial cells lining the capillaries 
interfacing the alveoli was observed using confocal imaging.  This accumulation 
was also detectable with MRI.  This observation is consistent with reports in the 
electron microscopy literature of CF binding to the anionic endothelial cell surface 
as well as uptake of CF into endothelial vesicles (Brody et al., 1984).  
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Furthermore, CF uptake might be used to study lung disease with MRI, because 
substantial binding of CF to the anionic alveolar basement membrane has been 
observed with electron microscopy after severe damage to the endothelial lining 
(Barrowcliffe & Jones, 1987; Brody et al., 1984).  In healthy lungs, CF should not 
pass the endothelial barrier. CF labeling to study lung function with MRI is a 
potential area for future investigation.
Splenic uptake of CF was observed in both MRI and 
immunofluorescence, with heavy labeling of the red pulp in CF inoculated 
spleens.  There was also substantial background fluorescence in spleen 
histological sections prepared for confocal imaging, likely due to large number of 
monocytes and endogenous ferritin in the spleen.  CF appears to be taken up 
into the macrophages at the interface between the white and red pulp.
Although TEM has shown that CF decorates the endothelial 
plasmalemma and fenestra of the mouse pancreas after intravenous injection (M. 
Simionescu, Simionescu, Silbert, & Palade, 1981), we were unable to see a 
difference in fluorescence between pancreases of CF-injected and control rats. It 
is likely that not enough CF accumulated in the pancreases observed in this 
study to produce a fluorescent signal above the signal from non-specific antibody 
binding. Furthermore, no signal differences in GRE-MRI were observed in 
pancreases in this study. We do not conclude from these results that CF does not 
bind in the pancreas, but instead that our experiment lead to no observable 
signal changes that may be attributed to the binding of CF in the pancreas. 
Previously studies have shown that chronic exposure to CF yields 
elevated levels of anti-cationized horse spleen apoferritin in the plasma 
(Iskandar, Zhang, & Rodriguez, 1986), though the exposure is approximately 25 
times the total dose used in this work over the period of a week. Antibody 
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reactivity might be minimized by producing recombinant ferritin to match the 
recipient species (Santambrogio et al., 1993; Uchida et al., 2008). Furthermore, 
rabbits have been shown to develop proteinurea after intravenous injection of CF 
(Batsford, Sasaki, Takamiya, & Vogt, 1983), though we have yet to observe 
proteinurea in rats used in our experiments. These are certainly avenues for 
further exploration as the use of CF as an MRI-visible contrast agent advances, 
though we are encouraged by our results that suggest minimal toxic effects of 
CF.
The goal of this work was to determine the toxicity and distribution of CF 
after intravenous administration. By measuring common toxicity biomarkers and 
total leukocyte counts, we found that CF is neither nephrotoxic nor hepatotoxic at 
detectable doses nor does it elicit a significant immune response. Furthermore, 
we have established that CF accumulates in a number of organs in the body, 
including liver, kidney, lungs, and spleen, likely by binding to the extracellular 
matrix and endothelial glycocalyx.  The organs studied in this work were selected 
because they contain fenestrated capillaries and were therefore likely to be 
labeled by CF. We expect that whole-body, 3D MRI may reveal other potential 
targets of CF. However, as evidenced by the range of TE values required to 
image the organs presented in this work,  whole-body experiments would have to 
carefully take into account the background T2* of each organ.
CF, when used as a MRI-detectable contrast agent, has potential 
advantages because it is small enough (~13 nm) to fit through capillary 
endothelial fenestrations and has a highly affinity to exposed anionic basement 
membrane such as the glomerular basement membrane. The optimization of CF-
delivery and MRI-acquisition in will further improve the specific detection of 
anionic structures both in vivo and ex vivo.
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Conclusions. We have shown that CF is neither nephrotoxic nor 
hepatotoxic in healthy rats at MRI-detectable doses. Furthermore, total leukocyte 
counts suggest that there is not a significant immune response to intravenously 
injected CF. We detected CF accumulation in the kidney, liver, lungs and spleen 
using immunohistochemistry and MRI. These results suggest opportunities to 
study of physiological structure and function of the ECM in vivo through the use 
of CF as an MRI contrast agent.
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CHAPTER 6
CATIONIZED FERRITIN AS A MRI PROBE TO DETECT 
MICROSTRUCTURAL CHANGES IN A RAT MODEL OF NON-ALCOHOLIC 
STEATOHEPATITIS
INTRODUCTION
Chronic liver disease accounts for ~30,000 deaths per year in the United 
States (National Center for Health Statistics, 2011). Non-alcoholic-steatohepatitis 
(NASH), an advanced and chronic form of non-alcoholic fatty liver disease 
(NAFLD), is associated with type 2 diabetes and obesity and affects ~6 million 
people in the United States (Erickson, 2008). With increases in the incidence of 
type 2 diabetes and obesity, the number of people who will develop NASH is 
likely to rise. Left untreated, NASH may progress to cirrhosis. Several 
complications develop in the case of cirrhosis including hepatic encephalopathy, 
renal failure, and hepatocellular carcinoma (Bataller, 2005). Microstructural 
changes due to the deposition of excess extracellular matrix (ECM) and the loss 
of endothelial fenestrations (Farrell et al., 2008; Friedman, 2000; Iredale, 2007; 
Lough et al., 1987; Martinez-Hernandez & Amenta, 1995) reduce access of 
plasma molecules to the hepatic parenchyma and therefore reduce hepatic 
function (Benyon & Iredale, 2000; Friedman, 2000). A robust method to detect 
these microstructural and functional changes to the liver would be an important 
diagnostic tool. 
 Here we demonstrate a magnetic resonance imaging (MRI) technique to 
detect changes in macromolecular access to the perisinusoidal space of the liver 
due to NASH. The perisinusoidal space (Disse’s space) is the major site of 
molecular exchange between the blood plasma and hepatocytes in the liver. It is 
situated beneath a layer of fenestrated endothelia that serve as a sieve, allowing 
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passage of proteins and other plasma molecules into the perisinusoidal space 
while retaining cells in the hepatic sinusoid capillary space (Wisse, 1970). 
Beneath the fenestrated endothelial layer, inside the perisinusoidal space, is a 
layer of ECM that is critical to normal hepatic structure and function: impacting 
cell migration, proliferation, differentiation and gene expression (Bedossa & 
Paradis, 2003; Friedman, 2000; Iredale, 2007). Chronic liver disease often leads 
to a thickening of the ECM and a loss of endothelial fenestrations (Farrell et al., 
2008; Friedman, 2000; Iredale, 2007; Lough et al., 1987; Martinez-Hernandez & 
Amenta, 1995) that ultimately reduce macromolecular access to the 
perisinusoidal space. This in turn leads to reduced plasma exchange with 
hepatocytes and altered hepatic function (Friedman, 2000; Iredale, 2007). 
  Rodent models are important for investigating the molecular and cellular 
mechanisms of NAFLD. There are a large number of genetic and dietary models 
of NAFLD, including the db/db and ob/ob genetic mouse models and high 
carbohydrate and high fat diets, though these specific genetic and dietary models 
often only result in steatosis (Farrell et al., 2008). The methionine-choline 
deficient (MCD) dietary model results in rodents developing hepatic changes that 
closely resemble those of NASH in humans. These changes include steatosis, 
focal inflammation, fibrosis, and necrosis of hepatocytes (George et al., 2003; 
Rinella et al., 2008; Teramoto, Bowers, Khettry, Palombo, & Clouse, 1993). 
Furthermore, it has been suggested that this model may also exhibit loss of 
endothelial fenestrations (McCuskey et al., 2004).
 Typically, NASH is differentiated from NAFLD by biopsy. However, due to 
the diffuse nature of liver fibrosis, diagnoses based on liver biopsy can be subject 
to sampling errors (Bedossa et al., 2003; Siddique et al., 2003). Biopsy may also 
cause pain and major complications (Thampanitchawong & Piratvisuth, 1999). 
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Recently, imaging techniques have been developed to assess the extent of liver 
fibrosis throughout the entire organ using ultrasound elastography (Ophir, 
Céspedes, Ponnekanti, Yazdi, & Li, 1991). This method detects viscoelastic 
changes that occur during the development of fibrosis (Sandrin et al., 2003; Yeh 
et al., 2002). MRI also shows promise in detecting liver disease because it is 
non-invasive, three dimensional, high resolution, and provides excellent soft-
tissue contrast. Magnetic resonance elastography (MRE) techniques have been 
developed based on applying mechanical waves to measure tissue stiffness 
(Huwart et al., 2006; Manduca et al., 2001; Muthupillai et al., 1995). Current MRE 
techniques are noninvasive and practical to detect gross changes in liver 
structure. Nonetheless, there remains a strong need to distinguish focal changes 
to microstructure and function that develop due to chronic liver disease. 
 A potential strategy to detect structural and functional changes in the liver 
due to steatohepatitis is to develop a MRI contrast agent that specifically targets 
the perisinusoidal ECM of the liver. Targeted MRI contrast agents have been 
developed to detect molecules and cells throughout the body (Cormode et al., 
2010; Geninatti Crich et al., 2005; S. Zhang et al., 2003). Iron oxide nanoparticles 
of approximately 10-50 nm are one type of contrast agent that creates a 
detectable change in the MRI signal. Ferritin, a 13 nm protein-based iron oxide 
nanoparticle, has been proposed as a useful natural nanoparticle contrast agent 
because of its uniform size, biocompatibility, and ease of functionalization in both 
natural and modified states (Bennett, Shapiro, Sotak, & Koretsky, 2008; Bulte et 
al., 1995; Uchida et al., 2008). Because the ferritin nanoparticle has an iron oxide 
core, its accumulation creates a darkening in the MR image that can be detected 
using T2*-weighted MRI. It was previously shown that the ECM in the kidney 
glomerulus may be imaged using MRI after the intravenous injection of a 
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cationized ferritin (CF) (Beeman et al., 2011; Bennett, Zhou, Sumner, Dodd, 
Bouraoud, et al., 2008; Heilmann et al., 2012). This technique is based on the 
passage of CF through the endothelial fenestrations of the glomerular capillary 
wall and subsequent electrostatic binding of CF to the anionic proteoglycans of 
the ECM. Intravenous CF is also non-toxic at MRI-detectable doses (Beeman et 
al., 2012).
 Here we investigate the use of CF to detect reduced macromolecular 
access to the perisinusoidal space in a rat model of NASH.
METHODS
 Synthesis of Cationic Ferritin. Cationized ferritin (CF) was synthesized 
from native horse spleen ferritin per Danon et.al (Danon et al., 1972). 1-ethyl-3(3-
dimethyl-aminopropyl) carbodiimide hydrochloride (EDC) was used to conjugate 
commercial horse spleen ferritin (Sigma-Aldrich, Saint Louis MO) to N,N-
dimethyl-1,3-propanediamine (DMPA). This was accomplished by first adjusting a 
2 M solution of DMPA to a pH of 6 using 2 N and 0.2 N HCl and NaOH. Once a 
pH of 6 was achieved, 0.5 ml of 55 mg/ml horse spleen ferritin was added to the 
solution, followed by 200 mg of EDC. The pH of the solution was monitored for 2 
hours after addition of EDC to ensure the pH remained at 6. The solution was left 
covered at room temperature for 12 hours. The CF solution was dialyzed 2 times 
against 3.5 L of phosphate buffered saline (PBS) at a pH of 7.3 and 4 °C for 
12-24 hours for each pass. The CF solution was stored at 4 °C. Native horse 
spleen ferritin has an iron oxide core and a per particle T2 relaxivity of ~2,455 
mM-1 s-1 (35). Cationized ferritin shares the same iron oxide core and relaxivity as 
native ferritin (data not shown). 
 Animal Preparation. A total of 30 male Sprague-Dawley rats were used 
in this study. All animal protocols were approved by the Arizona State University 
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Institutional Animal Care and Use Committee and performed in accordance with 
the NIH guide for the care and use of laboratory animals. The 30 animals were 
split into two groups – the first (12) to study CF-labeling of the perisinusoidal 
ECM in healthy animals, and the second (18) to study the use of CF and MRI in a 
rat model of non-alcoholic steatohepatitis (NASH). All injections were performed 
while the animals were anesthetized with a 5% isoflurane mixture in oxygen. A 
total CF dose of 5.75 mg / 100 g was given in three bolus doses (~0.5 ml per 
dose) spaced 1.5 hours apart. 
 The first group, consisting of 12 healthy rats weighing 293 ± 13 g, was 
used to demonstrate the labeling of the perisinusoidal ECM by CF in healthy rats 
administered intravenous bolus doses of CF. A group of three rats administered 
CF was compared to a group of three rats administered an equivalent dose of 
native ferritin (NF) and to a group of three naive rats receiving no contrast agent. 
The rats were imaged with MRI in vivo and then sacrificed via transcardial 
perfusion of PBS and formalin 1.5 hours after the last injection. Livers were 
resected and prepared for ex vivo MRI, histology, and TEM. The final three rats 
were prepared in the same way and perfused 2 days, 4 days, and 7 days after 
injection to observe the distribution of CF in the liver over time. Transmission 
electron microscopy (TEM), MRI, and histology are detailed below. 
 The second group, consisting of 18 rats, was used to study the use of CF 
in a rat model of non-alcoholic steatohepatitis (NASH). Nine rats were fed a 
methionine choline deficient (MCD) diet (George et al., 2003; McCuskey et al., 
2004; Rinella et al., 2008; Teramoto et al., 1993) and nine were fed a control diet 
of the same composition supplemented with methionine and choline. All rats 
were weighed weekly, as animals on an MCD diet tend to lose weight (Fig. 6.4). 
Serum alanine transaminase (ALT) was measured by photometric absorbance 
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(Charles River Laboratories, Wilmington, MA) in six of the rats fed the MCD diet 
and six of the rats fed the control diet to determine disease maturity. All 
experiments took place after serum ALT in MCD-fed animals were approximately 
three times the serum ALT of animals fed the control diet (12). This occurred 14 
weeks after starting the special diet. Six MCD fed rats and six control diet fed rats 
were imaged in vivo with MRI before and after injection of CF and sacrificed by 
transcardial perfusion of PBS and 10% neutral buffer formalin immediately after 
the post-injection MRI. Livers were resected and prepared for ex vivo MRI, 
histology, and TEM. The remaining three MCD fed rats and two control diet fed 
rats remained naive and were sacrificed by transcardial perfusion without being 
injected with CF. Livers from these animals were resected and prepared for ex 
vivo MRI, histology and TEM. One sample from the un-injected control group was 
removed due to failure to properly perfuse the animal. MRI, histology, and TEM 
are detailed below.
 In vivo MRI. For in vivo MRI, rats were prepared as described above. 1.5 
hours after the final injection of CF, rats were anesthetized with a 5% isoflurane 
mixture in oxygen by nose cone and imaged at 7T on a Bruker 7T/35 scanner 
(Bruker, Billerica, MA) using a 72-mm quadrature transmit/receive radio 
frequency coil (Bruker). A series of axial T2*-weighted 2D-gradient echo fast low 
angle shot (FLASH) sequences were acquired using a flip angle of 30°. Five 
different TE values were used (4, 5, 6, 7, and 8 ms). A TR of 60 ms was used for 
each scan. In vivo images were collected with a resolution of 234x234x1000 µm 
(field of view = 6x6 cm, matrix size = 256x256, scan time = 4 min. 36 sec.). T2* 
maps were calculated using the series of FLASH images (data analysis 
described below). Twenty-four averages were collected for each scan to improve 
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SNR and reduce motion artifacts (the total scan time was 4 minutes 36 seconds 
per scan).
 Ex vivo MRI. Perfused, excised livers were imaged on a Bruker 7T/35 
scanner and a 72-mm rat volume transmit coil and a rat brain surface coil 
(Bruker). A high resolution 70x70x1000 µm (field of view = 2.1x2.1 cm, matrix 
size = 300x300) T2*-weighted 2D-gradient echo fast low angle shot (FLASH) 
sequence was collected on each liver with a TE/TR = 15/23 ms and a flip angle 
of 30° (100 averages, scan time = 8 min. 36 sec.). The TE/TR used to image the 
perfused, fixed livers ex vivo is different than that used to image livers in vivo 
because the presence of blood in vivo shortens T2*. To measure T2*, a 2D multi-
gradient echo sequence was used to collect 26 images with 26 evenly spaced 
echoes times between 2.48 ms and 42.54 ms. A TR of 1000 ms was used with 
the multi-gradient echo sequence along with a flip angle of 30° and a resolution 
of 280x280x1000 µm (field of view = 2.1x2.1 cm, matrix size = 75x75, no 
averaging, scan time = 57 sec.). T2* maps were calculated from 26 gradient echo 
images (data analysis described below).
 Immunofluorescence. Immunofluorescence (IF) confocal microscopy 
was performed on excised livers to determine the distribution of injected CF. 
Tissue fixed for IF was bathed in 15% sucrose overnight followed by 3 days in 
30% sucrose. Sucrose-infiltrated tissue was rapidly frozen to -80 °C in optimal 
cutting temperature (OCT) compound. Embedded tissue was sectioned at 35 µm 
at -20 °C in a cryostat (Leica Microsystems CM3050 S, Buffalo Grove, IL). 
Sections were washed three times in PBS, permeabilized with 0.3% triton, and 
blocked in Image-iT FX signal enhancer (Invitrogen, Carlsbad, CA) and goat 
serum for one hour each. Sections were then incubated overnight at 4 °C in 
chicken anti-fibronectin (1:400) and rabbit anti-horse spleen ferritin (1:500) 
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primary antibodies (Invitrogen). Sections were then washed and incubated at 
room temperature for two hours in Alexa488 goat anti-chicken and Alexa594 goat 
anti-rabbit secondary antibodies (Invitrogen). Nuclei were stained with 4',6-
diamidino-2-phenylindole (DAPI) for 15 minutes to stain cell nuclei and then 
washed three times in PBS. Sections were mounted on slides with Prolong Gold 
anti-fade reagent (Invitrogen). The slides were imaged with a Zeiss 710 laser 
scanning confocal microscope.
 Transmission Electron Microscopy. Pieces of liver tissue ~1 mm3 were 
collected from CF-injected and naive rats fed the MCD and control diets. The 
specimens were placed in a 2% glutaraldehyde/ 0.1 M cacodylate solution. 
Tissue was dehydrated with a series of ethanol mixtures ranging from 70% to 
100% and infiltrated with and embedded in epoxy resin. Sections were cut at a 
thickness of 70 nm and lightly stained with 0.2% osmium tetroxide in 0.1 M 
cacodylate buffer for 2 hours. Osmium tetroxide precipitates were removed via a 
12-minute digestion with 1% periodic acid. Images were acquired on a Phillips 
CM12 transmission electron microscope.
 Inductively Coupled Plasma Optical Emission Spectroscopy. ~1 g of 
liver tissue from each of the 18 rats in the NASH model study was digested in 9 
ml nitric acid + 1 ml hydrochloric acid. After 15 min of pre-digestion at room 
temperature in the acid solution, the samples were fully digested by microwave 
heating to 200 °C at 400 W (CEM corporation, Matthews, NC). Once completely 
digested, iron content of each liver was measured using Inductively Coupled 
Plasma Optical Emission Spectroscopy (ICP-OES) (Thermo Scientific, Waltham, 
MA).
 Data Analysis. In vivo T2* values were calculated from the five T2*-
weighted FLASH gradient echo images (see ‘In vivo MRI’ above) using MATLAB 
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(The Mathworks, Inc. Natick, MA). Ex vivo T2* values were calculated from the 26 
gradient echo images of the multi-gradient echo sequence. Because ex vivo T2* 
values obtained using the multi-gradient echo sequence are the same as those 
obtained from a series of ex vivo FLASH images (data not shown), a multi-
gradient echo sequence was used ex vivo to collect more echoes and reduce 
scan total scan time across the entire ex vivo sample set. T2* values were 
calculated from the image series by fitting the each voxel magnitude value at 
each time point to the equation S(t)=S0e-t/T2*, where S(t) is the voxel signal 
magnitude value at the given TE, S0 is the extrapolated signal magnitude value at 
TE = 0 ms, and t = TE.  
Average signal magnitude and T2* values we obtained by manually 
segmenting the livers from the MRI images or T2* maps and averaging the 
remaining voxels. Average liver signal magnitude was compared across animals 
my normalizing to the signal magnitude of the muscle surrounding the spine in 
the same image (a circular region of interest was manually drawn to obtain the 
signal magnitude value of the muscle). T2* histograms we produced from the 
segmented T2* maps and intra-sample voxels were binned by their T2* value.
Statistical analyses were run in MATLAB as two-sample, two-tailed 
Student’s t-tests to test the null hypothesis that the mean difference between 
groups is zero (α = 0.05). All values in the text are represented as the inter-
sample mean ± the standard mean error (SEM).
RESULTS
 Intravenous CF labels the healthy perisinusoidal ECM and is 
detected with MRI. We first investigated whether intravenous cationized ferritin 
(CF) can be used to detect the perisinusoidal space in the liver using MRI. We 
injected CF into healthy Sprague-Dawley rats. For comparison, we also injected 
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healthy rats with native ferritin (NF) and used a group of naive, un-injected rats 
as negative controls (n = 3 per group). We imaged rats in vivo 1.5 hours after 
injection on a Bruker 7T MRI scanner using a gradient-echo pulse sequence. In 
the resulting MR images (Fig. 6.1 A-C), we observed dark striations throughout 
the livers of CF-injected rats, consistent with the distribution of hepatic sinusoids 
in the liver. The livers of NF-injected rats appeared dark in the images, and livers 
from naive controls were bright. The average normalized MRI signal magnitudes 
in livers from CF- and NF-injected rats and naive control rats were all significantly 
different (alpha = 0.05, Fig. 6.1 D). These in vivo results suggest that CF uniquely 
labels the liver and that the labeling is detectable in vivo using MRI.
 We used ex vivo MRI of the perfused, excised livers to further explore the 
differences in labeling between the CF-injected, NF-injected, and naive rats (Fig. 
6.1 E-G). Dark striations were visible with ex vivo MRI in CF-inoculated livers, 
consistent with in vivo MRI. No striations were visible in livers from NF-injected or 
naive control rats. Line profiles through the images (Fig. 6.1 H) revealed an 
~50% difference in signal magnitude between hepatic sinusoids and liver 
parenchyma in livers from rats injected with CF. We used immunofluorescence 
and transmission electron microscopy (TEM) to confirm the MRI results and to 
determine the location of injected CF in the liver. In immunofluorescence (Fig. 6.2 
A-C), CF (red) was co-localized with fibronectin (green), suggesting that CF was 
bound to the ECM. Little ferritin-related fluorescence was seen in the livers of 
naive rats (Fig. 6.2 G-I). In TEM, CF was also observed in the perisinusoidal 
space (Fig. 6.8 E). NF was mostly found in Kupffer's cells and endothelial cells of 
the hepatic sinusoid (Fig. 6.2 D-F).  Taken together, our immunofluorescence and 
TEM results thus confirmed that CF accumulated in the perisinusoidal space of 
the liver.
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Figure 6.1. CF-labeling of the ECM of the hepatic sinusoid is detectable using 
MRI. In vivo with MRI (A-C) revealed detectable differences in contrast between 
rats injected with CF (A), NF (B), and naive control animals (C). Image signal 
magnitude in the liver was normalized to surrounding muscle (D). The differences 
in average normalized signal magnitude were statistically significant between all 
groups (α = 0.05). Ex vivo MRI (E-G) revealed dark striations in CF-labeled livers 
(E). Livers of NF-inoculated rats show diffuse signal darkening throughout the 
entire liver (F) whereas those of naive rats were bright (G). Striations in the 
images of CF-labeled liver are consistent with the distribution of hepatic 
sinusoids. Line profiles in images of the ex vivo livers show discernible MRI 
signal decrease in the hepatic sinusoid of CF-labeled livers as compared to NF 
and unlabeled control livers (H). n = 6 per group. Error bars equal ± the standard 
error of the mean.
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Figure 6.2. CF labels the perisinusoidal ECM 1.5 hours after intravenous 
injection, as shown in 63X immunofluorescence imaging. A-C show that CF (red) 
and fibronectin (green) are co-localized, consistent with ECM labeling with CF. 
No co-localization of NF with fibronectin is observed (D-F); instead NF appears to 
be taken up into macrophages and endothelial cells. Minimal ferritin 
immunofluorescence was observed in the unlabeled control liver (G-I). Scale bar 
= 20 µm, cell nuclei are stained with DAPI (blue).
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   To better understand the timing of CF uptake in the liver, we performed 
ex vivo MRI on livers that were perfused, fixed, and excised 1.5 hours, 2, 4, and 
7 days after CF-injection. T2*-weighted MRI images revealed that the dark 
striations due to the accumulation of CF are apparent 1.5 hours injection (Fig. 6.3 
A) but become diffuse throughout the liver 2 and 4 days after CF-injection (Fig. 
6.3 B-C). CF was no longer detectable in the liver after 7 days (Fig. 6.3 D). We 
also performed immunofluorescence microscopy on livers perfused and fixed 1.5 
and 3 hours after CF-injection. Immunofluorescence shows that CF was taken 
into hepatocytes, Kupffer’s cells, and endothelia by 3 hours after injection (Fig. 
6.3 E-F). These data suggest that labeling of the perisinusoidal ECM is transient 
and most evident with MRI 1.5 hours after injection of CF. Furthermore, CF 
appears to be cleared from the liver within 7 days.
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Figure 6.3. Specific, transient labeling of the perisinusoidal ECM. CF is moved 
into the liver parenchyma three hours after injection and is cleared from the liver 
by one week after injection. Immunofluorescence imaging of the liver from a 
healthy rat sacrificed 1.5 CF injection (A) shows that CF (red) is specifically 
labeled to the ECM (green). Immunofluorescence of the liver from a healthy rat 
sacrificed 3 hours after injection shows that CF has been internalized into 
hepatocytes, Kupffer’s cells, and endothelia (B). Cell nuclei are stained with 
DAPI and fluoresce blue. Scale bar = 20 µm. T2*-weighted MRI 1.5 hours after 
injection reveals a spatial pattern of CF-accumulation consistent with the 
distribution of hepatic sinusoids. CF distribution, observed with MRI, appears 
diffuse throughout the liver parenchyma at 2 days and 4 days after injection (C - 
E). CF is no longer detectable in the liver 7 days after injection (F).
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 Perisinusoidal ECM labeling by CF decreases with steatohepatitis. 
We performed experiments to establish whether CF-accumulation in the 
perisinusoidal space is altered by the development of non-alcoholic 
steatohepatitis (NASH) in a rat model. Rats were fed a methionine choline 
deficient (MCD) diet, which has been shown to precipitate NASH-like symptoms 
(George et al., 2003; McCuskey et al., 2004; Rinella et al., 2008; Teramoto et al., 
1993). The rats began to lose weight as soon as one week after the start of the 
MCD diet (Fig. 6.4 A) but showed no other signs of disease. Serum alanine 
transaminase (ALT) measurements indicated that the dietary NASH model was 
established by 14 weeks in rats fed the MCD diet (Fig. 6.4 B). At this point, MCD-
fed and control rats were imaged in vivo with MRI before and after injection of 
CF. Before CF injection, the livers of rats fed the MCD diet had decreased MRI 
signal magnitude compared to controls (Fig. 6.5 A-D), indicating a decrease in T2* 
with the development of NASH. Importantly, the average in vivo signal magnitude 
(Fig. 6.5 E) of the livers of rats fed the MCD diet did not darken after CF 
administration (α = 0.05). 
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Figure 6.4. Rats fed a methionine choline deficient (MCD) diet begin to lose 
weight as soon as one week after the start of the diet (A). ALT values in rats fed 
the MCD diet were significantly higher (α = 0.05) than those from rats fed the 
control diet, indicating that NASH had been established in rats fed the MCD diet 
(B). n = 6 rats per group. Error bars equal ± the standard error of the mean.
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Figure 6.5. Reduced CF-labeling of the perisinusoidal ECM of the liver is 
detectable in vivo in the rat model of non-alcoholic steatohepatitis (NASH) using 
T2*-weighted MRI. In vivo MRI shows darkening in the images of MCD liver tissue 
before injection of CF compared to naive control (A, C). Signal magnitude did not 
change in liver tissue of MCD rats after injection of CF (B), while substantial 
darkening of liver tissue occurred in control rats after CF injection (D). To quantify 
the group differences, the liver signal was compared to surrounding muscle (E). 
Liver to muscle signal ratios from MRIs of pre- and post-injection control rats are 
statistically different, but pre- and post-injection ratios from rats fed the MCD diet 
are not (α = 0.05). n = 6 for each group. Error bars equal ± the standard error of 
the mean.
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 The in vivo MRI signal magnitude differences were consistent with in vivo 
liver T2* measurements (Fig. 6.6 A-D). Histograms (Fig. 6.6 E-F) showed a broad 
shift in T2* in control rats after the injection of CF. No such shift was seen in MCD-
fed rats. The average in vivo T2* (Fig. 6.6 G) in rats fed the MCD diet was 5.7 ± 
0.7 ms before injection of CF and 5.6 ± 0.5 ms after injection, which was not 
significantly different (α = 0.05). The average in vivo T2* in control rats was 12.3 ± 
0.8 ms before injection of CF and 7.5 ± 0.8 ms after injection. There was a 
significant decrease (~40%, α = 0.05) in T2* of age-matched healthy rats after 
CF-injection. 
 The in vivo MRI results were confirmed by our ex vivo liver T2* 
measurements (Fig. 6.6 H-K). Histograms (Fig. 6.6 L-M) of T2* in the entire liver 
confirmed a decrease in T2* in control rats after injection of CF. No such decrease 
was observed in MCD-fed rats. The average ex vivo T2* (Fig. 6.6 N) in rats fed 
the MCD diet was 6.3 ± 0.4 ms before injection of CF and 6.7 ± 0.3 ms after 
injection, which was not significantly different (α = 0.05). The average ex vivo T2* 
in control rats was 14.3 ± 1.3 ms before injection of CF and 7.3 ± 0.9 ms after 
injection. There was a significant decrease (~50%, α = 0.05) in T2* of healthy rat 
livers after CF-injection in ex vivo MRI.
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Figure 6.6. Reduced CF-labeling of the perisinusoidal ECM of the liver in the rat 
model of NASH is detectable in vivo and ex vivo by generating maps of 
measured T2* (A-D, H-K). Histograms (E-F and L-M) of T2* in the entire liver 
show a broad shift in T2* in control rats after injection of CF, both in vivo and ex 
vivo. No such shift was seen in MCD-fed rats. A significant (α = 0.05) reduction in 
average in vivo and ex vivo T2* (G, N) was observed after CF injection in livers 
from rats fed the control diet. T2* did not change significantly after CF injection in 
livers from rats fed the MCD diet. n = 6 per group for in vivo T2* measurements. n 
= 2 for the ex vivo pre-injection control group. n = 3 for the ex vivo pre-injection 
MCD-fed group. n=6 for both ex vivo post-injection groups. Error bars equal ± the 
standard error of the mean.
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 We used immunofluorescence, TEM, and inductively coupled plasma 
optical emission spectroscopy (ICP-OES) to investigate the mechanism of CF-
labeling in MCD-fed and control rats. There were distinct differences in the spatial 
distribution of intravenously delivered CF between the livers of healthy rats and 
rats fed the MCD diet, as observed with immunofluorescence microscopy. 
Reduced ferritin immunofluorescence in the livers from rats fed the MCD diet 
compared to controls suggested reduced CF-labeling with NASH (Fig. 6.7 B). 
The redistribution of fibronectin immunofluorescence suggests thickening of the 
ECM and tissue displacement by lipid droplets. With TEM we observed CF in the 
perisinusoidal ECM in livers of both control and MCD-fed rats (Fig. 6.8 E, F). 
While it was difficult to quantify CF content using TEM due to the limited field of 
view, in the sections we examined there was less CF bound in the perisinusoidal 
space of livers from MCD-fed rats. We also observed lipid droplets displacing the 
hepatic parenchyma in livers from rats fed the MCD diet (Fig. 6.7 A-B, and Fig. 
6.8 B). TEM revealed wide (~150 nm) fenestrations in the healthy endothelium 
(Fig. 6.8 E). In contrast, endothelia of livers from rats fed the MCD diet appear 
abutted against one other (Fig. 6.8 F), suggesting reduced exposure of blood to 
the perisinusoidal space. This reduced exposure of the blood to the ECM may 
account for the decrease in CF uptake we observed in MRI, 
immunofluorescence, and TEM. The reduced accumulation of CF in the livers of 
MCD-fed rats is further supported by liver iron concentration measurements 
made using ICP-OES (Fig. 6.9). Liver iron concentrations in MCD-fed rats 
increased 98 µg/g liver after injection of CF versus 217 µg/g liver in healthy rats. 
The increase in liver iron concentration after CF injection is exclusively due to the 
iron core of the accumulated CF. These data indicate that MCD-fed rats bind 
55% less CF in the liver than their healthy counterparts.
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Figure 6.7. Distinct differences in the spatial distribution of intravenously 
delivered CF are apparent between the livers of healthy rats and rats fed the 
MCD diet (C, D), as observed with immunofluorescent microscopy. Reduced 
ferritin immunofluorescence in the livers from rats fed the MCD diet compared to 
controls indicated reduced CF-labeling with NASH. The ECM (green) pattern in 
MCD livers appears redistributed compared to control livers due to thickening 
and displacement by lipid droplets (A, B). Tissue was collected from animals 
three hours after CF administration. Cell nuclei are stained with DAPI and 
fluoresce blue. Scale bar = 20 µm.
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Figure 6.8. CF is localized to the perisinusoidal space in control and MCD-fed 
rats (E, F). The perisinusoidal space of rats not inoculated with CF is clear of CF 
(C, D). Wide (~150 nm) endothelial fenestrations are visible in livers from control 
rats (E) while endothelia appear abutted in livers from rats fed the MCD diet (F). 
2.65 kx transmission electron microscopy images show large lipid droplets inside 
of hepatocytes in livers from rats fed the MCD diet (B). No such droplets were 
seen in livers from rats fed the control diet (A). White scale bars = 5 µm, black 
scale bars = 200 nm.
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Figure 6.9. Liver iron concentrations were measured by inductively coupled 
plasma optical emission spectroscopy (ICP-OES). Liver iron concentrations in 
MCD-fed rats increased 98 µg/g liver after injection of CF versus 217 µg/g liver in 
healthy rats. The increase in liver iron concentration after CF injection is 
exclusively due to the iron core of the accumulated CF. These data indicate that 
MCD-fed rats bind 55% less CF in the liver than their healthy counterparts. Pre-
injection MCD n = 3, pre-injection CTRL n = 3, post-injection MCD n = 6, post-
injection CTRL n = 6. Error bars equal ± the standard error of the mean.
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 Taken together, our data indicate that CF specifically labels the 
perisinusoidal ECM and that this labeling is detectable in vivo using MRI. The 
labeling of the perisinusoidal ECM was transient, peaking within three hours of 
injection. There was reduced CF-labeling of the perisinusoidal ECM in rats fed 
the MCD diet, as observed with in vivo and ex vivo MRI, immunofluorescence, 
and TEM. ICP-OES indicated that the CF-labeling of the perisinusoidal space 
was 55% less in MCD-fed rats compared to their healthy counterparts. TEM 
suggested that circulatory access of CF to the perisinusoidal space is blocked in 
disease by abutted endothelia. We conclude that the reduced perisinusoidal 
labeling by CF is thus due to excessive ECM deposition and loss of endothelial 
fenestrations associated with the advancement of NASH. 
DISCUSSION
 This work demonstrates that cationic iron oxide nanoparticles (CF) may 
be used to target and detect the ECM of the hepatic sinusoid using MRI, and that 
the binding of cationic nanoparticles may be used to detect structural and 
functional changes in the hepatic sinusoid in a rat model of non-alcoholic 
steatohepatitis (NASH). 
 It is likely that CF passes through the endothelial fenestrations of the 
normal hepatic sinusoid and bind to the perisinusoidal ECM through an 
electrostatic interaction between the cationic nanoparticle and anionic 
proteoglycans that comprise the ECM. The binding of CF to the perisinusoidal 
ECM appears to be highly specific and transient (Figs. 6.2-6.3). 
Immunofluorescence microscopy suggests that the cationic nanoparticles used in 
this study are internalized into the liver parenchyma after three hours. 
  One potential concern about the use of CF as a contrast agent is 
whether it is toxic in MRI-detectable doses. To address this, we have recently 
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found that CF has minimal acute or chronic toxicity at these doses, measured by 
renal and hepatic enzyme markers and lymphocyte counts (Beeman et al., 
2012). In the future, the dose of CF used here may likely be reduced ~100-fold 
via modification of the metal core of the apoferritin protein to increase ferritin 
relaxivity (Bulte et al., 1995; Clavijo Jordan et al., 2010; Uchida et al., 2008).
 We have shown that the amount of specific binding of CF to the 
perisinusoidal ECM is reduced in a rat model of NASH. This reduced binding of 
CF to the perisinusoidal ECM is observable with MRI (Figs. 6.5-6.6). One 
concern for in vivo imaging is the fact that the echo time (TE) is on the order of 
the T2* in the liver in the animals with NASH. This raises the possibility that CF-
accumulation did occur but was not detected because of the reduced dynamic 
range of the T2* measurement. This is not the case, however, because ex vivo 
imaging with a higher background T2* and a greater range of TE values showed 
the same reduced CF-accumulation. The reduced accumulation of CF in the 
livers of MCD-fed rats was also confirmed with ICP-OES, which revealed 55% 
less iron added to the tissue after CF injection in MCD-fed rats compared to their 
healthy counterparts. Since the increase in liver iron concentration after CF 
injection is exclusively due to the iron core of the accumulated CF, these data 
indicate 55% less CF binding in MCD-fed rats.
 The reduced binding of CF to the perisinusoidal ECM in rats fed the MCD 
diet is likely caused by changes to the perisinusoidal ECM and loss of endothelial 
fenestrations (Farrell et al., 2008; Friedman, 2000; Iredale, 2007; Lough et al., 
1987; Martinez-Hernandez & Amenta, 1995). Changes to the structure of and 
macromolecular access to the perisinusoidal ECM were identified in our 
immunofluorescence and TEM images, which show distinct differences in 
perisinusoidal fibronectin distribution and thickness (Fig. 6.7), reduced 
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accumulation of CF in the perisinusoidal space (Figs. 6.7-6.8), and suggest a 
loss of endothelial fenestrations (Fig. 6.8). We propose that the deposition of scar 
tissue in the hepatic sinusoid and the loss of endothelial fenestrations blocks 
macromolecular access to the perisinusoidal space. Detecting the reduced 
accumulation of CF in the perisinusoidal space with MRI might therefore serve as 
a molecular imaging biomarker for changes in macromolecular access to the 
hepatic parenchyma in chronic liver disease.
 Conclusions. The goal of this work was to establish a non-invasive, 
ECM-specific molecular imaging biomarker to detect NASH-related changes in 
macromolecular access to the hepatic parenchyma. We have shown that 
intravenous injection of cationized ferritin (CF) allows for MRI detection of the 
perisinusoidal ECM through accumulation of the particles in the extracellular 
matrix. Furthermore, there is an MRI-detectable reduction in binding of CF to the 
perisinusoidal ECM in a rat model of NASH. The reduced binding of CF to the 
perisinusoidal ECM in the NASH model is likely caused by reduced 
macromolecular access to the perisinusoidal space due to fibrosis and loss of 
endothelial fenestrations. To our knowledge, this is the first report of an in vivo 
targeted imaging agent that is sensitive to NASH-related changes in 
macromolecular access to the perisinusoidal space. The reduced, transient 
accumulation of intravenously injected cationic nanoparticles may report on 
changes in macromolecular access to the liver parenchyma in chronic liver 
diseases such as non-alcoholic steatohepatitis.
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CHAPTER 7
SUMMARY AND FUTURE DIRECTIONS
 The work presented in this volume has focused on the development of a 
non-toxic MRI probe to detect tissue microstructure. Specifically, we set out to 
develop a cationic probe that specifically targets and renders visible the 
extracellular matrix (ECM) underlying fenestrated endothelia. It was with this goal 
in mind that five projects were defined and executed. These five projects will be 
summarized and potential future applications for this cationic MRI probe will be 
explored in the coming pages.
SUMMARY
 Detecting kidney glomeruli in vivo and ex vivo. The kidney glomerulus 
is the first line of filtration in the nephron. A single human kidney has as many as 
2,000,000 nephrons that are responsible for maintaining blood ion and glucose 
concentrations as well as removal of metabolic waste and regulation of blood pH. 
Changes in the number (Nglom) and size (Vglom) of glomeruli have been linked 
to a host of renal and systemic disease (Brenner et al., 1988; Hoy et al., 2008; 
Puelles et al., 2012), though techniques to measure Nglom and Vglom require 
resection and destruction of the entire kidney (Bertram et al., 1992). Furthermore, 
these methods merely extrapolate measurements from a small sample 
population of approximately 40 glomeruli. A method that measures every 
glomerulus in the kidney and is non-destructive would prove vital in preclinical 
research and potentially in clinical diagnostics.
 In the work presented in Chapter 2 we injected rats intravenously with the 
naturally derived, MRI-visible cationized ferritin (CF) nanoparticle. We then 
perfused the rats, resected their kidneys, and imaged the kidneys ex vivo with 
T2*-weighted MRI. We show that CF specifically labels the glomerulus of the rat 
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kidney and that this accumulation of CF renders each glomerulus visible when 
the kidney is imaged with T2*-weighted MRI. Furthermore, we show that labeled 
glomeruli may be identified, counted, and their sizes measured from the T2*-
weighted MRI volumes. We compare the measurements of Nglom and Vglom 
made with the MRI-based technique with those made using the gold-standard 
acid maceration and disector/fractionator methods and find that the MRI-based 
method yields similar results to the histological methods. Furthermore, we show 
that the MRI-based method may be used to measure the intra-renal glomerular 
volume distribution - a measurement that was previously unobtainable using 
histology. In this work we conclude that the presented MRI-based technique 
yields comparable measurements of glomerular volume and size while providing 
the unique intra-renal glomerular volume distribution measurement.
 Chapter 3 introduced an important extension of the work of Chapter 2. In 
this work we inoculated fresh human transplant kidney with CF with the goal of 
measuring Nglom and Vglom with MRI. This work is presented as a proof of 
concept that human glomeruli may be targeted with CF and subsequently 
visualized with MRI. We show that this is also possible to measure the number 
and size of human glomeruli using this technique. As with the study performed in 
rat kidneys, the intra-renal glomerular volume distribution may be measured - a 
measurement never before obtained in human kidneys. This technique may 
provide an opportunity to assess the viability of transplant kidneys before they 
have been grafted into a recipient and may be a big step towards measuring 
Nglom and Vglom in the clinic.
 Finally, in Chapter 4 we introduce a novel ferritin based nanoparticle with 
a highly paramagnetic core for improved in vivo detection of glomeruli. 
Unmodified CF is a superparamagnetic nanoparticle that causes spin dephasing, 
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rendering a darkened signal at the site of CF accumulation. This provides 
excellent contrast in perfused, ex vivo organs that lack a dark blood background. 
Unfortunately, this dephasing is quite difficult to distinguish in vivo in highly 
vascularized organs with a dark blood background. It is for this reason that we 
have set out to develop a nanoparticle that behaves in the same way as CF 
when injected, with the exception that it creates a bright signal contrast instead of 
dark. In this chapter we show that the iron core of ferritin may be doped with 
tungsten. The tungsten dopant prevents exchange coupling within the metallic 
core of the protein. This reduces the r2 of the nanoparticle while retaining its 
paramagnetic properties and effectively yields a large, paramagnetic nanoparticle 
with a high longitudinal relaxivity (r1). We go on to show that the tungsten doped 
ferritin nanoparticle can be cationized, yielding a novel targeted nanoparticle 
called paraCF that may be used to detect anionic ECM components that underly 
fenestrated endothelia. We also show that paraCF may be used to detect kidney 
glomeruli in vivo based on the accumulation of paraCF in the glomerular 
basement membrane. The binding of paraCF to the glomerulus is highly 
detectable against the strong blood background of the kidney with T1-weighted 
MRI. This highly detectable MRI contrast agent may be used to detect glomerular 
structure and function in vivo with a spatial resolution that has previously been 
impossible.
 Nanoparticle toxicity and biodistribution. The results presented in 
Chapters 2-4 suggest that CF may eventually be used for routine assessment of 
glomerular integrity via intravenous injection and subsequent MRI. The goal of 
the work presented in Chapter 5 was to establish the nephro-, hepato- and 
immunotoxicity of intravenously injected CF as well as the clearance rate of 
accumulated CF. We also investigate other organs with a fenestrated 
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endothelium for CF-accumulation using MRI and immunofluorescence 
microscopy. We find that intravenously injected CF does not affect renal function, 
hepatic function, or change total leukocyte counts at the MRI-detectable doses 
and report a CF clearance rate of ~ 7 days. Furthermore, we find that, in addition 
to labeling the glomerulus, CF labels the extracellular matrix of the hepatic 
sinusoid of the liver, the extracellular glycocalyx of the alveolar endothelia, and 
the macrophages of the spleen. While there is still substantial work to be done to 
prove that CF is completely non-toxic, we conclude from this work that CF may at 
least serve as a useful, minimally toxic contrast agent to detect a number of 
structures in the body.
 Detecting microstructural changes in chronic liver disease. In 
Chapter 5 we showed that CF labels the ECM of the perisinusoidal space in the 
liver and that this accumulation is detectable with MRI. We expanded upon this 
observation in Chapter 6, presenting a CF-based MRI technique to detect 
microstructural changes to the hepatic sinusoid in chronic liver disease. The 
perisinusoidal space is the site of molecular exchange between the blood plasma 
and the liver parenchyma (the hepatocytes). The perisinusoidal space lies 
between a fenestrated endothelium and the hepatocytes inside of the hepatic 
sinusoid. Chronic liver diseases such as non-alcoholic steatohepatitis (NASH) 
are known to cause major microstructural changes to the liver, including 
excessive deposition of ECM in the perisinusoidal space as well as a loss of 
endothelial fenestrations in the hepatic sinusoid (Farrell et al., 2008; Friedman, 
2000; Iredale, 2007; Lough et al., 1987; Martinez-Hernandez & Amenta, 1995). In 
this work we demonstrate that the ECM-specific CF may be used to detect 
healthy perisinusoidal ECM in vivo with MRI. We further show that the binding of 
CF to the perisinusoidal ECM is reduced by 55% in a rat model of NASH, and 
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that this reduced binding is detectable in vivo with MRI. Immunofluorescence and 
electron microscopy indicated that the reduced binding is due to limited 
macromolecular access to the perisinusoidal space caused by NASH-related 
microstructural changes. The reduced accumulation of intravenously injected CF 
may report on changes in macromolecular access to the liver parenchyma in 
chronic liver diseases such as NASH. 
FUTURE DIRECTIONS
 T2* susceptibility volume versus the actual volume of glomerulus. In 
Chapters 2 and 3 we have demonstrated that glomerular volume (Vglom) may be 
measured from MRI volumes of kidneys based on the volume of susceptibility 
artifact caused by the accumulation of CF in the glomerular basement 
membrane. While we have empirically shown this technique to be accurate, the 
nature of superparamagnetism should also be considered when making such 
measurements. The accumulation of a superparamagnetic probe can cause a 
susceptibility artifact that reaches far beyond the region in which the probe has 
accumulated. This appears to not be the case when glomeruli are labeled with 
CF, but we would like to prove that the volume of susceptibility artifact caused by 
the accumulation of CF in the GBM is indeed an accurate representation of 
glomerular volume. 
 We intend to accomplish this by taking a very small biopsy from a CF-
labeled kidney (~ 1 mm3) and performing a T2*-weighted gradient echo on the 
sample. We will then measure Nglom and Vglom from the MRI volumes in the 
same manner as Chapters 2 and 3. Once, the MRI-based measurements are 
complete we will prepare the biopsy for disector/fractionator stereology and 
measure Nglom and Vglom of the biopsy by sampling every glomerulus in the 
biopsy. Because the biopsy is so small, we will be able to co-localize glomeruli 
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visualized with MRI with the same glomeruli in our histological section. This will 
allow us to directly compare our MRI-based measurements of individual 
glomerular volumes with those made using stereology. Furthermore, this 
experiment will allow us to directly test the ability of our MRI-based method to 
identify glomeruli. With our MRI volume co-registered with the histological volume 
we will be able to compare false-positives and false-negatives from the algorithm.
 Glomerular populations. One of the strong advantages of the MRI-
based technique is its ability to sample every glomerulus in the kidney. This is 
something that has never been possible due to the huge number of glomeruli in a 
single kidney. It is our belief that the complete sampling of kidney glomeruli may 
be exploited to define unique glomerular populations in healthy and diseased 
kidneys.
 We believe that unique populations of glomeruli may be defined by their 
CF-labeling intensity (the amount of CF that has accumulated in a glomerulus), 
and location in the kidney. We have run initial analyses on the images of CF-
labeled rat kidneys to extract such data. A three dimensional histogram of 
glomerular location (normal distance from the surface of the kidney) versus 
relative glomerular labeling intensity (as measured by the ‘darkness’ of the 
glomerulus with MRI) suggests two distinct populations of glomeruli (Fig. 7.1). 
These populations are separated mostly by their labeling intensity. It is likely that 
the amount of CF that binds to the GBM is proportional to the plasma filtration 
rate across the glomerular capillary wall and/or the amount of GBM that is 
exposed to the capillary space. Future work will certainly be directed towards 
relating the labeling magnitude of glomeruli to glomerular health (which will be 
further discussed below).
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Figure 7.1. A three-dimensional histogram of relative glomerular labeling intensity 
(defined as the ‘darkness’ of the glomerulus as measured by with MRI) versus 
the normal distance of a glomerulus from the surface of the kidney. The color of 
each cell represents the number of glomeruli binned at the coordinate of the cell. 
This histogram suggest two distinct populations of glomeruli separated by their 
labeling intensity.
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 Assessing glomerular health by dynamically measuring CF-uptake. 
A potential method to assess glomerular health would be to dynamically track the 
accumulation of CF in the glomerulus using a fast MRI sequence. The manner in 
which the glomerulus filter macromolecules such as ferritin is still quite 
contentious (Deen & Lazzara, 2004; Deen, Lazzara, & Myers, 2001; Smithies, 
2003). We would like to avoid this decades-long debate and simply take the two 
facts that we have developed in the foregoing text - that cationized ferritin binds 
to the GBM and that the accumulation of CF in the GBM renders glomeruli 
detectable with MRI - to assess the health of nephrons. 
 The exact metric for assessing glomerular health with MRI will depend on 
an in vitro experiment that we must conduct. We propose to perfuse a fresh rat 
kidney with an isolated organ perfusion pump. Using this pump we will regulate 
the intra-capillary pressure and the intra-capillary CF concentration. This 
experiment is designed to answer one important question - Is the accumulation of  
CF in the GBM driven by diffusion or by plasma flow across the capillary wall 
(GFR). The rate of CF accumulation in the GBM will be assumed to be 
proportional to the rate at which a voxel containing a glomerulus grow darker. If 
this experiment reveals that the accumulation of CF is independent of intra-
capillary pressure then it stands to reason that the accumulation of CF is strictly 
diffusion driven. If the accumulation of CF in the GBM increases with intra-
capillary pressure then its accumulation has a flow component. Either result is 
acceptable but each leads to a unique conclusion. If we find CF accumulation to 
be strictly diffusion driven then we are effectively measuring the exposed 
glomerular filtration surface area by dynamically monitoring CF uptake. the 
exposed filtration surface area is a very important metric that has strong 
implications about the state of a glomerulus. An abnormally large amount of GBM 
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is exposed to the intra-capillary space suggests that the glomerulus is growing in 
size to account for filtration deficits. This process may ultimately lead to 
hyperfiltration that is damaging to the glomerulus and ultimately leads to sclerosis 
of the whole nephron (Puelles et al., 2012). If we find that there is a flow 
component, then we have found a method to measure the single nephron 
glomerular filtration rate (snGFR) of every perfused glomerulus in the kidney. 
This would have major implications on the way kidney disease is diagnosed and 
monitored.
 The experiment described above would take place in vitro, allowing for a 
resolution that is not attainable in vivo. This means that in vivo measurements of 
snGFR, Nglom, and Vglom are not likely in the ways that we have described in 
vitro. In vivo we are likely to have approximately 10-20 glomeruli in a 1-2 mm3 
voxel but, by dynamically monitoring CF accumulation in vivo, we can still make 
physiologically important measurements. Based on the results of the experiment 
described above, we will either be able to measure the the total glomerular 
filtration surface area within a voxel - a measurement that may report on whether 
the local glomeruli are hyperfiltering, or we will be able to measure the GFR of 
the 10-20 glomeruli in a single voxel - a measurement that provides 
approximately 10,000 times more information than the bulk GFR measurements 
currently made in the clinic (assuming one million glomeruli across both kidneys 
of a human).
Tubules
 Another future goal of this work is to identify the tubules of the nephron 
based on the binding of CF that has leaked through the glomerulus. We have 
noticed in the MRI volumes of healthy rat kidneys that there is are dark striations 
originating at a labeled glomerulus that point towards the center of the kidney. 
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Immunofluorescence microscopy suggests that these striations may be 
visualization of CF-labeled proximal tubules (Fig. 7.2).
 We have identified these tubules (Fig. 7.3) based on their signal 
magnitude values and an origin at the glomerulus. We then measured the 
volume and the relative labeling intensity (defined as the amount of signal 
darkening caused by CF-accumulation) of each tubule and its attached 
glomerulus. This process was done ex vivo in a healthy rat kidney and in a 
kidney from a rat with glomerularsclerosis. It turns out the the ratio of glomerular 
volume to tubular volume is 0.5816 ± 0.3429 in the healthy rat and 0.4780 ± 
0.2702 in the rat with glomerularsclerosis and the ratio of glomerular labeling 
intensity to tubular labeling intensity is 0.9067 ± 0.0631 in the healthy rat and 
0.8033 ± 0.0362 in the rat with glomerularsclerosis. It is likely that the volume 
ratio is lower in the rat with glomerularsclerosis not because the glomerulus is 
smaller in the sclerotic kidney but instead because more of the tubule was 
labeled due to excessive leakage of CF into the proximal tubule. Conversely, 
most labeling of the proximal tubule is prevented by the glomerulus in the healthy 
kidney. The same can be said for the differences in labeling intensity. These 
preliminary data suggests that the ratio of glomerular volume and labeling 
intensity, as measured with MRI, may be related to the progression of kidney 
disease.
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Figure 7.2. CF-labeling of the proximal tubule. Dark striations originating at 
labeled glomeruli and pointing towards the center of the kidney are visible in 
gradient echo MRI volumes of kidneys inoculated with CF (B). No such striations 
are visible in the control kidneys (A). Immunofluorescence microscopy (C) 
suggests that these dark striations are caused by CF-labeling (red) of the 
proximal tubule. An area ofCF-related fluorescence in a tubule is identified by the 
arrow.
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Figure 7.3. CF-labeled tubules may be identified based on their signal magnitude 
value and an origin at a glomerulus. Glomeruli are overlain with red and tubules 
are overlain with blue.
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 Translation to humans. Finally, Chapter 3 has strong implications 
regarding the use of CF in humans. It was shown that CF does indeed 
specifically bind to the GBM of the human glomerulus and that the accumulation 
of CF in the glomerulus is MRI-detectable. Furthermore, our initial study of CF 
toxicity and biodistribution suggests that CF does not adversely affect renal 
function. This is promising evidence if CF is ultimately going to be applied as a 
diagnostic tool in the clinic. Of course, this data merely suggests that CF is non-
toxic at MRI detectable doses. Substantial preclinical work needs to be done 
before the agent can ever be injected into a human.
 We believe that the first step towards translation of CF to the clinic is to 
recombinantly produce MRI-detectable human ferritin in bacteria. This has 
already been shown to be possible by Uchida, et at. (Uchida et al., 2008). An 
MRI contrast agent for use in humans that is based on human ferritin should 
minimize biocompatibility issues. The recombinant production of human ferritin 
and the cationization will have to conform to good manufacturing practice. We 
have established a relationship in the biomanufacturing industry to set up 
facilities that conform to good manufacturing practices.
 Once the process of synthesizing and cationizing human ferritin has been 
developed in accordance with good manufacturing practices, we will confirm that 
the cationized recombinant human ferritin has the same targeting- and signal-
darkening effect as CF and begin thorough toxicity screening in a rodent model. 
During the toxicity testing we will test a minimum of three doses on adult rodents. 
The acute toxicity studies will take place within 2 hours of exposure to the agent, 
sub-chronic testing will take place over a period of 90-days after exposure, and 
chronic toxicity studies will take place over a period of 12-24 months after 
exposure. Carcinogenicity and reproductive, developmental, dermal, ocular, 
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neuro-, and genetic toxicity will also be assessed during this time. All preclinical 
research protocols are subject to change based on consultation with the U.S. 
Food and Drug Administration’s Pre-investigational new drug consultation 
program.
 Once all of the preclinical toxicity data has been collected, a 
investigational new drug (IND) application will be filed. If cleared we will interface 
with physicians, clinical facilities, and industry experts to begin a phase 1 clinical 
trial. 
CONCLUSIONS
 The goal of the work presented in this volume was to develop a cationic, 
MRI-detectable probe for non-invasive detection of kidney glomeruli and the 
perisinusoidal space of the liver. The preceding chapters have shown that the 
specific binding of intravenously injected cationized ferritin renders individual 
glomeruli of the kidney MRI-visible ex vivo. Detection of individual glomeruli with 
MRI has allowed for comprehensive measurements of glomerular number and 
size - parameters that have broad implications about systemic health but have 
previously been unattainable in the clinic due to the destructive nature of 
established techniques. We also demonstrate in vivo detection of glomeruli and 
detection of glomeruli in human transplant kidneys. These results have strong 
implications about the potential use of cationized ferritin in the clinic to diagnose 
renal diseases. Translation of cationized ferritin to human will be the focus of 
future work.
 We have also shown in this work that cationized ferritin specifically binds 
to the extracellular matrix of the perisinusoidal space - the site of exchange 
between the hepatic parenchyma and the blood plasma. Chronic liver disease is 
detrimental to hepatic function in part because it blocks macromolecular access 
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to the perisinusoidal space. We have shown that cationized ferritin is a marker for 
macromolecular access to the hepatic parenchyma and may be a useful tool for 
monitoring chronic liver disease.
 Finally, we have shown an initial study on the toxicity of intravenously 
injected cationized ferritin which reports minimal impact on renal, hepatic, and 
immune function. Furthermore, we show that cationized ferritin binds in a number 
of other organs.
 The data presented in this volume suggests that cationized ferritin may 
find broad application in detecting and monitoring kidney and liver diseases in 
both preclinical and clinical settings.
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IACUC Use Only 
Date: 
 
 IACUC Protocol No.: 12-1235R 
 
 
ANIMAL USE PROTOCOL  
ARIZONA STATE UNIVERSITY INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE 
(revised October 2011) 
 
Please read “Instructions for Completing the Animal Use Protocol” before completing. Upon approval, this 
protocol will become a public record so please follow instructions carefully. 
 
PROJECT/PROGRAM TITLE: Extracellular Matrix Targeting MRI Contrast Agents 
SPECIES REQUESTED: Rats and Mice  
I. PERSONNEL INFORMATION 
A. A single member of the university faculty and/or Principal Investigator (PI) is considered the responsible 
individual. 
NAME:  Kevin M. Bennett  TITLE:  Assistant Prof. 
AFFILIATION: SBHSE Office Phone #  480-727-9790 
Cell Phone #: 443-789-8679 E-Mail: Kevin.m.bennett@asu.edu 
 
B. Additional contact, if any, for IACUC business 
NAME:   TITLE:   
AFFILIATION:  Office Phone #   
Cell Phone #:  E-Mail:  
C. Protocol Type 
 Non-funded research 
 Grant / Contract (Also submit grant proposal with this protocol) 
Granting Agency: American Heart Association Deadline:  
Proposal Title: MRI-based techniques to measure whole-kidney nephron endowment 
ASU Proposal # or Award #:  12BGIA9840020  
Co-Investigator(s): Wu (Comp Sci), Bertram (Monash U) 
 
   Teaching 
 Course Number and Title:  
 
 
D. Protocol Status:  
 New 
 2 
  Renewal—Previous Protocol #: 09-1021R 
 
 Revision—Previous Protocol #:  
 
 
 
E. List the PI and all persons who will work with live animals under this protocol. 
 
 
 
 
 
Name 
 
 
 
 
 
Title 
 
 
 
 
 
ASURITE 
name 
Role in Protocol (What 
procedures will each 
person be doing on live 
animals?) 
Species with 
which individual 
will have direct 
contact (“none, 
“all”, or list 
species)* 
IACUC 
USE 
ONLY 
Training 
(mm/yy) 
Kevin Bennett Assistant 
Professor 
Kmbenne1 Conducting all 
experiments and 
surgery 
all 
Basic & 
Rat 
8/11, 
Mice 
12/11, 
HSQ 
Scott Beeman Graduate 
student 
Sbeeman Brain tumor 
inoculation 
(surgery), cationic 
ferritin (CF) 
administration, 
euthanasia all 
12/11 
HSQ 
Maria (Veronica) 
Clavijo Jordan  
Graduate 
Student  
mclavijo Brain tumor 
inoculation 
(surgery), CF 
administration, 
euthanasia all 
12/11 
HSQ 
Bradley Hann Graduate 
student 
bdhann Brain tumor 
inoculation 
(surgery), CF 
administration, 
euthanasia all 
Basic, 
Rat 
7/10, 
Mice 
12/11, 
HSQ 
Rachel Ginn 
Undergraduate 
RA rginn 
Brain tumor 
inoculation 
(surgery), CF 
administration, 
euthanasia all 
Basic, 
Rat 
3/11, 
Mice 
12/11 
HSQ 
Joseph Georges Graduate 
Student 
jfgeorg Viral synthesis, 
cloning, and animal 
all 12/11, 
HSQ 
done 
 3 
surgery to inject 
DNA 
  
 
For each individual, describe the individual’s training and years of experience with all listed species and 
procedures they will be conducting under this protocol:    
 
 Kevin Bennett – Kevin is an Assistant professor in SBHSE. He has experience with both rat and mouse 
experiments (starting from 7/1998 until the present for rats, including surgery to implant tumors and inject 
contrast agents into the brain, anesthesia, imaging, perfusion, tail- and central vein injections and 
intubation, and from 1/2004 – 1/1008 for mice, including surgery, imaging, anesthesia, and tail vein 
injections and intubation). Since coming to ASU in Jan 2008 he has trained several students in the 
proposed techniques.   
 Scott Beeman – Trained by Kevin Bennett and DACT staff. 3.5 years experience with rats in his PhD 
work, including tail vein injections, perfusions, anesthesia, and post-op care. He has recently started 
working with mice since 8/11 for this work, doing perfusions, IV injections, and imaging.  
 Veronica CLavijo-Jordan- Trained by Kevin Bennett. 4 years experience (since August 2008) with rats 
in PhD work. She has performed anesthesia, intracranial tumor cell inoculations, and imaging.  
Bradley Hann- Trained by Kevin Bennett. 4 years experience in UG and grad research with rats. As and 
UG research assistant at Yale, he performed anesthesia, intracranial injections, perfusions, and imaging. 
At ASU, since 2010, he has been performing anesthesia, biomaterials implantation, and imaging in rats.  
Rachel Ginn- Trained by Kevin Bennett. 1 year experience as part of UG research in the Bennett lab. 
Since 1/2011 she has performed intracranial inoculations, anesthesia, and perfusion.  
Joseph Georges – Trained by Kevin Bennett. A graduate student in the School of Life Sciences since 
2008. He has experience with all the viral synthesis protocols conducted in this research, as he has been 
working with expression of aquaporin 1 on tumor cells for the last 3 years while working at Translational 
Genomics Research Center where he has also been performing intracranial tumor inoculations for the 
same period of time. 
* The answer provided in this column dictates which Level II species-specific IACUC training modules are 
required for each individual. An individual only needs to complete Level II certification for those species 
with which he or she will directly work. 
 
 Note: ASU requires that all personnel engaged in animal research or teaching be qualified through 
training or experience in order to conduct the work humanely.  The IACUC requires that all personnel 
must complete Level I (The Humane Care and Use of Laboratory Animals) and Level II (species-specific) 
training prior to being approved on a protocol.  This training must be renewed every 3 years.  You can 
access the training modules at http://hazel.forest.net/latanet/client/asu/introduction.htm.  Additionally, all 
individuals are required to receive Level III training as needed and submit training documentation to the 
IACUC office.  Please see the IACUC web site (http://researchintegrity.asu.edu/training/animals) for the 
Level I and II modules, Level III training requirements, and the Level III Training Documentation Form. 
 
F. Do you plan to use Department of Animal Care & Technologies (DACT) personnel and resources? If yes, 
describe the support needed?  (If this use is new or an expansion of previous use, please contact the 
DACT well in advance of need).   
Yes, husbandry. 
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II.    PROJECT DESCRIPTION AND PROGRAM REQUIREMENTS 
 The Institutional Animal Care and Use Committee (IACUC) is composed of both active animal users and 
lay persons.  Regardless of background, each member has a vote, so it is particularly important that the 
language of the application be understood by all.  This applies to all sections of the application, but it is 
especially important that the goals and justifications of the proposed research be spelled out in the 
clearest possible terms.  NOTE:  Upon approval, this protocol will become a public record, so please do 
not disclose proprietary information. 
 
A. Please provide a brief (300 words or less) synopsis in LAYMEN TERMS of proposed research.   
 
The goal of this work is to make contrast agents for magnetic resonance imaging (MRI). These agents are small 
particles that are magnetic and are visible with MRI. On the outside of the agents, we place various chemicals 
that stick to different tissues in the body, and we test how these agents work by imaging the animals after the 
injections and by studying the tissues after the animals have been sacrificed. We have made a group of contrast 
agents that stick to various parts of the basement membrane, which is a thin sheet of molecules that guides cells 
during development and allows them to communicate. We will use these agents to detect the basement 
membrane structure from outside the body.  
 
B. PLANNED USE OF ANIMALS.  Begin with a clear statement of purpose and briefly provide 
background information and references to previous work (especially if this is a renewal protocol).  
Include a clear description of the experimental design for all animal experiments planned and explain 
why the experiments must be performed.  It is critical that for each procedure you provide a detailed 
sequence of events that effectively describes what happens to the animals from acquisition to euthanasia 
(if applicable).  Flow charts, diagrams or tables are strongly recommended for complicated experimental 
designs.  Please state how the research is expected to benefit the human community, the animal 
community, and/or society as a whole.  (Details regarding surgical procedures and drug treatments are 
not necessary, as they will be addressed later.) 
  
Purpose  
 The goal of this work is to develop molecular MRI contrast agents that bind to the extracellular matrix 
after systemic or local injection, and to understand how the MRI signal is affected by them. Specifically, we 
are developing superparamagnetic and paramagnetic MRI contrast agents that bind to various extracellular 
matrix (ECM) components, which accumulate after binding and can be detected with MRI. Because the 
relaxivity of the agents has been studied in vitro, we can estimate the local concentrations of the agents on 
the MRI signal. Because the applications of this work are broad, we propose to test the agents in healthy 
adult and developing animals to study their biodistribution. Additionally, we will test the efficacy of local 
injection of the contrast agents into the brain in an animal model of an invasive glioma tumor to detect 
changes in the ECM with tumor growth. We have extended this work to investigate the use of cationic ferritin 
(CF) to detect alterations in the renal basement membrane and the liver. We have added these protocols 
here. 
 
Background and Scientific Merit 
 
The basement membrane (BM) is a major functional component of the extracellular matrix. Endothelial 
and epithelial cells are lined by a three-dimensional matrix of proteins and proteoglycans comprising and 
surrounding the BM. The BM is structurally remodeled by cells during movement and proliferation. 
Remodeling of the BM is a normal process that occurs throughout development [1], and breach of the BM is a 
critical step for malignant cells to invade locally and metastasize [2, 3].  The BM plays a formative role in 
development, and synthetic matrices are being developed to support tissue regeneration after tissue injury [4]. 
In several organs, the basement membrane is covered by a fenestrated endothelium, which directly exposes 
the BM to the circulation. The fenestrations allow molecules to be selectively filtered through the BM or 
retained in the bloodstream [5-7]. Due to the functional importance of the basement membrane and its role in 
many cellular processes and organ functions, a method for detecting the integrity of the BM may allow 
noninvasive and early detection of developmental and disease processes. Noninvasive magnetic resonance 
imaging (MRI) is well suited to detect basement membrane alterations because MRI can be tuned to detect 
small differences in contrast, allowing visualization of soft tissues.  Functional and targeted contrast agents 
can be developed to spatially localize molecular targets in the body [8-12].  
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The goal of our previous work was to develop an MRI-visible contrast agent that is specifically 
targeted to the BM in the kidney.  The kidney is an excellent organ in which to study BM-targeted contrast 
agents, since 150 L of filtrate must pass through the glomerular basement membrane (GBM) in humans each 
day. The kidney contains ~104 (rat) to 106 (human) nephrons, each comprised of a single glomerulus and 
tubule. Each glomerulus contains a capillary tuft providing a high surface area for filtration. The functional 
filtration unit consists of fenestrated endothelial cells, a surrounding GBM, and specialized epithelial cells 
(podocytes). The glomerulus filters based on charge and size, and retains large or anionic proteins in the 
blood [6, 13]. Endothelial cells lining the glomerular capillaries are fenestrated by 30-100 nm openings into the 
GBM, and GBM contains proteoglycans which form an anionic charge barrier. The fenestrations are large 
enough to allow nanoparticles, useful as MRI contrast agents, access to the GBM. Podocyte foot processes 
attached to the external GBM surface form inter-cellular filtration slits, which form a secondary site to filter 
proteins and solutes [14].  
  The loss of glomerular integrity is a common feature of renal disease in humans and animals. The 
breakdown of the filtration barrier leads to proteinuria, which can cause renal tubular damage and progression 
of kidney disease [15]. However, direct examination of human glomerular structure and disease is impractical 
without biopsy. One method for assessing GBM integrity in animals relies on the accumulation of cationic 
tracer molecules in the GBM, which is detected ex-vivo using immunohistochemistry or electron microscopy. 
Obviously, this is impractical to use in humans. A noninvasive method to detect and identify mechanisms of 
GBM and glomerular disorders is greatly needed [16-20].   
 Animal models have been developed to study glomerular disease. Injection of puromycin 
amnionucleoside (PAN) induces focal (only some glomeruli involved) and segmental (involving only a portion 
of a glomerulus) glomerular sclerosis and massive proteinuria. This is a good model of human focal and 
segmental glomerulosclerosis (FSGS), which is a major cause of end-stage renal failure in children and 
young adults [21, 22]. Early diagnosis of human FSGS is difficult because sclerosis is heterogeneous and 
renal biopsy might not be able to detect the lesion, especially at the early stage. In the FSGS model, it is 
suggested that glomerular integrity is compromised by a breakdown of the glomerular and podoctye charge 
barrier, and repeated injection of PAN causes pathological damage similar to human FSGS. 
 In our previous work, the GBM of rat kidney glomeruli was labeled in vivo by systemic injection of cationic 
iron oxide nanoparticles (ferritin) which accumulate by electrostatic interaction at sites of negative charge. 
Small cationic particles are known to accumulate in the BM of the kidney, pancreas, brain, and other organs, 
and have been used for electron microscopy [23-30].  Ferritin is a protein which oxidizes and stores iron. 
Typically 1500-3000 irons are sequestered in the ferritin core, enabling ferritin to be used as an endogenous 
and exogenously delivered contrast agent for MRI [31]. Ferritin nanoparticles were used in this work because 
of their small size (13 nm) relative to the endothelial fenestrations (80 nm).  Cationic ferritin (CF) [32] is 
created by the attachment of positively charged amine groups, and is used as a probe for electron microscopy 
to detect charged molecules in cells and tissue. Here we show that the selective accumulation of CF in the 
GBM can be detected with MRI, and a change in CF accumulation can be used to detect glomerular 
dysfunction in vivo. This raises the possibility of non-invasively detecting molecular changes in the basement 
membrane throughout the body.  
 In this early work, we observed that CF also accumulated selectively in the basement membrane of the 
pancreas, spleen, heart, and certain organs in the brain, and was shown to be taken up into a rat model of an 
invasive glioma tumor. The latter is particularly interesting, because it leads to the possibility that the 
destruction and formation of basement membrane by malignant tumors can be detected noninvasively with 
MRI. The long-term use of this technology is to detect the structure of the basement membrane noninvasively 
in humans to study development, organ function, and malignancy. Therefore, this proposal is aimed at 1. 
Determining the biodistribution of systemically injected cationic iron oxides and 2. Measuring the uptake of 
cationic nanoparticles in a brain tumor after local and systemic injection. 
 
 
Injection of magnetic nanoparticles for MRI has been shown to be effective and safe [Beeman et al, AJP Renal 
2011] 
  
Experimental Design  
 
Animals to be transported to Barrow’s Neurological Institute (BNI) or Translational Genomics Research Institute 
(TGEN) for imaging and/or housing will be done according to the Standard Institutional Guideline – Off-Campus 
Transport of non-USDA Regulated Species by Laboratory Personnel. 
 
Part I: 
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IA. Biodistribution of intravenously-injected cationic nanoparticles  
 
Native horse spleen ferritin (NF) and cationized horse spleen ferritin (CF) will be purchased from Sigma 
Aldrich (Sigma, St. Louis). CF will be developed by the method of Danon et al. [32]. Because the relaxivity of 
NF and CF are relatively low, we will make magnetoferritin (MNF or MCF) which has a core that is completely 
filled with iron. The details of this procedure are described below [33-35].  
 
In Vivo Preparation and Imaging  
Rats and mice will be anesthetized with a 30% oxygen/70% nitrogen (oxygen-enhanced air) gas 
mixture containing isoflurane by nose-cone and given an injection of 3.3mg/100 g of either native horse 
spleen ferritin (NF, Sigma, St. Lous) or cationized horse spleen ferritin, in physiological saline. Alternatively, 
the rats and mice may be anesthetized with ketamine/xylazine anesthetic mixture (ketamine hydrochloride 
and xylazine, 90mg/kg ketamine + 5 mg/kg xylazine, IM/IP for rats and 80-100 mg/kg ketamine and 10 mg/kg 
xylazine IP for mice – booster doses of ketamine only (30% of the loading dose) will be administered to 
maintain anesthesia as needed). Because NF- and CF- inoculated rats will be matched for weight (to 5 g 
accuracy for rats) and mice matched for age in each experiment, the same volume will be given to each 
animal. A single bolus of NF (control) or CF will be given intravenously through either the tail vein (rats or 
mice) or penile vein (rats), injected over 1 minute to animals.  Mice may be procured from the vendor with 
jugular venous catheters already in place for ease of vascular access.   The animals will be allowed to 
recover, and the procedure will be repeated one to five more times in 1.5 hour intervals.  If ketamine is used 
rather than isoflurane, boosters will be delivered so that animals are anesthetized during the entire 
experiment. The animals will be sacrificed 1-5 hours after the final injection by perfusion with saline for 
approximately 30 minutes, and then with 4% paraformaldehyde for ten minutes.  
 
For the glioma (I.B), nephritis (I.C), and liver fibrosis (Part III) models, the animals may be imaged 
temporally across time to monitor disease progression.  The animal would be anesthetized and a baseline 
image obtained.  Then either CF or NF would be administered followed approximately 1.5 hrs later with a 
second image.  The animal would then be recovered and imaged again at a later time point OR remain under 
anesthesia and be euthanized and perfused. 
 
I.B. Detecting basement membrane structure in a rat glioma model 
 
The C6 line was originally purchased from ATCC and transfected with DNA encoding dsRed, allowing the 
cells to be seen in fluorescence. Briefly, animals will be inoculated intracranially with the tumor cells (10 
uL containing 500,000 cells/10 uL), and the MRI contrast agents will be delivered after the tumors have 
formed.  Tumor formation is expected two weeks after inoculation and will be confirmed with pilot MRI. 
They will undergo up to four imaging sessions (minimum imaging interval would be daily), with contrast 
agent delivered just before imaging. The animals will then be euthanized directly after the last imaging 
session (still under anesthesia) and the biodistribution of the contrast agents will be assessed 
histologically.  
 
I.C.  Measuring whole-kidney nephron endowment in mice 
 
We have recently shown that we can use systemic injection of CF, coupled with MRI, to measure whole-kidney 
nephron endowment. In order to establish our technique in congenital diseases affecting nephron endowment, we 
will compare our counts in wild type mice from this protocol with mice that develop ~50% fewer nephrons. Mice 
heterozygous (+/-) with respect to the OS2 gene, will be obtained from the Jackson Laboratories. The OS2/- 
mouse strain, with a single OS2 allele, develops approximately 50% fewer glomeruli than wild type 
counterparts, and will serve as a comparison group for ex vivo and in vivo counting. These mice will be 
administered CF (or NF as a control) and undergo MRI imaging temporally across time.  The number of imaging 
sessions will be based on results obtained during each imaging session.  Because these animals do not develop 
clinical disease as part of the phenotype, we will be able to have a minimum imaging interval of 7 days.  For the 
final imaging session, the mice will undergo the same terminal injection and imaging sequence as described 
under I.A above.   There will be 48 mice that receive CF (24 +/+ wild type and 24 +/-) and 5 mice (+/+ wild type) 
that receive NF (control).   
 
We will purchase the MRL/LPR (+/l+) strain of mice, 4-8 weeks old, from Jackson Laboratories. Several well-
characterized mouse models of glomerulonephritis (GN) are available. Among these, we chose to focus on 
MRL/lpr because the strain develops severe, progressive autoimmune nephritis, similar to human lupus nephritis. 
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Mice will be housed in the ASU animal facility for up to 14 weeks, and monitored every 2-3 days for development 
of gross signs of nephritis (proteinuria measured via urine test strips).   
 
58 mice will be used in this part of the study.  24 MRL/lpr (+/+) mice and 24 healthy age-matched MRL(-/-) 
controls. Once nephritis is confirmed, the mice will be anesthetized with a 30% oxygen/70% nitrogen (oxygen-
enhanced air) gas mixture containing isoflurane by nose-cone and given an injection of 3.3mg/100 g of CF.    5 
MRL/lpr (+/+) mice and 5 healthy age-matched MRL(-/-) controls will receive NF (control).   These mice will 
undergo the same injection and imaging interval and frequency (including the terminal imaging paradigm) as 
described above for the OS2/- mouse strain.  
 
Part II. Aquaporin overexpression via DNA delivery (work to be done at TGEN and BNI – animals will be 
shipped to ASU from the vendor and then transported to TGEN and BNI for the experiment). 
 
Aquaporin1 (AQP1) is a 28kDa water channel that controls water movement across cell membranes. Previous 
studies of AQP 1 expression in brain tumors indicated direct relationship with tumor grade1. Also, studies have 
shown that AQP1 overexpression is correlated with tumor invasion. We intend to use the overexpression of AQP1 
as a MRI reporter gene. Taking advantage of the fact that this channel promotes bulk movement of water, we will 
test the hypothesis that overexpression of this channel in tumor cells will promote a change in local diffusion 
coefficient measured with MRI. 
 
The current protocol describes the detection of basement membrane and other extracellular membrane 
components noninvasively with MRI. Specifically a rat glioma tumor model is described to investigate ECM 
characteristics and role during tumor progression.  In order to study if AQP1 promotes an observable diffusion 
difference with MRI the study will be performed as follows: 
 
Rats wil be inoculated with a gfp-expressing lentiviral vector containing human AQP1 cdna in the 
caudate/putamen and scanned with MRI several days after infection, namely, after 1, 3, 5, and 10 days.  This will 
be done at either TGEN or BNI. Anesthesia for imaging will be the same as described under Part I, I.A.  As 
controls, the empty vector and the viral vector encoding a mutant AQP1 will be inoculated as well.   The mutant 
AQP1 contains a point mutation that blocks water transport providing an appropriate control to this experiment. 
Overexpression of AQP1 in the infected brain cells will be checked with histological immunostaining. All 
histological studies will be performed after euthanizing the animals. All work will be done at TGEN and/or BNI.  
 
All surgery technique will be performed using the same surgical technique as for the glioma cell injection (with the 
exception of the different coordinates for the injection location). 
 
None of this work has been done under the expiring protocol. This is a new addition to the proposed work that 
arose from experimental observations.   
  
References: 
1. S Saadoun et.al. “Increased aquaporin 1 water channel expression in human brain tumors” Br.J.Cancer, 2002 
September 9. 87(6): 621–623 
 
Part III. ECM in Liver 
 
In our studies in the kidney, we have examined the liver post-mortem and found evidence that, within the liver, our 
agent may bind selectively to the Disse space surrounding the sinusoids (while still binding to ECM in other 
organs), , indicating its possible use to detect early changes in the ECM with non-alcoholic fatty liver disease. We 
have also found accumulation in the glomerular basement membrane of the kidney. We therefore request to 
extend this protocol to study rats and mice that model human non-alcoholic steatohepatitis (NASH), The protocols 
used here are derived from the work by Kirsch et al (1,2).  We have performed the pilot study and demonstrated 
that we can detect changes with NASH. This proposal is focused on developing the technique to be generally 
useful in multiple models of NASH in mice.    
 
We will use a total of 48 male Wistar rats, 48 ob/ob mice (model of obesity) and 48 dgat mice (model of liver 
fibrosis without fat).   Each group of 48 animals will be divided into 12 animals per group that are evaluated at 
different stages of the disease process.  To induce NASH in rats, the animals will be fed a methionine and choline 
deficient (MCD) diet for 4-16 weeks, ad lib, and control animals will be fed the same diet supplemented with 
choline bitartrate (2g/kg) and DL-methionine (3g/kg). The rats will be weighed every week. Rats on the MCD have 
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been shown to have reduced growth during this time (approximately 50% smaller size compared to controls).  
Animals will be imaged and receive either NF or CF as described above.   Imaging will be done at the ASU/BNI 
preclinical imaging center at the BNI. We have a joint MOU that allows us to house our animals there under the 
same protocol, and we have both surgical and holding facilities adjacent to the MRI.  
 
References: 
 
Kirsch et al. J Gastroent and Hepatology (2006) 21, 174-182. 
Kirsch et al. J Gastroent and Hepatology (2003) 18, 1272-1282. 
 
C. RATIONALE FOR INVOLVING ANIMALS AND THE APPROPRIATENESS OF THE SPECIES AND 
NUMBER USED.  Keeping in mind the principles of the “3 R’s” (Refinement, Reduction, and 
Replacement answer the following: 
 
1. Why must live vertebrates be used in this study? 
 
Because we are studying uptake of molecular MRI contrast agents for potential use in humans, vertebrate 
animals provide the closest approximation to the end-use for this technology.  
 
2. Why are you using the requested species rather than other species? 
 
Rats are ideal to study the progression and invasion of human brain tumors in vivo, as their neural tissue 
yields similar brain tumor growth as in humans.  Thus, rat models have been widely used and accepted to 
study brain tumor growth, and to study the delivery of contrast agents. Additionally, the size of the vascular 
structures in the rat is large enough for imaging on the available MRI system.  Mice are used for some studies 
since there are many transgenic and knock out animals that are models for human diseases.  
 
3. What is the rationale supporting the numbers of animals proposed? Typically, a power analysis 
should be performed to support the proposed sample sizes.  A table depicting the number of animals to be 
used is required.  
 
 The methods used here are well established with respect to the CF and NF contrast agent doses (Bennett et 
al, 2008), and to the growth of the tumor (Bennett km et al, 2004). We have also performed a preliminary study 
and have determined that 5 mg/100 g of CF is an optimal contrast agent dose.  
 
For most of our experimental groups in the two main goals, we are requesting 5-6 rats or mice per experimental 
group. In our experience, this is the number of animals that it typically takes to get statistically significant results 
for each experiment. For the experiments we haven’t performed before, we have doubled this number to 
accommodate adjustments in the dosage and the amount of time needed to develop disease.  
A power analysis was done using the Power Analysis Tool 
(http://www.dssresearch.com/toolkit/spcalc/power_a2.asp). With an expected 20% difference in contrast between 
two groups, and a 15% standard deviation in signal intensity, this yields a statistical power or 95.5%, or <5% 
chance of accepting the null hypothesis that the two groups are the same.  
 
Part I, I.A: Determine the biodistribution of systemically injected cationic iron oxides ex vivo. 
 
- 20 rats to receive intravenous injection of charged iron oxide nanoparticles (CF) at 4 different delivery doses 
(N=5 per dose)  
- 20 rats to receive intravenous injection of native iron oxide nanoparticles (NF) at 4 different delivery doses 
(N=5 per dose) 
- 20 C57BL/6 mice to receive intravenous injection of charged iron oxide nanoparticles (CF) at 4 different 
delivery doses (N=5 per dose)  
- 20 C57BL/6 mice to receive intravenous injection of native iron oxide nanoparticles (NF) at 4 different 
delivery doses (N=5 per dose)  
 
Total Number of Rats = 40 
Total Number of Mice = 40 
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Part I, I.B:  Measure the uptake of cationic nanoparticles in a brain tumor after local and systemic injection ex 
vivo. 
  
- 30 rats to receive intracranial C6 glioma cells followed by systemic injection of native (n = 15) and cationic (n 
= 15) nanoparticles 1 week after tumor cell inoculation. 5 animals are needed for statistical significance. 
The inoculation site must be precise, so we have provided 3 repetitions for each group to account for 
variance in inoculation site. 
- 30 rats to receive intracranial C6 glioma cells followed by systemic injection of native (n = 15) and cationic (n 
= 15) nanoparticles 2 weeks after tumor cell inoculation. Justification for sample size is the same as 
above. 
- 12 rats to receive intracranial sterile PBS followed by systemic injection of CF (N=6) or NF (N=6) at the most 
effective timepoint in tumor growth. 6 animals per group are needed for statistical significance. We 
determine the most effective time-point for tumor growth by looking for signs of gross tumor with MRI, 
characterized by a mass of ~2cm in diameter. 
 
Total Number of Rats = 72 
 
Part I, I.C: Measure whole-kidney nephron endowment in mice:  
 
- 24 healthy OS +/+ and 24 OS +/- to receive intravenous injection of cationic nanoparticles (CF) and 5 
healthy OS +/+ to receive intravenous injection of native nanoparticles (NF) = 53 total. The number of mice 
was chosen because we need 6 animals per group for statistical significance. Our CF administered group 
will be broken into 4 subgroups of 6 animals to test OS +/+ versus OS +/- as well as 2 different dosing 
schemes. We have found that we need some (6 per group) backups in case tissue is destroyed during 
processing when it is sectioned for stereology (in Australia). Total: 4 groups of 6 and 6 extra animals per 
group as backup. 
- 24 MRL/lpr (+/+) and 24 healthy, age-matched MRL/lpr (-/-) controls to receive intravenous injection of 
cationic nanoparticles (CF) and 5 MRL/lpr (+/+) and 5 healthy, age-matched MRL/lpr (-/-) controls to 
receive intravenous injection of native nanoparticles (NF) = 58 . Our CF administered group will be broken 
into 4 subgroups of 6 animals to test MRL/lpr (+/+) versus MRL/lpr (+/-) as well as 2 different dosing 
schemes. The number of mice was chosen because we need 6 animals per group for statistical 
significance, plus we have found that we need some backups in case tissue is destroyed during 
processing when it is sectioned for stereology (in Australia). Total: 4 groups of 6 and 6 extra animals per 
group as backup. 
 
Total Number of Mice = 111 
 
Total Number of Rats for Part I = 112 
Total Number of Mice for Part I = 151  
 
Part II 
Aquaporin overexpression via DNA delivery 
 
A total of 45 rats will be needed for the in vivo transfection study (5x3reps) of empty vector vs AQP1 positive 
inoculation and (5x3reps) of empty vector versus AQP1 mutant and (5x3 reps) of AQP1 mutant versus AQP1 
positive. 5 animals are needed for statistical significance. The inoculation site must be precise, so we have 
provided 3 repetitions for each group to account for variance in inoculation site.  
 
Total Number of Rats for Part II: 45       
 
Part III  
ECM in liver  
 
48 rats = 12 rats/disease stage time point 
48 ob/ob mice = 12 mice/disease process time point 
48 dgat mice = 12 mice/disease process time point 
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(The numbers of mice and rats were chosen because we need 6 animals per group for statistical significance, 
plus we have found that we need some backups in case tissue is destroyed during processing when it is 
sectioned for stereology (in Australia). Total: 2 groups of 6 and 6 extra animals per OS experiment – see above.) 
 
Total Number of Rats:  48 
Total Number of Mice: 48 x 2 strains = 96 
 
Summary for the Protocol: 
 
Grand Total Number of Rats:  205 
Grand Total Number of Mice:  247  
 
4. What refinements, if any, have been made to reduce the number of animals used and the potential 
detrimental effects on the study animals? 
 
As discussed above, we have done work to minimize the amount of agent required for detection by filling ferritin 
completely with iron, thus reducing the number of animals required to achieve statistical significance. Also, both in vivo 
and ex vivo studies will be done on multiple organs at each time, thereby reducing the total numbers of studies to be 
performed, even though the physiological basis of agent uptake and implications for uptake in each organ are different.  
 
IV. EMERGENCY  CONTACT 
 
A. Who should be contacted in case of an animal emergency? Note: This information will be redacted if 
this protocol is requested as a public document. 
  Name:   Kevin M. Bennett 
   Home Phone # 
 
 
   Office Phone # 480-727-9790  
   Cell Phone #:  443-789-8679  
 
V.  DUPLICATION AND ALTERNATIVES 
 
The Animal Welfare Act requires that you document your justifications with data from two or more 
sources. One source must be a set of searches of a relevant database: name the database 
searched, the keyword and keyword combinations searched, the date the search was performed 
and the date range searched. The second source can be a set of searches of a second relevant 
database, or consultation with a laboratory animal science veterinarian, or 
courses/meetings/consultations with qualified personnel. Sufficient documentation, such as the 
consultant's name and qualifications and the date and content of the consult, should be provided to the 
IACUC to demonstrate the expert's knowledge of the availability of alternatives in the specific field of 
study. Examples of appropriate databases to search include PUBMED and Web of Science.  [Note: 
USDA Animal Welfare Information Center provides an in depth listing of database resources on their 
website at http://awic.nal.usda.gov/nal_display/index.php?info_center=3&tax_level=1&tax_subject=184] 
  
A. Provide the following details for the most recent literature search used to explore for duplicative research.   
(The literature search documents that the research will not unnecessarily duplicate previous research). 
Teaching protocols do not need to conduct this search. 
 
Date that search was conducted (Must be within 60 days of the IACUC review date):  
12/3/11 
Database used: pubmed 
Publication years covered by the search:1975-2011 
 Keywords used: charged nanoparticle+mri, cationic+ferritin+mri 
12/9/11 
Database used: Web of Science 
Publication years covered by the search:1975-2011 
 Keywords used: charged nanoparticle+mri, cationic+ferritin+mri 
 
B. Provide the following details for the most recent literature search used to explore for alternatives to 
animal use and alternatives to painful procedures.  Alternatives should be considered for any aspect 
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of the protocol that may cause more than momentary or slight pain or distress to the animal. 
Alternatives to be considered include those that would: 1) refine the procedure to minimize discomfort that 
the animal(s) may experience; 2) reduce the number of animals used overall; or 3) replace animals with 
non-animal alternatives (e.g., computer models or tissue culture).  All protocols (research and 
teaching) MUST conduct this search. 
 
Date that search was conducted (Must be within 60 days of the IACUC review date12/3/11 
Database used: pubmed 
Publication years covered by the search: 1975-2011 
Keywords used: animal+research+alternative+charged+nanoparticle+mr+mri+basement membrane 
Database used: web of science 
Publication years covered by the search: 1975-2011 
Keywords used: animal+research+alternative+charged+nanoparticle+mr+mri+basement membrane 
 
C. Results of search for alternatives: Please comment on the application(s) of any identified alternatives, 
including how these alternatives may be or may not be incorporated to modify a procedure to either 
lessen or eliminate potential pain and distress.  You must include sufficient information for the IACUC to 
determine that a reasonable, good faith effort was made to determine the availability of alternatives.  If the 
search identified any alternative methods (ones that could be used to accomplish the goals of the animal 
use proposal), you must clearly explain and justify why this alternative cannot be used. 
 
None because there are no alternatives. This is the first proposed method (to the best of our knowledge) 
based on the above-mentioned database searches, peer-review in recent publications, and attendance at 
scientific meetings, to detect alterations in the basement membrane. The primary interest in the technique 
is the potential to move this to a clinical trial in the future, and the reason the study is attracting attention 
is that is has never been done before. Additionally, we know of no possible alternatives to studying 
structure and function in the basement membrane other than the use of live animals. The C6 glioma 
model is critical because it is a well established model of a high-grade glioma that exhibits characteristics 
of human tumors. There are spontaneous tumor models, but they are prohibitively difficult to monitor for 
tumors, and the tumors do not always show up in the same place.  Therefore, surgical implantation of the 
tumor directly into the brain provides the most reliable model for our studies.  With regard to our 
aquaporin1 studies, intracranial administration is the only method available to us to deliver the vectors to 
the location of application and interest. 
 
D. Describe any other procedures (e.g., participation in meetings, review of journals) that are used to explore 
and evaluate alternatives: participation in annual meetings (International society for magnetic resonance 
in medicine, society for molecular imaging), review of relevant literature 
 
E. Does this research replicate previous work?  
 
 No.  Proceed to section VI. 
 
  Yes.  Explain why the replication is necessary:  

 
 
 Not applicable.  This is a teaching protocol. 
 
 
VI. CATEGORY OF PAIN OR DISTRESS 
 
The USDA Regulations define a “painful or distressful procedure” as “any procedure that would 
reasonably be expected to cause more than slight or momentary pain or distress in a human being to 
which that procedure was applied; that is, pain in excess of that caused by injections or other minor 
procedures.”  Using the table below, list all species of live vertebrate animals to be used in the proposed 
study and indicate the number of animals to be used under the appropriate USDA category.  For an 
animal undergoing multiple procedures, list the animal under the highest level of pain expected for that 
animal.   
 
Species Number per USDA Category* Total number of 
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B C D E 
animals 
requested 
Rats  
 
  205   205 
 Mice      
  
247   247 
            
            
            
 
 
*USDA PAIN CATEGORIES: (see http://researchintegrity.asu.edu/animals/forms for a more complete 
description of the below categories) 
Classification B: Includes animals that are used solely for breeding (e.g., to produce experimental animals 
or to maintain experimental lines). 
Classification C:  Includes the use of animals in procedures involving no, momentary, or slight pain or 
distress (e.g., non-invasive parenteral drug delivery, peripheral blood collection, euthanasia, short-term 
manual or chemical restraint, toe clipping). 
Classification D:  Includes the use of animals used in procedures that could cause pain or distress but 
appropriate anesthetics, analgesics, and/or tranquilizing drugs or other methods for relieving pain or 
distress are used  (e.g., surgery, perfusion, administration of irritating chemicals, humane endpoint 
euthanasia). 
Classification E:  Includes the use of animals in procedures that have the potential to involve pain or 
distress that will not be relieved with anesthetics, analgesics, tranquilizer drugs, or other method for 
relieving pain or distress (e.g., negative conditioning, unrelieved post-surgical pain, death without 
euthanasia). 
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VII. ASSURANCE: 
 
The information contained herein is accurate to the best of my knowledge.  I have carefully compared the 
proposed work with the current state of knowledge in this field by reviewing the literature and it is my 
professional opinion that the proposed work meets high standards of scientific merit.  If the study involves 
pain and distress to the animal, whether or not it is relieved by anesthetics or analgesics, I have (1) reviewed 
the literature related to this work and have found no significant studies which could make this protocol 
unnecessarily duplicative, and (2) considered alternatives to animal use and found none available, as 
described above.  Procedures involving animals will be carried out humanely and all procedures will be 
performed by or under the direction of trained or experienced persons.  Any revisions to animal care and use 
in this project will be promptly forwarded to the Institutional Animal Care and Use Committee for review. 
Revised protocols will not be used until Committee clearance is received.  The use of alternatives to animal 
models has been considered and found to be unacceptable at this time. 
  
The principal investigator, by signing below, and the IACUC recognize that other medications may be given to 
the animals for veterinary care purposes (including humane euthanasia of animals in pain that cannot be 
controlled, as determined by the University Veterinarian or an euthanasia-certified principal investigator). 
 
 
Kevin M. Bennett, PhD           12/3/11 
     
 Principal Investigator – Please Print  Date 
    
     
 Principal Investigator Signature  Date 
        
     
 ***Department Chair  Date  
    
     
 ***College Dean           Date  
 
 
***ASU Polytechnic requires these signatures. 
 
 
NOTE:  Principal investigators and senior participants must submit a current curriculum vitae or biosketch that 
reflects their most recent pertinent experience.  
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DETAILED USE OF ANIMALS 
This section must be completed for each species used. 
Link to additional Detailed Use of Animals form: 
 
Common Name: Rat  
 
Scientific Name: Rattus norvegicus  
 
I. ANIMAL INFORMATION 
A. Is this a threatened or endangered species? 
  No. Proceed to section I. B. 
  Yes. Describe why this work must be done on this species and why the project will not have a 
significant negative impact on the species:  
 
 
 
B. Maximum # of animals to be used 
Per Year: 100 rats Entire three years of protocol: 205  
 
C. Sex:  m  Age or Weight Range:  100-600g rats 
 
D. Source (e.g., commercial, in-house breeding, captured from wild):  commercial 
 
 
E. Please LIST all labs and/or rooms outside of the ASU centralized vivaria where you intend to keep or 
use live animals in connection with the animal use covered under this protocol.  This list is for IACUC 
information to assure each location is inspected semi-annually.  Listing rooms here does not assure 
approval of this space for use.   
 
Building Room 
# 
Max Length of 
Stay 
Method of Transport Purpose 
ISTB1 244 Up to 8 hours Cage or Transport 
container 
Surgery and perfusions 
BNI- Preclinical imaging 
 center 
holding room Up to 6 weeks 
 
Cage Housing, imaging, and  
perfusions 
 
TGEN holding Up to 30 days Cage Housing, surgery (cdna 
transduction),  
and perfusions 
 
 
II. MAJOR CATEGORIES OF USE 
  
A. Will animals be immunized for antibody production? 
 No.  Proceed to section II. B. 
 Yes.  Complete the following table. 
Injection: 
Volume of injectate Adjuvant Route Min. Frequency Max. # of injections 
     
I.  
Collection:  If terminal, check here   Otherwise complete the following. 
Route Max. Volume Min. Frequency Max. # of collections 
    
 
B. Will tissues, blood, or other body fluids be harvested (other than for antibody production)? 
 No.  Proceed to section II. C. 
 Yes. Will tissues, blood, or other body fluids be collected post-mortem only? 
 Yes.  Proceed to section II.C. 
 No. Complete Appendix 1. 
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C. Will animals be food restricted (calorically or specific constituents)? 
 No. Proceed to section II. D. 
 Yes. [note: restriction paradigms exceeding a single 24-hr period must follow the ASU IACUC 
Standard Institutional Guideline for Food and Water Restriction available at 
http://researchintegrity.asu.edu/animals/SIG] 
 
1. What are the restriction parameters? Provide scientific justification 
 
 
 
2. How will you monitor for negative effects of food restriction (include information on how you will 
account for animal growth)? 
 
 
D. Will animals be water restricted?  
 No. Proceed to section II. E. 
 Yes. [note: restriction paradigms exceeding a single 24-hr period must follow the ASU IACUC 
Standard Institutional Guideline for Food and Water Restriction available at 
http://researchintegrity.asu.edu/animals/SIG] 
 
1.  What are the restriction parameters? Provide scientific justification 
 
 
2.  How will you monitor for negative effects of water restriction (include information on how you will 
account for animal growth)? 
 
 
E.   Will animals be exposed to trauma, injury, burning, freezing, electric shock, UV radiation, magnetic fields, 
lasers, loud noise, or other physical agents that might cause distress? 
 No.  Proceed to section II. F. 
 Yes. List and justify each exposure. 
Provide scientific justification:  
 
F. Will animals be exposed to environmental stress (e.g., non-natural temperature exposure, prolonged 
physical restraint, forced exercise)? 
 No.  Proceed to section II. G. 
 Yes. List and scientifically justify each exposure. 
 
 
G.   Will animals undergo surgery? 
 No.  Proceed to section II. H. 
 Yes. Attach Appendix 2. 
 
H.  Will any animals have a device (e.g., thermocouple, cannula, electrode) that extends chronically through 
the skin? 
 No.  Proceed to section II. I. 
 Yes. Describe wound management measures to minimize chances of infection around the device 
where it penetrates the skin: 
 
 
I. Will animals need any special husbandry considerations, including but not limited to single housing 
individuals of social species (e.g., rodents) or altering standard cage type, cage change 
frequencies, or housing temperature? 
 No.   Proceed to section II. J. 
 Yes.  Describe special procedures and provide scientific justification: 
 
 
J.  Will any animals need to be individually identified? 
 No.   Proceed to section III. 
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 Yes. Describe the marking technique to be used, why that technique was chosen, how it will be 
performed, and on what age range of animals? 
Tail marker with sharpie based on simplicity of use.  The rat will be hand restrained to be 
marked.  
 
III. CHEMICALS AND OTHER POTENTIAL HAZARDS  
(if you answer yes to any of the following questions, this information may be forwarded to another 
oversight unit to aid you in assuring safe practices.  Approval by these units may be required prior to 
using any of these materials) 
 
A.  Does this protocol involve the use of DEA-listed control substances (e.g., ketamine, pentobarbital, 
androgens, diazepam, buprenorphine)? 
 No.  Proceed to section III. B. 
  Yes. List all DEA-listed Controlled Substances:       
ketamine 
 
B. Will drugs or chemicals be used in animals? 
 No. Proceed to section III. C. 
 Yes. For each drug or chemical, list the agent, dose, route, purpose, and grade in the table below: 
 
Agent Dose Route Purpose Pharmaceutical 
grade (Y/N)? 
isoflurane 1-5% inhalation Anesthesia for injections 
and imaging 
y 
ketamine 90 mg/kg IP/IM Anesthesia y 
xylazine 5 mg/kg IP/IM Anesthesia  
buprenorphine 0.01-0.05 mg/kg SQ Analgesic y 
meloxicam 1 mg/kg SQ Analgesic y 
Native horse 
spleen ferritin 
5 mg/100 g max IV Labeling prior to MRI 
imaging 
n 
Cationic 
ferritin 
5 mg/100 g max IV Labeling prior to MRI  
imaging 
n 
 
1. For each drug or chemical that is not pharmaceutical grade, indicate whether no pharmaceutical 
grade equivalent exists or provide scientific justification for using the non-pharmaceutical grade 
product.  
 
  The NF and CF are not available in a pharmaceutical grade equivalent. 
 
C. Does this project involve the use of biohazardous agents in the animals (microorganisms, microbial 
toxins, recombinant DNA, or other biological agents that can infect and/or cause disease in humans)? 
 No. Proceed to section III. D. 
 Yes. List the agent, animal biological safety level (ABSL), dose, route, and purpose in the table 
below: 
 
Agent & concentration ABSL Dose Route Purpose 
Human AQP1 cdna 
All done at TGEN or BNI, not 
ASU 
2 1 ug intracranial Establish aqp1 effect in 
imaging 
     
 
1.  Provide the Institutional Biosafety Committee (IBC) approval #: [not required since work done at 
another institution] 
 
 
D.  Does this project involve irradiation or the use of radiological material in animals? 
 No. Proceed to section III. E. 
 Yes. List the agent, dose, route, and purpose in the table below: 
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Agent Dose Route Purpose 
 
    
    
 
1.  Provide the Radiation Safety Committee approval #:  
 
 
E.  Describe any additional hazardous equipment or materials as well as any non-routine means (e.g., 
vaccinations, PPE, training, SOPs) used to assure human and animal safety from hazards. 
 
Paraformaldehyde perfusion will be conducted in a chemical fume hood. 
IV.   DETRIMENTAL SEQUELAE 
 
A. Will animals possibly experience clinical signs intentionally or as a possible side effect of the study? 
 No. Proceed to section V. 
 Yes. Complete the following. 
Possible Clinical Effect Probability of Occurrence Treatment 
Intracranial tumor growth with  
neurologic signs 
100% Imaged and euthanized prior 
to development of clinical 
signs or at the time symptoms 
develop 
Reduced body mass with MCD 
diet 
100% None – animals are clinically 
Healthy despite their 
decreased overall size and 
mass 
 
 
V. END POINT CRITERIA 
 
A. What clinical signs will be used as a basis for removal of an animal from the study? 
 
While no negative effects are expected other than reduced size with the MCD diet, if an animal develops 
signs of ill health including rough hair coat, lethargy, emaciation, or labored breathing, we will consult the 
clinical veterinarian or euthanize the animal. Based on our previous studies, we have observed massive 
tumor growth after 14 days with the C6 glioma cell line. We will therefore monitor the animals every day  
for any neurologic symptoms (circling, head pressing, seizures) and consult the clinical veterinarian or 
euthanize the animal. 
   
VI.  EUTHANASIA  
  
A. Chemical/Gas Methods used as the primary means of euthanasia, if any: 
Agent Dose Route 
Pentobarbital 120 mg/kg IP 
 
1.  If using a chemical method for euthanasia, what secondary physical means (e.g., thoracotomy) will 
be used to assure euthanasia?  
Thoractotomy 
 
B. Physical Methods used as the primary means of euthanasia, if any: 
 Cervical dislocation (mice, immature rats)* 
 Decapitation* 
 Exanguination under anesthesia 
For methods that are marked with an *, provide a scientific justification if the method is being 
conducted on an awake animal (provide references if possible): 
 
 
C. Name(s) and qualifications (years of experience with the species and euthanasia method(s) to be 
conducted under this protocol) of person(s) performing euthanasia: 
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Name 
 
 
 
 
 
Qualifications 
IACUC 
USE ONLY Level 
III Training 
(mm/yy) 
 
Kevin Bennett, PhD Performed euthanasia routinely in PhD and  
post-doctoral work, in IACUC-approved studies.  
Completed ASU online Animal training 
 
All students (listed above) trained by Bennett  
 
 
 
 
DETAILED USE OF ANIMALS 
This section must be completed for each species used. 
Link to additional Detailed Use of Animals form: 
 
Common Name: Mouse 
 
Scientific Name: Laboratory mouse  
 
J. ANIMAL INFORMATION 
D. Is this a threatened or endangered species? 
  No. Proceed to section I. B. 
  Yes. Describe why this work must be done on this species and why the project will not have a 
significant negative impact on the species:   
 
B. Maximum # of animals to be used 
Per Year: 100 Entire three years of protocol: 247 
 
C. Sex:  m  Age or Weight Range:  10-40 g mice 
 
J. Source (e.g., commercial, in-house breeding, captured from wild):  commercial 
 
 
K. Please LIST all labs and/or rooms outside of the ASU centralized vivaria where you intend to keep or 
use live animals in connection with the animal use covered under this protocol.  This list is for IACUC 
information to assure each location is inspected semi-annually.  Listing rooms here does not assure 
approval of this space for use.   
 
Building Room 
# 
Max Length of 
Stay 
Method of Transport Purpose 
ISTB1 242 Less than 6 hrs Cage or transport 
container 
Perfusions 
BNI- Preclinical imaging 
 center 
holding room Up to 6 weeks 
 
Cage Housing, imaging,  
perfusions 
 
 
II. MAJOR CATEGORIES OF USE 
  
E. Will animals be immunized for antibody production? 
 No.  Proceed to section II. B. 
 Yes.  Complete the following table. 
Injection: 
Volume of injectate Adjuvant Route Min. Frequency Max. # of injections 
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II.  
Collection:  If terminal, check here   Otherwise complete the following. 
Route Max. Volume Min. Frequency Max. # of collections 
 
    
 
F. Will tissues, blood, or other body fluids be harvested (other than for antibody production)? 
 No.  Proceed to section II. C. 
 Yes. Will tissues, blood, or other body fluids be collected post-mortem only? 
 Yes.  Proceed to section II.C. 
 No. Complete Appendix 1. 
 
G. Will animals be food restricted (calorically or specific constituents)? 
 No. Proceed to section II. D. 
 Yes. [note: restriction paradigms exceeding a single 24-hr period must follow the ASU IACUC 
Standard Institutional Guideline for Food and Water Restriction available at 
http://researchintegrity.asu.edu/animals/SIG] 
 
1. What are the restriction parameters? Provide scientific justification 
 
 
2. How will you monitor for negative effects of food restriction (include information on how you will 
account for animal growth)? 
 
 
H. Will animals be water restricted?  
 No. Proceed to section II. E. 
 Yes. [note: restriction paradigms exceeding a single 24-hr period must follow the ASU IACUC 
Standard Institutional Guideline for Food and Water Restriction available at 
http://researchintegrity.asu.edu/animals/SIG] 
 
1.  What are the restriction parameters? Provide scientific justification 
 
 
2.  How will you monitor for negative effects of water restriction (include information on how you will 
account for animal growth)? 
 
 
E.   Will animals be exposed to trauma, injury, burning, freezing, electric shock, UV radiation, magnetic fields, 
lasers, loud noise, or other physical agents that might cause distress? 
 No.  Proceed to section II. F. 
 Yes. List and justify each exposure. 
Provide scientific justification:  
 
L. Will animals be exposed to environmental stress (e.g., non-natural temperature exposure, prolonged 
physical restraint, forced exercise)? 
 No.  Proceed to section II. G. 
 Yes. List and scientifically justify each exposure. 
 
 
G.   Will animals undergo surgery? 
 No.  Proceed to section II. H. 
 Yes. Attach Appendix 2. 
 
H.  Will any animals have a device (e.g., thermocouple, cannula, electrode) that extends chronically through 
the skin? 
 No.  Proceed to section II. I. 
 Yes. Describe wound management measures to minimize chances of infection around the device 
where it penetrates the skin: 
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M. Will animals need any special husbandry considerations, including but not limited to single housing 
individuals of social species (e.g., rodents) or altering standard cage type, cage change 
frequencies, or housing temperature? 
 No.   Proceed to section II. J. 
 Yes.  Describe special procedures and provide scientific justification: 
 
 
 
J.  Will any animals need to be individually identified? 
 No.   Proceed to section III. 
 Yes. Describe the marking technique to be used, why that technique was chosen, how it will be 
performed, and on what age range of animals? 
 
Ear punch.  Ear tags cannot be used due to the MRI imaging.  The mouse will be hand restrained and 
the left and/or right ear punched on delivery (at ~6 weeks) to provide a unique identifying combination of 
notches. 
 
III. CHEMICALS AND OTHER POTENTIAL HAZARDS  
(if you answer yes to any of the following questions, this information may be forwarded to another 
oversight unit to aid you in assuring safe practices.  Approval by these units may be required prior to 
using any of these materials) 
 
A.  Does this protocol involve the use of DEA-listed control substances (e.g., ketamine, pentobarbital, 
androgens, diazepam, buprenorphine)? 
 No.  Proceed to section III. B. 
  Yes. List all DEA-listed Controlled Substances:       
ketamine 
 
E. Will drugs or chemicals be used in animals? 
 No. Proceed to section III. C. 
 Yes. For each drug or chemical, list the agent, dose, route, purpose, and grade in the table below: 
 
Agent Dose Route Purpose Pharmaceutical 
grade (Y/N)? 
isoflurane 1-5% inhalation Anesthesia for injections 
and imaging 
y 
ketamine 80-100 mg/kg IP Anesthesia y 
xylazine 10 mg/kg IP Anesthesia  
Native horse 
spleen ferritin 
5 mg/100 g max IV Labeling prior to MRI 
imaging 
n 
Cationic 
ferritin 
5 mg/100 g max IV Labeling prior to MRI 
imaging 
n 
 
2. For each drug or chemical that is not pharmaceutical grade, indicate whether no pharmaceutical 
grade equivalent exists or provide scientific justification for using the non-pharmaceutical grade 
product.  
 
  The NF and CF are not available in a pharmaceutical grade equivalent. 
 
F. Does this project involve the use of biohazardous agents in the animals (microorganisms, microbial 
toxins, recombinant DNA, or other biological agents that can infect and/or cause disease in humans)? 
 No. Proceed to section III. D. 
 Yes. List the agent, animal biological safety level (ABSL), dose, route, and purpose in the table 
below: 
 
Agent & concentration ABSL Dose Route Purpose 
OS+/- transgenic mice 2 - - These mice have reduced 
numbers of nephrons, so 
used as control for nephron 
128
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endowment counts. 
 
 
MRL/LPR transgenic mice 2 - - Mice develop autoimmune 
nephritis, similar to human 
nephritis. 
 
 
 
1.  Provide the Institutional Biosafety Committee (IBC) approval #: pending 
 
 
D.  Does this project involve irradiation or the use of radiological material in animals? 
 No. Proceed to section III. E. 
 Yes. List the agent, dose, route, and purpose in the table below: 
 
Agent Dose Route Purpose 
 
    
    
 
1.  Provide the Radiation Safety Committee approval #:  
 
 
E.  Describe any additional hazardous equipment or materials as well as any non-routine means (e.g., 
vaccinations, PPE, training, SOPs) used to assure human and animal safety from hazards. 
 
Paraformaldehyde perfusions will be conducted in a chemical fume hood. 
IV.   DETRIMENTAL SEQUELAE 
 
B. Will animals possibly experience clinical signs intentionally or as a possible side effect of the study? 
 No. Proceed to section V. 
 Yes. Complete the following. 
Possible Clinical Effect Probability of Occurrence Treatment 
Renal failure in the MRL/LRP 
strain 
100% by 14-16 weeks Imaging and euthanasia prior 
to development of overt 
clinical signs 
   
 
 
V. END POINT CRITERIA 
 
B. What clinical signs will be used as a basis for removal of an animal from the study? 
 
If an animal develops signs of ill health including rough hair coat, lethargy, emaciation, or labored 
breathing, we will consult the clinical veterinarian or euthanize the animal.   None of the mouse strains 
have a clinically significant phenotype other than the MRL/LRP strain described above. 
   
VI.  EUTHANASIA  
  
A. Chemical/Gas Methods used as the primary means of euthanasia, if any: 
Agent Dose Route 
Pentobarbital 120mg/kg IP 
 
1.  If using a chemical method for euthanasia, what secondary physical means (e.g., thoracotomy) will 
be used to assure euthanasia?  
Thoractotomy 
 
B. Physical Methods used as the primary means of euthanasia, if any: 
 22 
 Cervical dislocation (mice, immature rats)* 
 Decapitation* 
 Exanguination under anesthesia 
For methods that are marked with an *, provide a scientific justification if the method is being 
conducted on an awake animal (provide references if possible): 
 
 
 
C. Name(s) and qualifications (years of experience with the species and euthanasia method(s) to be 
conducted under this protocol) of person(s) performing euthanasia: 
 
 
 
 
 
 
Name 
 
 
 
 
 
Qualifications 
IACUC 
USE ONLY Level 
III Training 
(mm/yy) 
Kevin Bennett, PhD Performed euthanasia routinely in PhD and  
post-doctoral work, in IACUC-approved studies.  
Completed ASU online Animal training 
 
All students (listed above) trained by Bennett  
 
 
 
 
APPENDIX 1: ANTEMORTEM SPECIMEN COLLECTION 
 
 
I. BLOOD COLLECTION 
 
We will draw blood from rats by saphenous vein and mice by submandibular vein for toxicity measurements (liver and 
kidney) and to determine half life of CF and NF.  
 
A. Will blood be collected? 
 No.  Proceed to section II. 
 Yes.  Complete the following. 
Site Volume (ml) % BW Max. # of collections Min. Interval 
Saphenous vein 
 - rats 
Submandibular vein – 
mice 
0.25 
 
* 
0.1% 
 
* 
5 
 
* 
 
1 day 
 
* 
 
*based on the sensitivity of the assay (to be determined), we will collect blood from mice 
at the following intervals: 
1.  Min. interval of 1 day, max. volume not to exceed 10 uL 
2.  Min. interval of 7 days, max. volume not to exceed 100 uL 
3.  Min. interval of 14 days, max. volume not to exceed 200 uL 
 
B. Will anesthetics, sedatives, or other drugs be used during blood collection? 
 No. Proceed to section I. C. 
 Yes. Complete the following. 
Drug Dose Route Purpose 
isoflurane 1-5% inhalation Anesthesia for blood 
collection  
 
B. How will animals be physically restrained for blood collection? Provide scientific justification. Discuss 
method used to draw the blood. The frequency of bleeds, etc. 
 
Blood will be collected from the saphenous or submandibular vein of the awake, hand restrained rat or mouse.  In some 
instances, anesthesia may be used to provide immobilization if deemed necessary.  The saphenous or submandibular 
vein will be nicked with a needle (22 g) or lancet and blood collected according to the Standard Institutional Guidelines. 
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D. Who will draw the blood? 
Name: Kevin Bennett or students (listed above); Experienced DACT Personnel 
 
Qualifications: PhD and Post-doctoral work (for PI), with students to be trained by the PI or DACT. 
 
 
II. OTHER TISSUE/BODY FLUID COLLECTION 
 
A. Will other tissues or body fluids be collected prior to death? 
 No. Appendix 1 is completed. 
 Yes.  Complete the following.  Surgical procedures should be described more fully in Appendix 2. 
Tissue/Fluid Site and Method Amt # of collections Min Interval 
 
     
 
B. Will anesthetics, sedatives, or other drugs be used during tissue/body fluid collection?  
 No. Proceed to section II. C. 
 Yes. Complete the following. 
Drug Dose Route Purpose 
    
 
C. How will animals be physically restrained for tissue/body fluid collection? 
 
 
D.   Provide name and qualifications of individual who will collect tissues or body fluids.  
Name:  
 
Qualifications:  
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APPENDIX 2: SURGICAL PROCEDURES 
 
 
I. GENERAL INFORMATION 
 
A. Species 
Sprague Dawley rats 
 
B. Surgical Procedure(s) 
Glioma cell implantation or Aquaporin vector 
 
 
C. Room/location of surgery 
ISTB1 244 (Glioma) or offsite (Aquaporin) 
 
D. Name(s) and qualifications of person(s) performing surgery 
Kevin Bennett, Experience in PHD and Post-doctoral work. Roughly 10 years of experience with survival 
intracranial injections. 
Persons listed above will be trained by Dr. Bennett, including  
Veronica Clavijo Jordan, Rachel Ginn, Scott Beeman.  
 
II. SURGICAL PROCEDURE:  
 
  Survival   Nonsurvival 
 
A. Describe and justify scientifically each surgical procedure (e.g., approach, tissue manipulation, closure): 
 
 
Animals will be kept warm during the prepping and surgical procedures using a protective towel padding over a 
circulating warm water blanket. 
 
Animals will be anesthetized with a 30% oxygen/70% nitrogen (oxygen-enhanced air) gas mixture containing 5% 
isoflurane in an anesthetic chamber. After anesthesia is induced, it will be maintained using a nose cone under 
the same gas mixture, which will be reduced to 2% isoflurane. A thermistor type rectal probe is inserted into the 
rectum of the animal with the aid of K-Y gel. Rectal temperature will be monitored and maintained at 370 C 
throughout the remainder of the experiment by means of a feedback controlled warm water-circulating heating 
pad.  
 
Hair will be clipped from around the surgical site using a #40 surgical blade. Loose hairs will be wiped up using 
moist gauze. The animal’s head will then be secured to a stereotaxic frame by means of earpieces and a bite bar. 
Lidocaine gel (2%) will be applied into the ear canals to numb the ears. The surgical site will be scrubbed with a 
surgical scrub (Povidone-Iodine swabs) in a gradually enlarging circular pattern that starts in the middle and 
moves outward away from the proposed surgical incision site. The site will then be wiped with an alcohol swab 
using the same pattern. This procedure will be performed two more times. Eye lubricant will be used to prevent 
corneal dessication. 
 
Starting slightly behind the eyes, we will make a midline sagittal incision (about 2.0-3.0 cm) to expose the skull. 
Using a dissecting microscope and a pneumatic drill, a small burr hole (up to 1 mm diameter using a small burr 
bit) will be made at approximately 1 mm anterior and 2 mm lateral to the Bregma.  Bleeding will be controlled with 
bone wax. Approximately 500,000 cells, suspended in 10 ul PBS (or 10 ul PBS with no cells, for controls), will be 
injected at a depth of 1-3 mm and the needle will be slowly retracted over five minutes. The hole in the skull will 
be filled with bone cement and the skin will be sutured over the incision using a 4-0 monofilament suture. The 
animals will be allowed to recover before MRI, which will begin one week after the surgery.  Sutures will be 
removed at the time of the first MRI.  The same procedure will be used for the aquaporin1 injection but the 
coordinates will be 1.6 mm anterior, 5 mm interior, 3 mm lateral , and the volume to be injected will be 10-20 ul 
infused over 5 minutes. We may need to make slight (+/- 1 mm) adjustments to the injection site depending on the 
rats. 
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Rats will receive 4.0 cc warmed saline, SQ, post-op by investigator. Animals will be placed in a cage on a 
warming tray after surgery, until they awaken fully from anesthesia. Rats will be monitored until they have 
recovered from surgery and resumed normal activity. In order to receive daily post-op monitoring and care, rats 
will be returned to the facility after surgery and will remain there until they are used for imaging. Rats will be 
placed on the rack in the animal room for 24 hours. A dose of Buprenorphine, 0.05-0.1 mg/kg, SQ, in fluids will be 
administered by investigator prior to evening departure. Beginning the day after surgery the animals will receive 
buprenorphine twice daily for 24-48 hours and a nonsteroidal anti-inflammatory drug once daily for 72 hours. 
Animals should be doing well by the end of this regimen and if the veterinarian feels that the animal is still in pain 
after that time, they will be removed from the study and euthanized. Lab personnel performing the surgery will be 
responsible for the surgical animals until they are placed into the animal facility.  Animals will be monitored daily 
and any showing signs of pain, distress, or other complications will follow the course according to the Assessment 
and Intervention Chart (see below). Signs/symptoms to watch for would include animal inactivity, weight loss, 
rough hair coat, abnormal feeding/grooming, lethargy, hypothermia, inability to right itself, infection at incision site, 
and inflammation at injection site. 
 
 
 
B. Will pre-anesthetic drugs be used? 
 No. Proceed to section II. C. 
 Yes. Complete the following. 
 
Drug Dose Route Purpose 
 
    
 
Who will administer these drugs?  
 
C. Anesthetic regimen: 
Drug Dose Route 
isoflurane 
Lidocaine gel 
1-5% 
2% 
inhalation 
Topical in ears 
 
Describe measures used to indicate surgical plane of anesthesia to keep animals from getting both too light 
and/or too deep: No response to toe pinch, with stable breathing and pink mucous membranes.    
 
 Who will administer these drugs?  
surgeon (Bennett, Beeman, Hann, Clavijo-Jordan, Ginn). 
 
D. Pharmacological agents used during surgery (include analgesics, supportive medications, and research 
drugs):  
Drug Dose Route Purpose 
buprenorphine 0.01-0.05 mg/kg SQ analgesic 
meloxicam 1 mg/kg SQ analgesic 
  Who will administer these drugs? 
surgeon 
 
E. Describe the steps taken to maintain an aseptic surgery: 
For all surgical procedures, the following aseptic techniques will be used. The surgical area will be clipped 
and then alternately scrubbed with Povidone-Iodine and alcohol scrubs three times. A clean pair of gloves will 
be used from the prepping.  
 
The surgeon will wear a clean lab coat and face mask and a bonnet. Sterile gloves will be worn for the 
surgical procedure. A sterile surgical drape will be placed on the surgical site. Surgical instruments used will 
have been previously sterilized by autoclaving or by overnight placement (10+ hours) in cold sterilant 
(matricide 28). A glass bead sterilizer will be used for any subsequent sterilizing that may be needed for the 
day’s procedures involving similar surgeries.  
 
 
F. What is the maximum duration of surgery? 
3 hours 
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G. Will any animals recover from surgery? 
  No. This involves terminal, or non-survival, procedures; Appendix 2 is complete. 
X  Yes. Complete Section III.  
 
 
III.  POST-SURGICAL CARE  
 
A. Is post-operative pain or distress anticipated? 
 No. Proceed to section C. 
X Yes. 
 
B. Will analgesics be used? 
(For analgesic use in rodents see The Guidelines for Rodent Analgesia: 
http://researchadmin.asu.edu/compliance/iacuc/sop/rodentanalgesia.htm) 
 No.  Provide a scientific justification: 
 
 
 
X Yes. Complete the following.  
Drug Dose Route 
Buprenorphine 
 
 
Meloxicam 
0.01-0.05 mg/kg every 12 hrs for 
at least 24 hrs (up to 48 hrs if needed) 
 
1 mg/kg every 24 hrs for 3 days  
SQ 
 
 
SQ 
 
Who will administer these drugs? 
surgeon 
 
C. Post-operative routine care: 
 
What drugs will be administered, if any (e.g., antibiotics, fluids)?  
Drug Dose Route Purpose 
    
 
Who will provide routine post-operative support and what are their qualifications? 
After surgery, the surgeon will place the rat in a clean cage on a 37C warming tray. Animals will be 
monitored for return of normal activity (i.e., ambulatory, grooming, drinking) for at least two hours prior to 
returning to the animal housing facility. 
 
D. Is post-operative intensive care required?  
X No.  Proceed to section E. 
 Yes.  
What special care is required? 
 
Table 1.  Intervention and Endpoint Table rat injection of C6 glioma cells. 
Sign/Symptom Intervention Assessments Treatment actions/endpoints 
Awakening from survival surgery Check for body temp; check for 
dehydration. Check for response 
to physical stimulation. 
1. Keep animal warm with 
heated pad; inject fluids 
if needed.  
2. Euthanize if 
unresponsive.  
3. If animal appears 
normal/healthy, move 
back to holding facility in 
clean cage with bedding, 
water and food. Initiate 
yellow post-operative 
card, advise veterinarian. 
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Animal not active (somnolent) but 
otherwise appears healthy 
Weigh the animal when 
somnolence is observed and 
once daily afterward and 
compare to pre-surgical weight 
Monitor by veterinarian. 
Weight loss, rough hair coat not 
as active as normal (e.g. 
burrowing or not moving unless 
stimulated). 
Weigh the animal and compare 
to pre-surgical weight 
1. Weigh animal daily; 
provide fruit to stimulate 
appetite.  
2. Give fluids, if needed.  
3. Give analgesics, if 
needed. If animal does 
not respond within three 
days (e.g. gaining 
weight, active, alert) then 
euthanize. 
Inability to right itself, 
hypothermic 
None Euthanize 
 
Evidence of infection at incision 
site: swelling, hot to touch, 
exudates 
Culture the wound, clean the site. 1. Place on antibiotic 
treatment per veterinary 
instructions.  
2. Daily wound care (clean) 
3. Consider use in acute 
study or euthanasia 
depending on severity of 
infection and the 
judgment of the 
veterinarian. 
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Who will provide special care and what are their qualifications? 
 
 
 
For how long will special care be needed? 
 
 
E. Will animals undergo multiple survival surgical procedures? 
X No. Appendix 2 is complete. 
 Yes. Describe which surgeries, the sequence (timeline), and frequency.  Provide scientific justification: 
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